Heartbeam Inc
Annual Report 2018

Plain-text annual report

Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-Ký ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2018ORo TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _______ to _______Commission file number: 000-55039BioTelemetry, Inc.(Exact name of registrant as specified in its charter)Delaware 46-2568498(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)1000 Cedar Hollow Road #102 Malvern, Pennsylvania 19355(Address of principal executive offices) (Zip Code)(610) 729-7000(Registrant’s telephone number, including area code)(Former name, former address and former fiscal year, if changed since last report)Securities registered pursuant to Section 12(b) of the Act:Title of each class Name of each exchange on which registeredCommon Stock, $0.001 par value NASDAQ Global Select MarketSecurities registered pursuant to Section 12(g) of the Act: NoneIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ý No oIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes o No ýIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No oIndicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 ofthis chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No oIndicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’sknowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ýIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “largeaccelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.Large accelerated filer ý Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging growth company oIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act. oIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ýThe aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was $1.5 billion based on the closing sale price of the registrant’s common stock asreported by the NASDAQ Global Select Market on the last business day of the registrant’s most recently completed second fiscal quarter ended June 30, 2018. As of February 5, 2019,33,607,798 shares of the registrant’s common stock were outstanding.DOCUMENTS INCORPORATED BY REFERENCEPortions of the registrant’s definitive proxy statement for its 2019 annual meeting of stockholders, which proxy statement will be filed no later than 120 days after the close of theregistrant’s fiscal year ended December 31, 2018, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Table of ContentsBioTelemetry, Inc.Annual Report on Form 10-KFor The Fiscal Year Ended December 31, 2018TABLE OF CONTENTS PagePART I Item 1.Business4Item 1A.Risk Factors16Item 1B.Unresolved Staff Comments34Item 2.Properties34Item 3.Legal Proceedings35Item 4.Mine Safety Disclosures35 PART II Item 5.Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities36Item 6.Selected Financial Data37Item 7.Management's Discussion and Analysis of Financial Condition and Results of Operations40Item 7A.Quantitative and Qualitative Disclosures About Market Risk56Item 8.Financial Statements and Supplementary Data57Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure107Item 9A.Controls and Procedures107Item 9B.Other Information111 PART III Item 10.Directors, Executive Officers and Corporate Governance112Item 11.Executive Compensation112Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters112Item 13.Certain Relationships and Related Transactions, and Director Independence112Item 14.Principal Accountant Fees and Services112 PART IV Item 15.Exhibits and Financial Statement Schedules113Item 16.Form 10-K Summary114Exhibit Index115Signatures1172Table of ContentsUnless the context otherwise indicates or requires, the terms “we,” “our,” “us,” “BioTelemetry” and the “Company,” asused in this Annual Report on Form 10-K, refer to BioTelemetry, Inc. and its directly and indirectly owned subsidiaries as a combinedentity, except where otherwise stated or where it is clear that the terms mean only BioTelemetry, Inc. exclusive of its subsidiaries. Wedo not use the ® or ™ symbol in each instance in which one of our registered or common law trademarks appears in this AnnualReport on Form 10-K, but this should not be construed as any indication that we will not assert our rights thereto to the fullest extentpermissible under applicable law.CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the PrivateSecurities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and ourconfidence in our future. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,”“believe,” “promises” and other words and terms of similar meaning. Examples of forward-looking statements include statements wemake regarding our ability to increase demand for our products and services, to leverage our Mobile Cardiac Outpatient Telemetryplatform, to expand into new markets, to grow our market share, our expectations regarding revenue trends in our segments and theachievement of cost efficiencies through process improvement. Such forward-looking statements are based on current expectations andinvolve inherent risks and uncertainties, including important factors that could delay, divert or change any of these expectations, andcould cause actual outcomes and results to differ materially from current expectations. These factors include, among other things:•our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into ourbusiness;•our ability to educate physicians and continue to obtain prescriptions for our products and services;•changes to insurance coverage and reimbursement levels by Medicare and commercial payors for our products andservices;•our ability to attract and retain talented executive management and sales personnel;•the commercialization of new competitive products;•acceptance of our new products and services, such as our mobile cardiac telemetry (“MCT”) patch;•our ability to obtain and maintain required regulatory approvals for our products, services and manufacturing facilities;•changes in governmental regulations and legislation;•adverse regulatory action;•our ability to obtain and maintain adequate protection of our intellectual property;•interruptions or delays in the telecommunications systems that we use;•our ability to successfully resolve outstanding legal proceedings; and3Table of Contents•the other factors that are described in “Part I; Item 1A. Risk Factors” of this Annual Report on Form 10-K.We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, futureevents, or otherwise, except as may be required by law.PART IItem 1. BusinessOverviewBioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improvequality of life and reduce cost of care. We provide remote cardiac monitoring, remote blood glucose monitoring, centralized core labservices for clinical trials and original equipment manufacturing that serves both healthcare and clinical research customers.With over 30,000 unique referring physicians per month, we provide cardiac monitoring and reporting for over one millionpatients per year, processing over four billion heart beats per day. More information can be found at www.gobio.com.BioTelemetry operates under two reportable segments: Healthcare and Research. The Healthcare segment, which generated85% of our revenue in 2018, is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. Since wefocused on cardiac monitoring in 1999, we have developed a proprietary integrated patient management platform that incorporateswireless data transmission, U.S. Food and Drug Administration (“FDA”) cleared algorithms, medical devices and 24-hour monitoringservice centers. We offer cardiologists, electrophysiologists, neurologists and primary care physicians a full spectrum of solutions,which provides them with a single source of cardiac monitoring services. These services range from the differentiated MCT service, toevent, traditional Holter, extended-wear Holter, Pacemaker and International Normalized Ratio (“INR”) monitoring. The Researchsegment, which generated 13% of our revenue in 2018, is engaged in central core laboratory services providing cardiac monitoring,imaging services, scientific consulting and data management services for drug and medical device trials. During the first quarter of2018, as part of the LifeWatch AG (“LifeWatch”) integration, our forward-looking integration and rebranding plans, as well as re-evaluating the significance and materiality of our segments, we aggregated the Technology operating segment into the Corporate andOther category. See “Part II; Item 8. Financial Statements and Supplementary Data; Notes to Consolidated FinancialStatements; Note 18. Segment Information” below for further discussions related to segments.As of July 31, 2013, we reorganized to create a holding company structure. CardioNet, Inc., which was previously the publiccompany, became a wholly owned subsidiary of a newly formed entity, BioTelemetry, Inc., a Delaware corporation, and all theoutstanding shares of CardioNet, Inc. were exchanged, on a one-for-one basis, for shares of BioTelemetry, Inc. Our new holdingcompany continued trading on the NASDAQ Global Select Market under our same symbol “BEAT.”4Table of ContentsBusiness StrategyOur goals are to solidify our position as the leading provider of outpatient cardiac monitoring services, expand our presence inthe research market and leverage our monitoring platform in new markets. The key elements of the business strategy by which weintend to achieve these goals include:•Increase Overall Demand for Our Cardiac Monitoring Services. We believe that we can increase demand for ourcomprehensive portfolio of cardiac monitoring solutions by educating cardiologists, electrophysiologists, neurologists andprimary care physicians on the benefits of using our services, including MCT, to meet their arrhythmia monitoring needs,stressing the increased diagnostic yield and their ability to use the clinically significant data to make timely interventions andguide more effective treatments. We also believe we can become further incorporated into the practices’ workflow byoffering solutions such as the bi-directional integration of our data into Electronic Medical Record systems.•Expand Our Presence in the Research Market. We continue to focus our efforts on increasing our presence in theresearch market and on becoming a preferred global provider as it provides us with the ability to diversify our serviceofferings. We have experienced an increase in dual-service studies that require both cardiac and imaging service, which wesee as a key element of our strategic growth plan. We are also starting to have success incorporating our proprietaryePatch™ monitor as an element of our new cardiac studies creating cross-segment, top-line synergies.•Leverage Our Core Competencies to New Market Opportunities. We believe our core competencies can be leveraged forapplications in multiple markets. While our initial focus has been on arrhythmia diagnosis and monitoring, we intend toexpand into new market areas that require outpatient or ambulatory monitoring and management. During the second quarterof 2018, we announced the commercial introduction of our latest generation wireless Blood Glucose Monitoring (“BGM”)system, increasing our presence in the large and rapidly growing digital population health management market. Thiswireless BGM system transmits real-time results to a cloud-based analytical engine, which synthesizes the data, monitorstrends and provides caregivers with critical information about a patient’s health status and the potential need to intervene.We continue to evaluate numerous connected health technologies and solutions to better understand where we can bestleverage our capabilities.HealthcareThe Healthcare segment, or BioTel Heart®, is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythmdisorders. We offer cardiologists, electrophysiologists, neurologists and primary care physicians a full spectrum of solutions, whichprovides them with a single source of cardiac monitoring services. These services range from the differentiated MCT service, to event,traditional Holter, extended-wear Holter, Pacemaker and INR monitoring.Our MCT services incorporate a lightweight patient-worn sensor attached to electrodes that capture two-channelelectrocardiogram (“ECG”) data, measuring electrical activity of the heart, on a compact wireless handheld monitor. The monitoranalyzes incoming heartbeat-by-heartbeat information from the sensor on a real-time basis by applying proprietary algorithms designedto detect arrhythmias. The monitor can detect an arrhythmic event even in the absence of symptoms noticed by the patient. When themonitor detects an arrhythmic event, it automatically transmits the ECG to our monitoring centers. At our 24-hour monitoring centers,trained cardiac technicians analyze the data, respond to urgent events and report results5Table of Contentsin the manner prescribed by the physician. The MCT devices employ two-way wireless communications, enabling continuoustransmission of patient data to the monitoring centers and permitting physicians to remotely adjust monitoring parameters and requestprevious ECG data from the memory stored in the monitor. The MCT devices have the capability of storing 30 days of continuousECG data, in contrast to a maximum of 10 minutes for a typical event monitor and a maximum of 24 hours for a typical Holtermonitor.In 2016, we obtained FDA approval of our next generation MCT device, in a patch form factor. The MCT patch is a four-lead,two-channel system that provides the same best-in-class technology as our current MCT devices, in a more convenient form factor.The MCT patch was commercially launched in limited accounts during 2017, with a full launch in the first quarter of 2018.Our event monitoring services provide physicians with the flexibility to prescribe wireless event monitors, digital loop eventmonitors, memory loop event monitors and non-loop event monitors. Event data is transmitted, either through automatic transmissionof event data with wireless event monitors or through telephonic transmission of stored event data with our traditional event monitors,to one of our monitoring centers where our trained cardiac technicians analyze the data.Traditional Holter and extended-wear Holter monitors locally store, on a compact memory card, ECG data of every heartbeator irregularity. The device is mailed or the data is sent electronically through a secure web transfer to one of our Holter labs, where ourtrained cardiac technicians analyze the data. Our next generation Holter monitors, the CardioKey® and ePatch™ are small, lightweightcardiac monitors, which can continuously store up to 14 days of ECG data.We market our services generally throughout the United States and receive reimbursement for the monitoring provided topatients from government and commercial payors.ResearchThe Research segment, or BioTel Research™, is engaged in central core laboratory services that provide cardiac monitoring,imaging services, scientific consulting and data management services for drug and medical device trials. The centralized servicesinclude ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan (“MUGA”), afull range of imaging services, protocol development, expert reporting and statistical analysis. Our imaging services offerings werebolstered by our 2016 acquisition of VirtualScopics, Inc. (“VirtualScopics”), a leading provider of clinical trial imaging solutions andservices in the cardiac, oncology, musculoskeletal and neurologic therapeutic areas. Through our acquisitions, we gained globalexperience in central core laboratory services, which includes experience in Phase I-IV and Thorough QT Trials. We also provide afull range of support services that include project coordination, setup and management, equipment rental, data transfer, processing,analysis and 24/7 customer support and site training. Our data management systems enable complete customization for sponsors’preferred data specifications, and our web service, CardioPortal™, provides access to data from any web browser, without client-sideplug-ins. Our primary customers in this segment are pharmaceutical companies and contract research organizations.6Table of ContentsOther BusinessesThe “Corporate and Other” category contains our other operating business brands: BioTel Care® and BioTel Alliance™,which focus on the sale, manufacturing, engineering and development of non-invasive cardiac monitors and other population healthmanagement devices for leading healthcare companies worldwide. We have been able to build successful customer relationships byproviding reliable, quality products and engineering services. We offer contract manufacturing services, developing and producingdevices to the specific requirements set by customers.We manufacture various devices, including MCT monitors, cardiac event monitors and digital Holter monitors utilized by ourHealthcare and Research segments. Our facilities located in San Diego, CA and Concord, MA are responsible for research and productdevelopment under FDA guidelines. Manufacturing of devices is performed in part in our Eagan, MN facility. We believe that ourmanufacturing capacity will be sufficient to meet our manufacturing needs for the foreseeable future.We believe our manufacturing operations are in compliance with regulations mandated by the applicable regulatory governingbodies. We are subject to unannounced inspections by the FDA and we successfully completed routine inspections in recent years withno significant findings noted or warnings issued. Our Eagan, MN, San Diego, CA and Concord, MA facilities are ISO 13485 certifiedand registered with the FDA. ISO 13485 is an international quality system standard used by medical device manufacturing companiesand is the basis for acquiring European Conformity Marking (“CE Marking”) for medical device product distribution in the EuropeanUnion. In addition to FDA clearance, many of our devices also carry a CE Marking, which is a certification mark that indicatesconformity with health, safety and environmental protection standards for products sold within the European Economic Area (“EEA”).There are a number of critical components and sub-assemblies in the devices. The vendors for these materials are qualifiedthrough stringent evaluation and testing of their performance. We implement a strict no-change policy with our contract manufacturersto ensure that no components are changed without our approval.Research and DevelopmentWe make significant investments in research and development activities focused on developing new products andenhancements to our existing products. We intend to continue to develop proof of superiority of our technology through clinical data.Our aim is to create products that are smaller, faster, more efficient and that provide more useful and relevant information to physicianson a more timely basis. We employ a dedicated internal core research and development team, primarily based in San Diego. We havebeen consolidating parts of the process across the organization to bring cross-company synergies and benefits. Our San Diego locationalso houses our rapid prototype lab, which has 3-D printing capability. In addition, we consult with external consultants and partnerson certain projects or prototype work.The three primary sources of clinical data that we have used to date to illustrate the clinical value of MCT include: (i) arandomized 300-patient clinical study; (ii) our cumulative actual monitoring experience from our databases; and (iii) numerous otherpublished studies.We sponsored and completed a 17-center, 300-patient randomized clinical trial in March 2007 - Steven A. Rothman M.D. et al.“The Diagnosis of Cardiac Arrhythmias: A Prospective Multi-Center Randomized Study Comparing Mobile Cardiac OutpatientTelemetry Versus Standard Loop Event Monitoring,” Journal of Cardiovascular Electrophysiology. We believe this study representedthe largest7Table of Contentsrandomized study comparing two non-invasive arrhythmia monitoring methods. The study was designed to evaluate patients who weresuspected to have an arrhythmic cause underlying their symptoms but who were a diagnostic challenge given that they had already hada non-diagnostic 24-hour Holter monitoring session or four hours of telemetry monitoring within 45 days prior to enrollment. Patientswere randomized to either MCT or to a loop event monitor for up to 30 days. Of the 300 patients who were randomized, 266 patientswho completed a minimum of 25 days of monitoring were analyzed (134 patients using MCT and 132 patients using loop eventmonitors).The study specifically compared the success of MCT against loop event monitors in detecting patients with clinically significantarrhythmias and demonstrated the superiority of MCT for confirming the diagnosis of these types of arrhythmias. The study alsodemonstrated the advantage of using MCT compared to the loop event monitor in the detection of asymptomatic atrial fibrillation(“Afib”) or flutter. Diagnosis and treatment of Afib is important because it can lead to many other medical problems, including stroke.The study concluded that MCT provided a significantly higher diagnostic yield, in detecting an arrhythmic event in patients withsymptoms of cardiac arrhythmia, compared to traditional loop event monitoring, including such monitoring designed to automaticallydetect certain arrhythmias.With over 30,000 unique referring physicians per month, we provide cardiac monitoring and reporting for over one millionpatients per year, processing over four billion heart beats per day.In addition to the aforementioned 300-patient randomized clinical trial, MCT has been cited and referenced in over 40publications and abstracts, which lends support to its clinical efficacy.We also continue to research study setup automation and workflow management for use in our Research segment. Ourcontinued efforts to integrate machine learning and artificial intelligence to improve our automated patient management tracking in ourResearch segment services will drive efficiencies, and we believe it will help us acquire more dual-service studies from our partners.Additionally, we continue to build out our coaching platform for our wireless BGM, through patient and 3rd party feedback.We are analyzing data to determine where machine learning can provide additional technological leverage and efficiencies to thephysician and the patient.Sales and MarketingWe market our cardiac monitoring solutions in our Healthcare segment through our direct sales force primarily to cardiologists,electrophysiologists, neurologists and primary care physicians who most commonly diagnose and treat patients with arrhythmias. Wedifferentiate ourselves through the seemless integration of our data in the practice’s electronic medical records.We are the leading member of the Remote Cardiac Service Provider Group (“RCSPG”), with our Senior Vice President ofMedical Affairs being the current President of the RCSPG. The RCSPG collaborates with physician specialty societies as well as theAmerican Telemedicine Association to advocate to the Centers for Medicare and Medicaid Services (“CMS”) and Congress forappropriate valuation of remote diagnostic services that the RCSPG members provide.Our Healthcare segment experiences some seasonality during the third quarter as well as during the year-end holiday season.We believe that this is the result of patients electing to delay our monitoring services during the summer months or holidays.8Table of ContentsWe market our Research segment services to pharmaceutical companies, medical device companies, contract researchorganizations and academic research organizations. We are a founding member and the first cardiac core lab to join the Cardiac SafetyResearch Consortium (“CSRC”). Through the CSRC, we are able to network with key thought leaders and decision makers of majorpharmaceutical companies, as well as discuss key cardiac safety issues during the drug development process. Through our integrationof VirtualScopics, we have experienced an increase in acquiring studies that include both cardiac and imaging requirements.Expanding our research service offerings is a key element of our strategic growth plan, allowing us to more favorably compete forresearch studies requiring a wider range of research services. Our team has also had success incorporating our proprietary ePatchmonitor as a critical element of new cardiac studies creating cross-segment, top-line synergies.Our BioTel Alliance™ brand, currently included in the Corporate and Other category, markets our manufactured products tophysicians, hospitals and other cardiac monitoring providers. BioTel Care® is actively working to expand our position in the digitalpopulation health space, and continues to evaluate numerous connected health technologies and solutions to better understand wherewe can best leverage our capabilities. Specifically, we are engaged in increasing awareness and utilization of our wireless BGM andour Diabetes Management Platform. Our commercial team is primarily focused on securing contracted relationships for our diabetesmanagement services with:•commercial managed care plans;•accountable care organizations;•integrated delivery networks;•physicians groups;•durable medical equipment distributors; and•employer groups.We attend trade shows and medical conferences to promote our various product and service offerings. The trade shows andconferences we attend are related to organizations such as: the Heart Rhythm Society, American College of Cardiology, AmericanTelemedicine Association, Society of Thoracic Surgeons, American Heart Association, and the European Society of Cardiology. Wealso attend the Medica, Drug Information Association and Partnerships in Clinical Trials trade shows as well as the annual BostonAtrial Fibrillation Symposium. We have had limited product and service-based advertising in certain national newspapers and medicaljournals.Healthcare ReimbursementIn the Healthcare segment, services are billed to government and commercial payors using specific codes describing theservices. Those codes are part of the Current Procedural Terminology (“CPT”) coding system, which was established by theAmerican Medical Association to describe services provided by physicians and other suppliers. Physicians select the code that bestdescribes the medical services being prescribed. Approximately 34% of our total revenue is subject to reimbursement from theMedicare program, a federal government health insurance program administered by CMS, at rates that are set nationally and adjustedfor certain regional indices.9Table of ContentsIn addition to receiving reimbursement from government payors, we enter into contracts with commercial payors to receivereimbursement at specified rates for our services. Such contracts typically provide for an initial term of between one and three yearsand provide for automatic renewal thereafter. Either party can typically terminate these contracts by providing between 30 and180 days’ prior notice to the other party at any time following the end of the initial term of the agreement. The contracts provide for anagreed upon reimbursement rate, which in some instances is tied to the rate of reimbursement we receive from Medicare.In addition to receiving reimbursement from government and commercial payors, we have direct arrangements with physicianswho may purchase our monitoring services and then submit claims for these services directly to government and commercial payors. Insome cases, patients pay for their service out-of-pocket.CompetitionAlthough we believe that we have a leading market share in mobile cardiac monitoring in the U.S., the market in which ourHealthcare segment operates is fragmented and characterized by a number of smaller regional service providers.Our Research segment competes directly with other core labs as well as contract research organizations that offer core labservices. We believe that we compete favorably based on our comprehensive cardiac and imaging service offerings, the scale of ouroperation and our ability to support the entire life cycle of new drug development.We also compete directly with other original diagnostic equipment manufacturers.We believe that the principal competitive factors that impact the success of our businesses include some or all of the following:•quality of algorithms used to detect arrhythmias;•quality and accuracy of clinical data;•turnaround times;•ease of use and reliability of cardiac monitoring solutions for patients and physicians;•technology performance, innovation, flexibility and range of application generating the highest yields;•timeliness and clinical relevance of new product introductions;•quality and availability of superior customer support services;•size, experience, knowledge and training of sales and marketing staff;•reputation;•relationships with referring physicians, hospitals, managed care organizations and other third-party payors;•reporting capabilities;10Table of Contents•providing a full spectrum of cardiac monitoring solutions, ranging from MCT services to event, traditional and extended-wear Holter monitoring;•a widening range of clinical cardiac and imaging services and best-in-class solutions;•perceived value; and•extensive industry expertise.We believe that we compete favorably based on the factors described above. However, our industry is evolving rapidly and isbecoming increasingly competitive, and the basis on which we compete may change over time. In addition, if companies withsubstantially greater resources than ours enter our market, we will face increased competition.Intellectual PropertyWe rely on a combination of intellectual property laws, non-disclosure agreements and other measures to protect ourproprietary rights. We attempt to protect our intellectual property rights by filing patent applications for new features and products wedevelop. In addition, we also seek to maintain certain intellectual property and proprietary know-how as trade secrets, and generallyrequire our partners to execute non-disclosure agreements prior to any substantive discussions or disclosures of our technology orbusiness plans. Our business and competitive positions are dependent in part upon our ability to protect our proprietary technology andour ability to avoid infringing the patents or proprietary rights of others.We hold patents in the United States as well as many international jurisdictions on our products, processes and relatedtechnologies. In furtherance of our overall global intellectual property strategy, we also have patent applications currently on file in theUnited States and internationally. While we have several patents expiring through 2032, including patents that relate, in part, to our keyproducts, we do not believe such expirations will have a material impact on our ability to compete in the short term since ourtechnology is typically covered by several patents, creating a system of protected technology.Our trademarks, certain of which are material to our business, are registered or otherwise legally protected in the United Statesand in certain foreign countries and include, among others, the registered trademarks CardioNet®, BioTelemetry®, LifeWatch®,BioTel Care®, BioTel Heart® and the unregistered trademarks Mobile Cardiac Outpatient Telemetry™, MCOT™, ePatch™,CardioPortal™, BioTel Research™ and BioTel Alliance™. We also have a significant amount of copyright-protected materials.Government RegulationThe health care industry is highly regulated, with no guarantee that the regulatory environment in which we operate will notchange significantly and adversely in the future. We believe that health care legislation, rules, regulations and interpretations willchange, and we expect to modify our agreements and operations in response to these changes.U.S. Food and Drug Administration. The medical devices that we use to provide patient monitoring services are regulated bythe FDA under the Federal Food, Drug, and Cosmetic Act (“FDCA”). Unless exempt, medical devices distributed in the United Statesmust receive marketing authorization by the FDA through either a full Premarket Approval (“PMA”) or the Premarket Notification510(k) process. Based on the classification and characteristics of a medical device, it may receive marketing authorization through11Table of Contentsa PMA, pathway, which requires the demonstration of safety and effectiveness through adequate and well-controlled clinical studies,or receive clearance under the 510(k) pathway after demonstrating substantial equivalence to a predicate device. In addition tomarketing authorization requirements, device manufacturers must also comply generally with establishment registration, medical devicelisting, quality system regulation, labeling and medical device reporting requirements, and any special controls specific to a particulardevice and used to support reclassification.The algorithms we use in the MCT service maintain FDA 510(k) clearance as a Class II device. On October 28, 2003, theFDA issued a guidance document entitled: “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm.” Inaddition to conforming to the general requirements of the FDCA, including the Premarket Notification requirements described above,all of our cardiac related 510(k) submissions address the specific issues covered in this special controls guidance document. Thealgorithms we use in the BGM service also maintain FDA 510(k) clearance as a Class II device.Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, including certainsanctions, such as fines, penalties or injunctions; recall or seizure of our devices and intellectual property; operating restrictions; partialsuspension or total shutdown of production; withdrawal of 510(k) clearance of new components or algorithms; withdrawal of 510(k)clearance already granted to one or more of our existing components or algorithms; and criminal prosecution.CE Marking. Medical devices distributed within the EEA require the CE Marking, which is a certification mark that indicatesconformity with health, safety, and environmental protection standards for products sold within the EEA. The CE Marking is alsofound on products sold outside the EEA that are manufactured in, or designed to be sold in, the EEA. Although ISO 13485certification is not a direct requirement for CE marking medical devices under the European Medical Device Directives, it isrecognized as a harmonized standard by the European Commission. ISO 13485 is aligned with the three European medical devicedirectives that are applicable to different types of medical devices in Europe. Failure to maintain appropriate CE Marking could havean adverse effect on our ability to sell our devices within the European Union.Health Care, Fraud, Waste and Abuse. In the United States, state and federal laws and regulations restrict healthcare providersfrom billing and collecting for products or services connected with fraudulent, wasteful or abusive conduct. These state and federallaws include civil and criminal false claims provisions, health fraud and false statements provisions, anti-kickback provisions, physicianself-referral provisions, and more, violation of which may subject us to criminal penalties as well as potential exclusion from federalhealthcare programs and civil monetary penalties.Federal and state anti-kickback laws generally prohibit the payment or receipt of anything of value to induce prescription orreferral of reimbursed products or services. Stark law limits certain relationships between referring physicians and providers of certaindesignated healthcare services. Anti-kickback laws limit financial arrangements we may have with healthcare professionals in aposition to purchase, recommend or refer patients for our cardiac monitoring services or other products or services we may develop andcommercialize. Due to the breadth of some of these laws, it is possible that some of our current or future practices might be challengedunder one or more of these laws.Federal and state false claims laws prohibit anyone from presenting, or causing to be presented, claims for payment to third-party payors that are false or fraudulent. Violations may result in substantial civil penalties including treble damages, as well as criminalpenalties, including imprisonment, fines and exclusion from participation in federal health care programs. The False Claims Act(“FCA”) also contains “whistleblower” or “qui tam” provisions that allow private individuals to bring actions on behalf of the12Table of Contentsgovernment alleging false claims and potentially other violations of fraud and abuse laws. Various states have enacted laws modeledafter the FCA, including “qui tam” provisions, and some of these laws apply to claims filed with commercial insurers. Violation offederal and state fraud and abuse laws could have a material adverse effect on our business, financial condition and results ofoperations.The Patient Protection and Affordable Care Act. On March 23, 2010, the Patient Protection and Affordable Care Act wassigned into law, and on March 30, 2010, the Health Care and Education Reconciliation Act of 2010 was signed into law. Together, thetwo measures, collectively known as the Affordable Care Act (“ACA”), made fundamental changes to the United States health caresystem. The ACA expanded Medicaid eligibility, required most individuals have health insurance or pay a penalty, imposed newrequirements for health plans and insurance policy standards, established health insurance exchanges, changed Medicare paymentsystems to encourage more cost-effective care and new expanded tools to address fraud and abuse and required manufacturers ofmedical devices and other products reimbursed by Medicare to report annually to the government certain payments to physicians andteaching hospitals. In 2018, certain provisions of the ACA were modified and repealed effective 2019 and beyond.As a result of the passage of the ACA, manufacturers of certain medical devices are subject to an excise tax applicable to salesof taxable medical devices. Several devices that are manufactured by us are subject to these taxes. The tax equals 2.3% of the sale priceof the applicable medical device. As a manufacturer, we are responsible for remitting these taxes to the federal government. TheConsolidated Appropriations Act of 2016, enacted on December 18, 2015, included a moratorium on the medical devices taxcommencing on January 1, 2016 and ending on December 31, 2017. Budget legislation signed in January 2018 extended thatmoratorium through December 31, 2019.Health Insurance Portability and Accountability Act of 1996. The Health Insurance Portability and Accountability Act wasenacted in 1996, amended by the Health Information Technology for Economic and Clinical Health (“HITECH”) Act in 2009, andimplemented through regulation (collectively, “HIPAA”). HIPAA, together with other data privacy and security laws such as theGeneral Data Protection Regulations (“GDPR”), dictate privacy and security standards governing the collection, storage, maintenance,dissemination, use and confidentiality of individually identifiable patient health information. HIPAA applies directly to “coveredentities,” which include health plans, health care clearinghouses and many health care providers, who electronically transmit healthinformation and thereby engage in HIPAA “covered transactions.” HIPAA also applies to “business associates,” individuals whoperform certain functions or activities for or on behalf of covered entities that require the individual to create, receive, maintain, ortransmit protected health information (“PHI”). HIPAA is concerned primarily with the privacy of PHI when it is used and/or disclosed;the confidentiality, integrity and availability of electronic PHI; notifying federal regulators and impacted patients in the event of abreach of unsecured PHI; and the content and format of certain identified electronic health care transactions. The laws governing healthcare information privacy and security impose civil and criminal penalties for their violation. Compliance with these laws requiressubstantial expenditures of financial and other resources for information technology system compliance, maintenance, monitoring,validation and evaluation. Historically, state law has governed confidentiality issues, and HIPAA preserves these laws to the extentthey are more protective of a patient’s privacy or provide the patient with greater access to his or her health information. Many statescontinue to consider revisions to their existing laws and regulations that may or may not be more stringent or burdensome than thefederal HIPAA provisions.Medicare. Medicare is a federal program administered by CMS and its Medicare Administrative Contractors (“MAC”). TheMedicare program provides qualified persons with health care benefits that cover the major costs of medical care within prescribedlimits, subject to certain deductibles and co-13Table of Contentspayments. The Medicare program has established guidelines for local and national coverage determinations and reimbursement ofcertain equipment, supplies and services, which are subject to change. The methodology for determining coverage status and the basisand amount of Medicare reimbursement varies based upon, among other factors, the location in which a Medicare beneficiary receiveshealth care items and services, the type of items and services provided, and the benefits available to individual beneficiaries.The Medicare program is subject to statutory and regulatory changes, retroactive and prospective rate adjustments,administrative rulings, interpretations of policy, billing guidelines, MAC contractor local coverage determinations and governmentfunding restrictions. All of these policies may materially increase or decrease the rate of program payments to health care facilities andother health care suppliers and practitioners, including those paid for our cardiac monitoring services. Other regulations such as facilitystandards, billing requirements, rules of participation and other regulations affecting the provision of and reimbursement for productsand services also affect the ability to provide, bill and receive reimbursement for services or products provided under the program. Anychanges in federal legislation, regulations or other policies affecting Medicare coverage, reimbursement or eligibility relative to ourcardiac monitoring services could have an adverse effect on our performance.Certain of our facilities are enrolled in Medicare as Independent Diagnostic Testing Facilities (“IDTFs”). An IDTF is definedby CMS as an entity independent of a hospital or physician’s office in which diagnostic tests are performed, often by licensed orcertified non-physician personnel, and under appropriate physician supervision. Medicare prescribes detailed certification standards thatevery IDTF must meet in order to obtain or maintain its billing privileges, including requirements to, among other things, operate incompliance with all applicable federal and state licensure and regulatory requirements for the health and safety of patients; maintain aphysical facility on an appropriate site meeting specific criteria; have a comprehensive liability insurance policy of at least $0.3 millionper location; disclose certain ownership information; have its testing equipment calibrated and maintained in accordance with specificstandards; have technical staff on duty with the appropriate credentials to perform tests; and permit on-site inspections. Theserequirements are subject to change. Our IDTF facilities are periodically inspected by CMS to confirm our compliance with the IDTFstandards, and we believe that our facilities are in compliance with these standards.Environmental Regulation. We use materials and products regulated under environmental laws, primarily in the manufacturingand sterilization processes. While it is difficult to quantify, we believe the ongoing cost of compliance with environmental protectionlaws and regulations will not have a material impact on our business, financial position or results of operations.Supply Chain Diligence and TransparencySection 1502 of the Dodd Frank Wall Street Reform and Consumer Protection Act was adopted to further the humanitariangoal of ending the violent conflict and human rights abuses in the Democratic Republic of the Congo and adjoining countries(“DRC”). This conflict has been partially financed by the exploitation and trade of tantalum, tin, tungsten and gold (so called “conflictminerals”) that originate from mines or smelters in the region. United States Securities and Exchange Commission (“SEC”) rulesadopted in August 2012 under Section 1502 require reporting companies to disclose annually on Form SD whether any such mineralsthat are necessary to the functionality or production of products they manufactured, or for which they contracted to manufacture,during the prior calendar year did, in fact, originate in the DRC and, if so, if the related revenue was used to support the conflict and/orabuses.14Table of ContentsSome of the products we manufacture may contain tantalum, tin, tungsten and/or gold. Consequently, in compliance with SECrules, we have adopted a policy on conflict minerals, which can be found on our website, and have implemented a supply chain duediligence and risk mitigation process with reference to the Organization for Economic Cooperation and Development (“OECD”)guidance approved by the SEC to assess and report annually whether our products are “conflict free.”We support efforts to end the violence and human rights abuses in the mining of certain minerals in the DRC. We expect oursuppliers to comply with the OECD guidance and industry standards and to ensure that their supply chain conforms to our policy andthe OECD guidance.Product Liability and InsuranceThe design, manufacture and marketing of medical devices and services of the types we produce entail an inherent risk ofproduct liability claims. In addition, we provide information to health care providers and payors upon which determinations affectingmedical care are made, and claims may be made against us resulting from adverse medical consequences to patients allegedly resultingfrom the information we provide. To protect ourselves from product liability claims, we maintain professional liability and generalliability insurance on a “claims made” basis. Insurance coverage under such policies is contingent upon a policy being in effect when aclaim is made, regardless of when the events which caused the claim occurred. While, as of the date of this Annual Report on Form10-K, a material product liability claim has never been made against us and we believe our insurance policies are adequate in amountand coverage for our current operations, there can be no assurance that the coverage maintained by us is sufficient to cover all futureclaims. In addition, there can be no assurance that we will be able to obtain such insurance on commercially reasonable terms in thefuture.EmployeesAs of December 31, 2018, we employed approximately 1,500 employees. None of our employees are represented by acollective bargaining agreement. We consider our relationship with our employees to be good.Available InformationWe file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports onForm 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of1934 (“Exchange Act”). We make these reports available on our website at www.gobio.com, free of charge. Copies of these reportsare made available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SECmaintains a website that contains reports, proxy and information statements, and other information regarding our filings, atwww.sec.gov. We do not utilize social media platforms as our primary means of distributing material company information.15Table of ContentsItem 1A. Risk FactorsThe factors discussed below are cautionary statements that identify important factors and risks that could cause actual results todiffer materially from those anticipated by the forward-looking statements described under “Cautionary Note Regarding Forward-Looking Statements” contained in this Annual Report on Form 10-K. For more information regarding the forward-looking statementscontained in this report, see the Table of Contents of this Annual Report on Form 10-K. You should carefully consider the risks anduncertainties described below, together with all of the other information included in this Annual Report on Form 10-K, in consideringour business and prospects. The risks and uncertainties described below are not the only ones facing BioTelemetry. Additional risksand uncertainties not presently known to us may also impair our business operations. The occurrence of any of the following riskscould affect our business, liquidity, results of operations, financial condition or cash flows.Reimbursement by Medicare is highly regulated and subject to change and our failure to comply with applicable regulations coulddecrease our revenue, subject us to penalties or adversely affect our results of operations.The Medicare program is administered by CMS, which imposes extensive and detailed requirements on medical product andservices providers, including, but not limited to, rules that govern how we structure our relationships with physicians, how and whenwe submit reimbursement claims, how we operate our monitoring centers and how and where we provide our arrhythmia monitoringsolutions. Our failure to comply with applicable Medicare rules could result in the discontinuation of our reimbursement under theMedicare payment program, a requirement to return funds already paid to us, civil monetary penalties, criminal penalties and/orexclusion from the Medicare program.Changes in the reimbursement rate that commercial payors and Medicare will pay for our products and services could adverselyaffect our revenue.We receive reimbursement for our products and services from commercial payors and from MAC with jurisdiction in the statewhere the services are performed. In addition, our prescribing physicians receive reimbursement for professional interpretation of theinformation provided by our products and services from commercial payors or Medicare. Average commercial reimbursement rateshave declined over a three and five year period. When commercial payors combine their operations, the combined company may electto reimburse for our products and services at the lowest rate paid by any of the participants in the consolidation. If one of the payorsparticipating in the consolidation does not reimburse for one of our products or services, the combined company may elect not toreimburse for such product or service. Additionally, commercial payors can typically terminate these contracts by providing between30 and 180 days’ prior notice at any time following the end of the initial term of the agreement. In addition, CMS may reduce thereimbursement rate for our services, as it has in the past. CMS updates the reimbursement rate via the Medicare physician fee scheduleannually. Furthermore, CMS has adopted a complex new system for reimbursing Medicare physician services as required by theMedicare Access and CHIP Reauthorization Act of 2015. Under the new program, which began January 1, 2017, physicians willeither report under the Merit-based Incentive Payment System or an Advanced Alternative Payment Model, and their 2017performance will impact 2019 rates. CMS published a final rule on November 1, 2018, modifying program requirements forperformance year 2019. The rule designates use of certain patient-generated health data with an active feedback loop as a “high”weighted activity for purposes of the Advancing Care Information bonus. We cannot predict the impact of this new framework orpotential future revisions to physician payment policy on reimbursement for our services. A decrease in Medicare or commercial16Table of Contentsreimbursement rates or termination of commercial payor contracts would adversely affect our financial results.Our operations and our interactions with our physicians and patients are subject to regulation aimed at preventing health carefraud and abuse and, if we are unable to fully comply with such laws, we could face substantial penalties.Our operations may be directly or indirectly affected by various broad state and federal health care fraud and abuse laws,including the Federal Healthcare Programs’ Anti-Kickback Statute and the FCA. For some of our services, we directly bill physiciansor other health care entities, that, in turn, bill payors. Although we believe such payments and practices are proper and in compliancewith laws and regulations, we may be subject to claims asserting that we have violated these laws and regulations. If our past or presentoperations are found to be in violation of these laws, we or our officers may be subject to civil or criminal penalties, including largemonetary penalties, damages, fines, imprisonment and exclusion from Medicare and Medicaid program participation. Furthermore, ifwe knowingly file, or “cause” the filing of, false claims for reimbursement with government programs such as Medicare and Medicaid,we may be subject to substantial civil penalties, including treble damages. The FCA also contains “whistleblower” or “qui tam”provisions that allow private individuals to bring actions on behalf of the government alleging that the defendant has defrauded thegovernment. In recent years, the number of suits brought in the medical industry by private individuals has increased dramatically.Various states have enacted laws modeled after the FCA, including “qui tam” provisions, and some of these laws apply to claims filedwith commercial insurers. Even if we are not found to have violated any of these federal or state anti-fraud or false claims acts, thecosts of defending these claims could adversely affect our results of operations.The operation of our monitoring centers is subject to rules and regulations governing IDTFs and state licensure requirements;failure to comply with these rules could prevent us from receiving reimbursement from Medicare and some commercial payors.We have several monitoring centers throughout the United States that analyze the data obtained from cardiac monitors andreport the results to physicians. In order for us to receive reimbursement from Medicare and some commercial payors, our monitoringcenters must be certified as IDTFs. Certification as an IDTF requires that we follow strict regulations governing how our monitoringcenters operate, such as requirements regarding certification of the technicians who review data transmitted from our monitors. Theserules can vary from location to location and are subject to change. If they change, we may have to change the operating procedures atour monitoring centers, which could increase our costs significantly. If we fail to obtain and maintain IDTF certification, our servicesmay no longer be reimbursed by Medicare and some commercial payors, which could have a material adverse impact on our business.Our failure to maintain accreditation could impact our DMEPOS operations.Accreditation is required by most of our managed care payors and became a mandatory requirement for all Medicare durablemedical equipment, prosthetics, orthotics and supplies (“DMEPOS”) providers effective October 1, 2009. In 2016, we acquiredTelcare Medical Supply, Inc. (“Telcare”), a diabetes care management company. In 2017, Telcare completed a nationwideaccreditation renewal process conducted by the Healthcare Quality Association on Accreditation, which renewed our accreditation foranother three years. We will undergo the next survey cycle in 2020. If we lose accreditation, our failure to maintain accreditation couldhave an adverse effect on our business, financial condition, results of operations, cash flow, capital resources and liquidity.17Table of ContentsFailure to appropriately track and report certain payments to physicians and teaching hospitals may violate certain federalreporting laws and subject us to fines and penalties.Section 6002 of the ACA requires certain medical device manufacturers that produce devices covered by the Medicare andMedicaid programs to report annually to the government certain payments and transfers of value to physicians and teaching hospitals.If we fail to appropriately track and report such payments to the government, we could be subject to civil fines and penalties, whichcould adversely affect the results of our operations.Audits or denials of our claims by government agencies and commercial payors could reduce our revenue and have an adverseeffect on our results of operations.As part of our business operations, we submit claims on behalf of patients directly to, and receive payments from, Medicare,Medicaid and other third-party payors. We are subject to extensive government regulation, including requirements for submittingreimbursement claims under appropriate codes and maintaining certain documentation to support our claims. Medicare contractors andMedicaid state agencies periodically conduct pre-and post-payment reviews and other audits of claims and are under increasingpressure to more closely scrutinize health care claims and supporting documentation. The Medicare and Medicaid programs also havebroad authority to impose payment suspensions and supplier number revocations when they believe credible allegations of fraud orother supplier standard noncompliance issues exist. We have previously been subject to pre-and post-payment reviews as well as auditsof claims under CMS’ Recovery Audit Program and may experience such reviews and audits of claims in the future. Such reviews andsimilar audits of our claims could result in restrictions on our ability to bill for our services, material delays in payment, as well asmaterial recoupments or denials, which would reduce our net sales and profitability, or result in our exclusion from participation in theMedicare or Medicaid programs. We are also subject to similar review and audits from commercial payors, which may result inmaterial delays in payment and material recoupments and denials. In addition, state agencies may conduct investigations or submitrequests for information relating to claims data submitted to commercial payors.We have a concentrated number of payors and losing one of them would reduce our sales and adversely affect our business andoperating results.Medicare, our largest payor, represents a significant percentage of our revenue. For the year ended December 31, 2018,Medicare accounted for approximately 34% of our total revenue. No other payor accounted for more than 6% of total revenue. Ouragreements with commercial payors typically allow either party to the contract to terminate the contract by providing between 30 and180 days’ prior written notice to the other party at any time following the end of the initial term of the contract. Our commercial payorsmay elect to terminate or not to renew their contracts with us for any reason and, in some instances, can unilaterally change thereimbursement rates they pay. A commercial payor who terminates or does not renew their contract with us may, or may not, alter theircoverage of our services. In the event any of our key commercial payors terminate their agreements with us, elect not to renew or enterinto new agreements with us upon expiration of their current agreements, or do not renew or establish new agreements on terms asfavorable as are currently contracted, our business, operating results and prospects would be adversely affected.18Table of ContentsOur cardiac monitoring and INR testing businesses are dependent upon physicians prescribing our services and failure to obtainthose prescriptions may adversely affect our revenue.The success of our cardiac monitoring and INR testing businesses are dependent upon physicians prescribing our services. Oursuccess in obtaining prescriptions will be directly influenced by a number of factors, including:•the ability of the physicians with whom we work to obtain sufficient reimbursement and be paid in a timely manner for theprofessional services they provide in connection with the use of our cardiac monitoring solutions;•our ability to continue to establish ourselves as a comprehensive cardiac monitoring and INR services provider;•our ability to educate physicians regarding the benefits of our services over alternative diagnostic monitoring solutions; and•the clinical efficacy of our devices.If we are unable to educate physicians regarding the benefits of our products and obtain sufficient prescriptions for our services,revenue from the provision of our cardiac monitoring and INR solutions could potentially decrease.If we are unable to provide service in a timely manner, physicians may elect not to prescribe our services, and our revenue andgrowth prospects may be adversely affected.While our goal is to provide each patient with the appropriate device in a timely manner, we have experienced, and may in thefuture experience, service delays or delays due to the availability of devices. This can occur when converting to a new generation ofdevice or in connection with the increase in prescriptions following acquisitions of other companies.We may also experience shortages of devices due to manufacturing difficulties. Multiple suppliers provide the components usedin our devices, but our Minnesota and Massachusetts facilities are registered and approved by the FDA as the manufacturer of recordof our devices. Our manufacturing operations could be disrupted by fire, earthquake or other natural disaster, a labor-related disruption,failure in supply or other logistical channels, electrical outages or other reasons. If there were a disruption to our facilities in Minnesotaor Massachusetts, we would be unable to manufacture devices until we have restored and re-qualified our manufacturing capability ordeveloped alternative manufacturing facilities.Our success in obtaining future cardiac monitor prescriptions from physicians is dependent upon our ability to promptly deliverdevices to our patients, and a failure in this regard would have an adverse effect on our revenue and growth prospects.We are increasingly dependent on sophisticated information technology systems to operate our business, and if we fail to properlymaintain the integrity of our data or if our products do not operate as intended or we experience a cyber-attack or other breach ofthese systems, our business could be materially affected.We are increasingly dependent on sophisticated information technology for our products and infrastructure. We rely oninformation technology systems to process, transmit and store electronic information in our day-to-day operations. The size andcomplexity of our information technology systems makes them vulnerable to increasingly sophisticated cyber-attacks, maliciousintrusion, breakdown,19Table of Contentsdestruction, loss of data privacy or other significant disruption. Our information systems require an ongoing commitment of significantresources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes ininformation processing technology, evolving systems and regulatory standards, the increasing need to protect patient and customerinformation and changing customer patterns. As a result of technology initiatives, recently enacted regulations, changes in our systemplatforms and integration of new business acquisitions, we have been consolidating and integrating the number of systems we operateand have upgraded and expanded our information systems capabilities.In addition, third parties may attempt to hack into our products or systems and may obtain data relating to patients with ourproducts or our proprietary information. If we fail to maintain or protect our information systems and data integrity effectively, wecould lose existing customers, have difficulty attracting new customers, have problems in determining product cost estimates andestablishing appropriate pricing, have difficulty preventing, detecting and controlling fraud, have disputes with customers, physiciansand other health care professionals, have regulatory sanctions or penalties imposed, have increases in operating expenses, incurexpenses or lose revenue as a result of a data privacy breach or suffer other adverse consequences. There can be no assurance that ourprocess of consolidating the number of systems we operate, upgrading and expanding our information systems capabilities, protectingand enhancing our systems and developing new systems to keep pace with continuing changes in information processing technologywill be successful or that additional systems issues will not arise in the future. Any significant breakdown, intrusion, interruption,corruption or destruction of these systems, as well as any data breaches, could have a material adverse effect on our business.Violation of federal and state laws regarding privacy and security of patient information may adversely affect our business,financial condition or operations.The use and disclosure of certain health care information by HIPAA-covered entities and their business associates have comeunder increased public scrutiny. Federal standards under HIPAA establish rules concerning how individually-identifiable healthinformation may be used, disclosed and protected. Historically, state law had governed confidentiality issues, and HIPAA preservesthese laws to the extent they are more protective of a patient’s privacy or provide the patient with more access to his or her healthinformation. Additionally, changes to HIPAA (e.g. HITECH) impose additional requirements relating to the privacy, security andtransmission of individually identifiable health information. We must operate our business in a manner that complies with all applicablelaws, both federal and state, and that does not jeopardize the ability of our customers to comply with all applicable laws. We believethat our operations are consistent with these legal standards. Nevertheless, these laws and regulations present risks for covered entitiesand their business associates that provide services to patients in multiple states. As we continue to see how government regulators andcourts interpret and enforce HIPAA’s requirements, we may need to adjust our interpretations of these laws and regulations over time.If a challenge to our activities is successful, it could have an adverse effect on our operations, may require us to forgo relationships withcustomers in certain states and may restrict the territory available to us to expand our business. In addition, even if our interpretations ofHIPAA and other federal and state laws and regulations are correct, we could be held liable for unauthorized uses or disclosures ofpatient information as a result of inadequate systems and controls to protect this information or as a result of the theft of information byunauthorized computer programmers who penetrate our network security.Violation of these laws against us could have a material adverse effect on our business, financial condition and results ofoperations. For example, in 2011, we experienced the theft of two unencrypted laptop computers and, as a result, were required toprovide notices under the HIPAA Breach Notification Rule and were subsequently investigated by the United States Department ofHealth and Human20Table of ContentsServices’ (“HHS”) Office for Civil Rights (“OCR”). Although we have been in compliance with our obligations stemming from theseincidents, and believe that our operations are consistent with the legal standards imposed by HIPAA, to avoid the uncertainty ofadministrative enforcement proceedings or protracted litigation, we elected to settle the investigation by OCR in April 2017 by paying$2.5 million and entering into a 3-year corrective action plan. This settlement did not contain any admission of liability by us.The FDA may recommend a different approach to measuring the cardiac impact and safety of drugs as part of the approvalprocess. Such changes could make the systems and processes of our research segment obsolete and adversely affect revenue andprofitability.As part of its approval process, the FDA has provided guidance reinforcing the need for cardiac safety testing of all compoundsentering the blood stream. The requirements vary based on the type and history of each compound. This testing is accomplished bydifferent methods, including cardiac imaging such as MUGA and ECG analysis, which involves measuring the QT/QTc interval forprolongation. We function as a core lab and have developed proprietary systems and processes to receive cardiac imaging studies andECGs for analysis. It is possible that, in the future, the FDA may recommend a different approach for evaluating the cardiac impactand safety of compounds which may diminish the need for a core lab. This would considerably reduce the value of our existingsystems and processes and would substantially decrease our revenue and profitability in our Research segment.In December 2015, the FDA published a report which called into question the need for certain QT studies. In a series of publicmeetings throughout 2016 discussing the report, FDA speakers indicated that certain studies were no longer mandatory and that futureregulations will include some combination of traditional study types along with early phase Exposure Response modeling. Furtherguidance around the performance of QT studies from the FDA is expected. We cannot assess the impact of this expected guidance atthis time, but it may substantially decrease our revenue and profitability in our Research segment.We are subject to numerous FDA regulations and decisions, and it may be costly to comply with these regulations and decisionsand to develop compliant products and processes.The devices that we manufacture are classified as medical devices and are subject to extensive regulation by the FDA. Further,we maintain establishment registration with the FDA as a distributor of medical devices. FDA regulations govern manufacturing,labeling, promotion, distribution, importing, exporting, shipping, advertising, promotion and sale of these devices. Our devices and ourarrhythmia detection algorithms have 510(k) clearance status from the FDA. Modifications to our devices or our algorithms that couldsignificantly affect safety or effectiveness, or that could constitute a significant change in intended use, would require a new clearancefrom the FDA. If in the future we make changes to our devices or our algorithms, the FDA could determine that such modificationsrequire new FDA clearance, and we may not be able to obtain such FDA clearances timely, or at all.We are subject to continuing regulation by the FDA, including general controls, special controls and quality system regulationsapplicable to the manufacture of our devices and various reporting regulations, as well as regulations that govern the promotion andadvertising of medical devices. The FDA could find that we have failed to comply with one of these requirements, which could resultin a wide variety of enforcement actions, ranging from a warning letter to one or more severe sanctions. These sanctions could includecriminal fines, injunctions and civil money penalties; recall or seizure of devices; operating restrictions, partial suspension or totalshutdown of production; refusal to grant 510(k) clearance of new components or algorithms; withdrawing 510(k) clearance alreadygranted to one or more of our21Table of Contentsexisting components or algorithms; and criminal prosecution. Any of these enforcement actions could be costly and significantly harmour business, financial condition and results of operations.The healthcare industry is the subject of numerous governmental investigations into marketing and other business practices. Theseinvestigations could result in the commencement of civil and/or criminal proceedings, substantial fines, penalties, and/oradministrative remedies, divert the attention of our management, and have an adverse effect on our financial condition and resultsof operations.As mentioned above, we are subject to rigorous regulation by the FDA and numerous other federal, state and foreigngovernmental authorities. These authorities have been increasing their scrutiny of our industry. We occasionally receive subpoenas orother requests for information from state and federal governmental agencies, including, among others, the United States Department ofJustice and the Office of Inspector General of HHS. These investigations typically relate primarily to financial arrangements withhealth care providers, regulatory compliance and product promotional practices.We cooperate with these investigations and respond to such requests. However, when an investigation begins, we cannotpredict when it will be resolved, the outcome of the investigation or its impact on us. An adverse outcome in one or more of theseinvestigations could include the commencement of civil and/or criminal proceedings, substantial fines, penalties and/or administrativeremedies, including exclusion from government reimbursement programs and entry into Corporate Integrity Agreements withgovernmental agencies. In addition, resolution of any of these matters could involve the imposition of additional and costly complianceobligations. Finally, if these investigations continue over a long period of time, they could divert the attention of management from theday-to-day operations of our business and impose significant administrative burdens, including cost, on us. These potentialconsequences, as well as any adverse outcome from these investigations or other investigations initiated by the government at any time,could have a material adverse effect on our financial condition and results of operations.Resolution of income tax matters may impact our financial condition, results of operations and cash flows.We are subject to income taxes in many U.S. and certain foreign jurisdictions, which requires significant judgment indetermining our effective income tax rate and in evaluating tax positions, particularly those related to uncertain tax positions. We haveprovided for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standardsprescribed by the accounting standard for uncertain tax positions. Changes in uncertain tax positions or other adjustments resultingfrom tax audits and settlements with taxing authorities, including related interest and penalties, impact our effective tax rate. Whenparticular tax matters arise, a number of years could elapse before such matters are audited and finally resolved. We believe ourpositions are appropriate, however, federal, state, or foreign tax authorities could disagree. If the settlement of any unrecognized taxreserves is different than accrued, it would impact our effective rate in the year of resolution. Any resolution of a tax matter may requirethe adjustment of tax assets or tax liabilities and/or the use of cash in the year of resolution.Our business is subject to the risks of international operations.Compliance with applicable United States and foreign laws and regulations, such as import and export requirements, anti-corruption laws, tax laws, foreign exchange controls and cash repatriation restrictions, data privacy requirements (e.g. GDPR),environmental laws, labor laws and anti-competition regulations, increases the costs of doing business in foreign jurisdictions.Although we have implemented policies and procedures to comply with these laws and regulations, a violation by our employees,contractors or agents could nevertheless occur. In some cases, compliance with the laws and regulations of one country22Table of Contentscould violate the laws and regulations of another country. Violations of these laws and regulations could materially adversely affect ourbrand, international growth efforts and business.If we do not obtain and maintain adequate protection for our intellectual property, it may adversely affect the value of ourtechnology and devices and future revenue and operating income.Our business and competitive positions are in part dependent upon our ability to protect our proprietary technology. To protectour proprietary rights, we rely on a combination of trademark, copyright, patent, trade secret and other intellectual property laws,employment, confidentiality and invention assignment agreements with our employees and contractors, and confidentiality agreementsand protective contractual provisions with other third parties. We attempt to protect our intellectual property position by filingtrademark applications and United States and international patent applications related to our proprietary technology, inventions andimprovements that are important to the development of our business.We do not believe that any single patent, trademark or other intellectual property right of ours, or combination of ourintellectual property rights, is likely to prevent others from competing with us using a similar business model. There are many issuedpatents and patent applications held by others in our industry and the electronics field. Our competitors may independently developtechnologies that are substantially similar or superior to our technologies, or design around our patents or other intellectual property toavoid infringement. In addition, we may not apply for a patent relating to products or processes that are patentable, we may fail toreceive any patent for which we apply or have applied, and any patent owned by us or issued to us could be circumvented, challenged,invalidated, or held to be unenforceable or rights granted thereunder may not adequately protect our technology or provide acompetitive advantage to us. If a third-party challenges the validity of any patents or proprietary rights of ours, we may becomeinvolved in intellectual property disputes and litigation that would be costly and time-consuming. All of our patents will eventuallyexpire. Some of our patents, including patents protecting significant elements of our technology, have expiration dates through 2032, atwhich point we can no longer enforce these against third parties to prevent them from making, using, selling, offering to sell orimporting our current clinical device. While we have several patents that have expiration dates through 2032, including patents thatrelate, in part, to our key products, our technology is typically covered by several patents, creating a system of protected technology.The expiration of our patents could expose us to more competition and have an adverse impact on our business.Although third parties may infringe on our patents and other intellectual property rights, we may not be aware of any suchinfringement, or we may be aware of potential infringement but elect not to seek to prevent such infringement or pursue any claim ofinfringement, and the third-party may continue its potentially infringing activities. Any decision whether or not to take further action inresponse to potential infringement of our patent or other intellectual property rights may be based on a variety of factors, such as thepotential costs and benefits of taking such action, and business and legal issues and circumstances. Litigation of claims of infringementof a patent or other intellectual property rights may be costly and time-consuming, may divert the attention of key managementpersonnel and may not be successful or result in any significant recovery of compensation for any infringement or enjoining of anyinfringing activity. Litigation or licensing discussions may also involve or lead to counterclaims that could be brought by a potentialinfringer to challenge the validity or enforceability of our patents and other intellectual property.To protect our trade secrets and other proprietary information, we generally require our employees, consultants, contractors andoutside collaborators to enter into written non-disclosure agreements. These agreements, however, may not provide adequate protectionto prevent any unauthorized use, misappropriation or disclosure of our trade secrets, know-how or other proprietary information. These23Table of Contentsagreements may be breached, and we may not become aware of, or have adequate remedies in the event of, any such breach. Also,others may independently develop the same or substantially equivalent proprietary information and techniques or otherwise gain accessto our trade secrets.Our ability to innovate or market our products may be impaired by the intellectual property rights of third parties.Our success is dependent, in part, upon our ability to avoid infringing the patents or proprietary rights of others. The cardiacmonitoring industry is characterized by a large number of patents and patent filings. Competitors may have filed applications for, orhave been issued, patents and may obtain additional patents and proprietary rights related to devices, services or processes that we useto compete. We may not be aware of all of the patents or patent applications potentially adverse to our interests that may have beenfiled or issued to others.United States patent applications may be kept confidential while pending in the Patent and Trademark Office. If othercompanies have or obtain patents relating to our products or services, we may be required to obtain licenses to those patents or todevelop or obtain alternative technology. We may not be able to obtain any such licenses on acceptable terms, or at all. Any failure toobtain such licenses could impair or foreclose our ability to make, use, market or sell our products and services.Based on the fact that we may pose a competitive threat to some companies who own or control various patents, it is possiblethat one or more third parties may assert a patent infringement claim seeking damages and to enjoin the manufacture, use, sale andmarketing of our products and services. If a third-party asserts that we have infringed on its patent or proprietary rights, we maybecome involved in intellectual property disputes and litigation that would be costly and time-consuming and could impair or forecloseour ability to make, use, market or sell our products and services. Lawsuits may have already been filed against us without ourknowledge. Additionally, we may receive notices from other third parties suggesting or asserting that we are infringing their patentsand inviting us to license such patents. We do not believe that we are infringing on any other party’s patents or that a license to anysuch patents is necessary. Should litigation over such patents arise, we intend to vigorously defend against any allegation ofinfringement.If we are found to infringe on the patents or intellectual property rights of others, we may be required to pay damages, stop theinfringing activity or obtain licenses or rights to the patents or other intellectual property in order to use, manufacture, market or sell ourproducts and services. Any required license may not be available to us on acceptable terms, or at all. If we succeed in obtaining suchlicenses, payments under such licenses would reduce any earnings from our products. In addition, licenses may be non-exclusive and,accordingly, our competitors may have access to the same technology as that which may be licensed to us. If we fail to obtain arequired license or are unable to alter the design of our product candidates to make a license unnecessary, we may be unable tomanufacture, use, market or sell our products and services, which could significantly affect our ability to achieve, sustain or grow ourcommercial business.We may not be able to consummate future acquisitions or successfully integrate acquisitions into our business, which could resultin unanticipated expenses and losses.We have grown, in part, through acquisitions of companies and technology, including our acquisitions of the assets of theePatch Division of DELTA Danish Electronics, Light & Acoustics (“DELTA”) in April 2016, VirtualScopics in May 2016, Telcarein December 2016 and LifeWatch in July 2017. Our strategy is largely based on our ability to grow through acquisitions of additionalbusinesses to build an integrated group. Consummating acquisitions of related businesses, or our failure to integrate24Table of Contentssuch businesses successfully into our existing businesses, could result in unanticipated expenses and losses. Furthermore, we may notbe able to realize any of the anticipated benefits from acquisitions.We anticipate that any future acquisitions we may pursue as part of our business strategy may be partially financed throughadditional debt or equity. If new debt is added to current debt levels, or if we incur other liabilities, including contingent liabilities, inconnection with an acquisition, the debt or liabilities could impose additional constraints and requirements on our business andoperations, which could materially adversely affect our financial condition and results of operation. In addition, to the extent ourcommon stock is used for all or a portion of the consideration to be paid for future acquisitions, dilution may be experienced byexisting stockholders.In connection with our completed and future acquisitions, the process of integrating acquired operations into our existing groupoperations may result in unforeseen operating difficulties and may require significant financial resources that would otherwise beavailable for the ongoing development or expansion of existing operations. Some of the risks associated with acquisitions include:•unexpected losses of key employees or customers of the acquired company;•conforming the acquired company’s standards, processes, procedures and controls with our operations;•negotiating with labor unions; and•increasing the scope, geographic diversity and complexity of our current operations.We may encounter unforeseen obstacles or costs in the integration of businesses that we may acquire. In addition, generaleconomic and market conditions or other factors outside of our control could make our operating strategies difficult or impossible toimplement. Any failure to implement these operational improvements successfully and/or the failure of these operational improvementsto deliver the anticipated benefits could have a material adverse effect on our results of operations and financial condition.Any due diligence by us in connection with an acquisition may not reveal all relevant considerations or liabilities of the targetbusiness, which could have a material adverse effect on our financial condition or results of operations.We intend to conduct such due diligence as we deem reasonably practicable and appropriate based on the facts andcircumstances applicable to any potential acquisition. The objective of the due diligence process will be to identify material issueswhich may affect the decision to proceed with any one particular acquisition target or the consideration payable for an acquisition. Wealso intend to use information revealed during the due diligence process to formulate our business and operational planning for, and ourvaluation of, any target company or business. While conducting due diligence and assessing a potential acquisition, we may rely onpublicly available information, if any, information provided by the relevant target company to the extent such company is willing orable to provide such information and, in some circumstances, third party investigations.There can be no assurance that the due diligence undertaken with respect to an acquisition will reveal all relevant facts that maybe necessary to evaluate such acquisition including the determination of the price we may pay for an acquisition target or to formulate abusiness strategy. Furthermore, the information provided during due diligence may be incomplete, inadequate or inaccurate. As part ofthe due diligence process, we will also make subjective judgments regarding the results of operations, financial condition and prospectsof a potential target. If the due diligence investigation fails to correctly identify25Table of Contentsmaterial issues and liabilities that may be present in a target company or business, or if we consider such material risks to becommercially acceptable relative to the opportunity, and we proceed with an acquisition, we may subsequently incur substantialimpairment charges or other losses.In addition, following an acquisition, we may be subject to significant, previously undisclosed liabilities of the acquiredbusiness that were not identified during due diligence and which could contribute to poor operational performance, undermine anyattempt to restructure the acquired company or business in line with our business plan and have a material adverse effect on ourfinancial condition and results of operations.The success of our business is partially dependent on our ability to raise capital, and failure to raise the necessary capital mayadversely affect our results of operations, financial condition and stock price.We believe that our existing cash and cash equivalents, together with our term loan and revolving credit facility pursuant to ourCredit Agreement with SunTrust Bank and Lenders named therein (the “SunTrust Credit Agreement” and “Lenders”,respectively), will be sufficient to meet our anticipated cash requirements for the foreseeable future. However, our future fundingrequirements will depend on many factors, including:•the results of our operations;•the reimbursement rates associated with our products and services;•our ability to secure contracts with additional commercial payors providing for the reimbursement of our services;•the costs associated with manufacturing and building our inventory of our current and future generation monitors;•the costs of hiring additional personnel and investing in infrastructure to support future growth;•the costs of undertaking future strategic initiatives, such as acquisitions or joint ventures;•the emergence of competing technologies and products and other adverse market developments;•the costs of preparing, filing, prosecuting, maintaining and enforcing patent claims and other intellectual property rights ordefending against claims of infringement by others; and•actions taken by the FDA, CMS and other regulatory authorities affecting cardiac monitoring devices and competitiveproducts.If we decide to raise additional capital in the future, such capital may not be available on reasonable terms, or at all. If we raiseadditional funds by issuing equity securities, dilution to existing stockholders would result. If we raise additional funds by incurringdebt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and financial ratios thatmay restrict our ability to operate our business.We have outstanding debt, and may incur other debt in the future, which could adversely affect our financial condition, liquidityand results of operations.As of December 31, 2018, we had an outstanding term loan pursuant to our SunTrust Credit Agreement with the Lenders of$198.5 million, net of $4.4 million of deferred financing costs. We may26Table of Contentsborrow additional amounts in the future and use the proceeds from any future borrowing for general corporate purposes, futureacquisitions or expansion of our business.Our incurrence of this debt, and any increases in our levels of debt, may adversely affect our operating results and financialcondition by, among other things:•requiring a portion of our cash flow from operations to make payments on this debt; or•limiting our flexibility in planning for, or reacting to, changes in our business and the industry.Our current credit facility imposes restrictions on us, including restrictions on our ability to create liens on our assets, incuradditional indebtedness, make acquisitions or dispose of assets, and also requires us to maintain compliance with specified financialratios. Our ability to comply with these ratios may be affected by events beyond our control. If we breach any of the covenants and donot obtain a waiver from our lender, then, subject to applicable cure periods, our outstanding indebtedness could be declaredimmediately due and payable.Our financing costs may be adversely affected by changes in LIBOR.LIBOR, the London interbank offered rate, is the basic rate of interest used in lending between banks on the London interbankmarket and is widely used as a reference for setting the interest rate on loans globally. We use LIBOR as a reference rate in our termloan and revolving credit facility to calculate interest due to our lender. On July 27, 2017, the United Kingdom’s Financial ConductAuthority, which regulates LIBOR, announced its intention to phase out LIBOR by the end of 2021. It is unclear if LIBOR will ceaseto exist at that time or if new methods of calculating LIBOR will be established such that it continues to exist after 2021. If LIBORceases to exist, we may need to renegotiate our SunTrust Credit Agreement with the Lenders. This could have an adverse effect on ourfinancing costs.Our business depends on our ability to attract and retain talented employees.Our business is based on successfully attracting and retaining talented employees, including our executive team. The market forhighly-skilled workers and leaders in our industry is extremely competitive. If we are less successful in our recruiting efforts, or if weare unable to retain key employees, our ability to develop and deliver successful products and services may be adversely affected.We have a concentration of risk related to the accounts receivable from Medicare and failure to fully collect outstanding balancesfrom this customer, or a combination of other customers, may adversely affect our results of operations.As of December 31, 2018, we have balances owed to us from Medicare representing approximately 15% of our total grossaccounts receivable. A change in our collection trends could have an adverse effect on our financial condition and operating results.Interruptions or delays in telecommunications systems could impair the delivery of our MCT, BGM and wireless event services.The success of our MCT, BGM and wireless event services is dependent upon our ability to transmit and process data. OurMCT, BGM and wireless event devices rely on third-party wireless carriers to transmit data over their data networks. We aredependent upon these third-party wireless carriers to provide data transmission services to us through our various agreements. If we failto maintain these relationships, or if we lose wireless carrier services, we would be forced to seek alternative providers of datatransmission services, which might not be available on commercially reasonable terms, or at all.27Table of ContentsAs we expand our commercial activities, an increased burden will be placed upon our data processing systems and theequipment upon which they rely. Interruptions of our data networks, or the data networks of our wireless carriers for any extendedlength of time, loss of stored data or other computer problems could have a material adverse effect on our business and operatingresults. Frequent or persistent interruptions in our cardiac monitoring services could cause permanent harm to our reputation and couldcause current or potential users of our remote monitoring services or prescribing physicians to believe that our systems are unreliable,leading them to switch to our competitors. Such interruptions could result in liability claims and litigation against us for damages orinjuries resulting from the disruption in service.Our business may be impacted by political events, war, terrorism, public health issues, natural disasters and other businessinterruptions.War, terrorism, geopolitical uncertainties, public health issues and other business interruptions have caused and could causedamage or disruption to commerce and the economy, and thus could have a material adverse effect on us, our suppliers, logisticsproviders and customers. Our business operations are subject to interruption by, among others, natural disasters, whether as a result ofclimate change or otherwise, fire, power shortages, nuclear power plant accidents and other industrial accidents, terrorist attacks andother hostile acts, labor disputes, public health issues and other events beyond our control. Such events could decrease demand for ourproducts, make it difficult or impossible for us to make and deliver products to our customers or to receive components from oursuppliers, and create delays and inefficiencies in our supply chain. Our potential customers and monitoring centers could be impactedby natural disasters such as hurricanes, tornadoes and earthquakes. In the event of a natural disaster, we could incur significant losses,require substantial recovery time and experience significant expenditures in order to resume operations.New products and technological advances by our competitors may negatively affect our market share, commercial opportunitiesand results of operations.The market for cardiac monitoring solutions is evolving rapidly and becoming increasingly competitive. The mobile cardiacmonitoring industry in the U.S. is highly fragmented and characterized by a number of smaller regional service providers. These thirdparties compete with us in marketing to payors and prescribing physicians, recruiting and retaining qualified personnel, acquiringtechnology and developing solutions complementary to our programs. In addition, as companies with substantially greater resourcesthan ours enter our market, we will face increased competition. If our competitors are better able to develop and patent cardiacmonitoring solutions than us, or develop more effective or less expensive cardiac monitoring solutions that render our solutionsobsolete or non-competitive, or deploy larger or more effective marketing and sales resources than ours, our business would be harmedand our commercial opportunities would be reduced or eliminated.Our efforts to develop new products may not be successful or the new products may not provide the revenue we expect.We plan to add to our product portfolio through internal development efforts, acquisitions and other strategic partnerships. Tobe successful, we must continue to develop and commercialize new products and to enhance versions of our existing products. Ourproducts are technologically complex and require significant research, planning, design, development and testing before they may bemarketed. These new products and technologies may fail to reach the market or may only have limited commercial success because of:•efficacy or safety concerns;28Table of Contents•the limited scope of approved uses;•excessive costs to manufacture, failure to establish or maintain intellectual property rights, or infringement of the intellectualproperty rights of others;•inability to achieve positive clinical outcomes;•inability to recruit engineers;•inability to timely and accurately identify new market trends;•inability to assess customer needs;•inability to obtain necessary regulatory approvals or minimize related costs;•inability to adopt competitive pricing;•inability to timely manufacture and deliver products;•inability to accurately predict and control costs associated with the development, manufacturing and support of our products;and•inability to anticipate and compete effectively with our competitors’ efforts.Even if we successfully develop new products or enhancements or new generations of our existing products, they may bequickly rendered obsolete by changing customer preferences, changing industry standards, or competitors’ innovations. Innovationsmay not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertaintyover third-party reimbursement. We cannot provide certainty as to when or whether any of our products under development will belaunched, whether we will be able to develop, license, or otherwise acquire products, or whether any products will be commerciallysuccessful. Failure to launch successful new products or technologies, or new indications or uses for existing products, may cause ourproducts or technologies to become obsolete, causing our revenues and operating results to suffer.We operate in an intensely competitive industry, and our failure to respond quickly to technological developments and incorporatenew features into our products could harm our ability to compete.We operate in an intensely competitive industry that experiences rapid technological developments, changes in industrystandards, changes in patient requirements and frequent new product introductions and improvements. If we are unable to respondquickly and successfully to these developments, we may lose our competitive position, and our products or technologies may becomeuncompetitive or obsolete. To compete successfully, we must maintain a successful research and development effort, develop newproducts and production processes and improve our existing products and processes at the same pace or ahead of our competitors. Ourresearch and development efforts are aimed at solving increasingly complex problems, as well as creating new technologies, and we donot expect that all of our projects will be successful. If our research and development efforts are unsuccessful, our future results ofoperations could be materially affected.29Table of ContentsChanges in the health care industry or tort reform could reduce the number of cardiac monitoring solutions ordered by physicians,which could result in a decline in the demand for our solutions, pricing pressure and decreased revenue.Changes in the health care industry directed at controlling health care costs or perceived over-utilization of cardiac monitoringsolutions could reduce the volume of services ordered by physicians. If more health care cost controls are broadly instituted throughoutthe health care industry, the volume of cardiac monitoring solutions could decrease, resulting in pricing pressure and declining demandfor our services, which could harm our operating results. In addition, it has been suggested that some physicians order cardiacmonitoring solutions, even when the services may have limited clinical utility, primarily to establish a record for defense in the event ofa claim of medical malpractice against the physician. Legal changes increasing the difficulty of initiating medical malpractice cases,known as tort reform, could reduce the number of our services prescribed as physicians respond to reduced risks of litigation, whichcould harm our operating results.Legislation and policy changes reforming the United States health care system may have a material adverse effect on our operatingresults and financial condition.The ACA makes the most sweeping and fundamental changes to the United States health care system since the creation ofMedicare and Medicaid. The ACA includes a large number of health-related provisions expanding Medicaid eligibility, requiring mostindividuals to have health insurance, establishing new regulations on health plans, establishing health insurance exchanges, requiringmanufacturers to report payments or other transfers of value made to physicians and teaching hospitals and modifying certain paymentsystems to encourage more cost-effective care.Several provisions of the ACA specifically affect the medical equipment industry. In addition to changes in MedicareDMEPOS reimbursement and an expansion of the DMEPOS competitive bidding program, the ACA provides that for sales on or afterJanuary 1, 2013, manufacturers, producers and importers of taxable medical devices must pay an annual excise tax of 2.3% of the pricefor which the devices are sold. Subsequent legislation, the Consolidated Appropriations Act of 2016, included a two-year moratoriumon the medical device excise tax commencing on January 1, 2016 and ending on December 31, 2017. Budget legislation signed inJanuary 2018 extended that moratorium through December 31, 2019.The ACA also establishes enhanced Medicare and Medicaid program integrity provisions, including expanded documentationrequirements for Medicare DMEPOS orders, more stringent procedures for screening Medicare and Medicaid DMEPOS suppliers, andnew disclosure requirements regarding manufacturer payments to physicians and teaching hospitals, along with broader expansion offederal fraud and abuse authorities. Subsequent legislation made additional changes to the DMEPOS reimbursement policy. Forinstance, the Consolidated Appropriations Act of 2016 caps Medicaid durable medical equipment reimbursement rates at Medicare fee-for-service rates applicable in the state, including applicable competitive bidding rates, beginning January 1, 2019, and the 21stCentury Cures Act moved up implementation of this provision to January 1, 2018. There can be no assurances that future legislationwill not adversely impact reimbursement for our products and services.In addition, various health care reform proposals have also emerged at the state level. We cannot predict the full effect that theselaws or any future legislation or regulation will have on us. However, the implementation of new legislation and regulation may lowerreimbursements for our products, reduce medical prescriptions for our services and adversely affect our business.30Table of ContentsIf we or our suppliers fail to achieve or maintain regulatory approval of manufacturing facilities, our growth could be limited andour business could be adversely affected.We currently assemble and manufacture our cardiac monitoring and BGM devices. We purchase INR monitoring devices fromthird parties. In order to maintain compliance with FDA and other regulatory requirements, our manufacturing facilities must beperiodically reevaluated and qualified under a quality system to ensure they meet production and quality standards. Suppliers ofcomponents and products used to manufacture MCT, BGM, event, and Holter devices and the manufacturers of the monitors used inINR services must also comply with FDA regulatory requirements, which often require significant resources and subject us and oursuppliers to potential regulatory inspections and stoppages. If we or our suppliers do not maintain regulatory approval for ourmanufacturing operations, our business could be adversely affected.If we fail to meet Medicare accreditation and surety bond requirements or DMEPOS supplier standards, it could negatively affectour business operations.Medicare DMEPOS suppliers (other than certain exempted professionals) must be accredited by an approved accreditationorganization as meeting DMEPOS quality standards adopted by CMS. Medicare suppliers also are required to meet surety bondrequirements. In addition, Medicare DMEPOS suppliers must comply with Medicare supplier standards in order to obtain and retainbilling privileges, including meeting all applicable federal and state licensure and regulatory requirements. Furthermore, many of ourmanaged care contracts for the provision of diabetes services require that we qualify as an accredited DMEPOS supplier. CMSperiodically expands or otherwise clarifies the Medicare DMEPOS supplier standards. We believe we are in compliance with theserequirements. If we fail to maintain our Medicare accreditation status and/or do not comply with Medicare surety bond or supplierstandard requirements in the future, or if these requirements are changed or expanded, it could adversely affect our profits and results ofoperations.Our dependence on a limited number of suppliers may prevent us from delivering our devices on a timely basis.We currently rely on a limited number of suppliers of components for the devices that we manufacture. If these suppliersbecame unable to provide components in the volumes needed, which has occurred, or at an acceptable price, we would have toidentify and qualify acceptable replacements from alternative sources of supply. The process of qualifying suppliers is lengthy. Delaysor interruptions in the supply of our required components could limit or stop our ability to provide sufficient quantities of devices on atimely basis and meet demand for our services, which could have a material adverse effect on our business, financial condition andresults of operations.We could be subject to medical liability or product liability claims, which may not be covered by insurance and which wouldadversely affect our business and results of operations.The design, manufacture and marketing of services of the types we provide entail an inherent risk of product liability claims.Any such claims against us may require us to incur significant defense costs, irrespective of whether such claims have merit. Inaddition, we provide information to health care providers and payors upon which determinations affecting medical care are made, andclaims may be made against us resulting from adverse medical consequences to patients resulting from the information we provide. Inaddition, we may become subject to liability in the event that the devices we use fail to correctly record or transfer patient informationor if we provide incorrect information to patients or health care providers using our services.31Table of ContentsOur liability insurance is subject to deductibles and coverage limitations. In addition, our current insurance may not continue tobe available to us on acceptable terms, if at all, and, if available, the coverage may not be adequate to protect us against any futureclaims. If we are unable to obtain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protectagainst any claims against us, we would be exposed to significant liabilities, which may adversely affect our business and results ofoperations.Our products may in the future be subject to product recalls that could harm our reputation and product liability claims.The FDA has the authority to require the recall of commercialized products in the event of material regulatory deficiencies ordefects in design or manufacture. Any recalls of our products or products that we distribute would divert managerial and financialresources, harm our reputation with customers and have an adverse effect on our financial condition and results of operations.Regulations related to conflict minerals may adversely impact our business.The Dodd-Frank Wall Street Reform and Consumer Protection Act contains provisions to improve transparency andaccountability concerning the supply of certain minerals, known as conflict minerals, originating from the DRC. Due to the materialsused in certain of the products manufactured by our subsidiaries, we must comply with annual disclosure and reporting rules adoptedby the SEC by assessing whether the subject minerals contained in our products originated in the DRC. Our supply chain is complexsince we do not source our minerals directly from the original mine or smelter. Consequently, we incur costs in complying with thesedisclosure requirements, including for due diligence to determine the source of the subject minerals used in our products and otherpotential changes to products, processes or sources of supply as a consequence of such verification activities. The rules may adverselyaffect the sourcing, supply and pricing of materials used in our products throughout the supply chain beyond our control, whether ornot the subject minerals are “conflict free.” Also, we may face reputational challenges if we determine that certain of our productscontain minerals not determined to be conflict free or if we are unable to sufficiently verify the origins for all subject minerals used inour products through our diligence process.We are reliant on the outsourcing of clinical research by pharmaceutical, clinical research and biotechnology companies.We are reliant on the ability and willingness of pharmaceutical, clinical research and biotechnology companies to continue tooutsource the types of research services that we provide. As such, we are impacted and subject to risks, uncertainties and trends thataffect companies in these industries. Any downturn in these industries or reduction in spending or outsourcing could adversely affectour business.Future sales of our common stock may depress our stock price.Future issuances in connection with acquisitions and sales of a substantial number of shares of our common stock in the publicmarket could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sellshares, could reduce the market price of our common stock. As of December 31, 2018, we had 33,406,364 outstanding shares ofcommon stock. In addition, as of December 31, 2018, we had 2,661,282 stock options, 358,683 restricted stock units (“RSUs”) and87,109 performance stock units (“PSUs”) outstanding to purchase shares of our common stock that will become exercisable over thenext four years or vest over the next three years. Further, we had 135,000 performance stock options that are exercisable as ofDecember 31, 2018. If exercised, vested or earned, additional shares would become available for sale.32Table of ContentsIn addition, in connection with the acquisition of Geneva Healthcare, Inc (“Geneva”) discussed under “Item 7:Management’s Discussion and Analysis of Financial Condition - Recent Developments,” each equity holder of Geneva shall beeligible to receive additional consideration on the third anniversary of the closing date based on Geneva’s performance following theclosing (the “Earn-Out Amount”). The Earn-Out Amount will be payable, at the election of the equity holder either (1) 100% in cash,(2) 50% in cash and 50% in shares of BioTelemetry common stock, or (3) 75% in cash and 25% in BioTelemetry common stock. Thenumber of shares of BioTelemetry common stock issuable to each electing equity holder in partial payment of the Earn-Out Amountwill be calculated based on a share price of $67.85.Anti-takeover provisions in our charter documents and Delaware law might deter acquisition bids for us that our stockholdersmight consider favorable.Our amended and restated certificate of incorporation and bylaws contain provisions that may make the acquisition ofBioTelemetry more difficult without the approval of our Board of Directors. These provisions:•establish a classified Board of Directors so that not all members of the board are elected at one time;•authorize the issuance of undesignated preferred stock, the terms of which may be established and shares of which may beissued without stockholder approval, and which may include rights superior to the rights of the holders of common stock;•prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of ourstockholders;•provide that the Board of Directors is expressly authorized to make, alter or repeal our bylaws; and•establish advance notice requirements for nominations for elections to our Board of Directors or for proposing matters thatcan be acted upon by stockholders at stockholder meetings.In addition, because we are incorporated in Delaware, we are subject to Section 203 of the Delaware General Corporation Lawwhich, subject to certain exceptions, prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging orcombining with us. These anti-takeover provisions and other provisions under Delaware law could discourage, delay or prevent atransaction involving a change of control of BioTelemetry, even if doing so would benefit our stockholders. These provisions couldalso discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and cause us to takeother corporate actions such stockholders desire.Our future profitability is uncertain.In recent years we have realized net income. We may not, however, be able to sustain or increase our profitability in the futureon a quarterly or annual basis. While our recent results have been positive, as of December 31, 2018, we had a total accumulateddeficit of approximately $115.9 million.We may not be able to realize our net operating loss carryforwards.We have deferred tax assets that include net operating loss carryforwards that can be used to offset taxable income in futureperiods and reduce income taxes payable in those future periods. The ultimate realization of deferred tax assets is dependent upon thegeneration of future taxable income during the33Table of Contentsperiods in which those temporary differences are deductible. The timing and manner in which we can utilize our net operating losscarryforward and future income tax deductions in any year may be limited by provisions of the Internal Revenue Code (“IRC”)regarding the change in ownership of corporations. Such limitation may have an impact on the ultimate realization of our carryforwardsand future tax deductions. Section 382 of the IRC (“Section 382”) imposes limitations on a corporation’s ability to utilize net operatinglosses if it experiences an “ownership change.” In general terms, an ownership change may result from transactions increasing theownership of certain stockholders in the stock of a corporation by more than 50 percentage points over a three-year period. Anyunused annual limitation may be carried over to later years, and the amount of the limitation may under certain circumstances beincreased by the built-in gains in assets held by us at the time of the change that are recognized in the five-year period after the change.Currently, a portion of our loss carryforwards is limited under Section 382.Item 1B. Unresolved Staff CommentsNone.Item 2. PropertiesAs of December 31, 2018, the following were our material leased facilities:LocationUseSegment/CategorySquarefeetLeaseexpiryMalvern, PACorporate shared services, operations and monitoringH, C&O61,0002021Rosemont, ILCorporate shared services, operations, monitoring anddistributionH, C&O58,0002024Ewing, NJMonitoringH28,0002019Rochester, NYResearch servicesR27,0002028Eagan, MNManufacturingC&O24,0002022San Francisco, CAMonitoring, research servicesH, R20,0002019Chester, PADistribution centerH16,0002020Rockville, MDResearch servicesR13,0002026Phoenix, AZDistribution centerH11,0002020San Diego, CAResearch, development and engineeringC&O8,0002020Norfolk, VAMonitoringH8,0002024Concord, MAResearch and development and distributionC&O7,0002019H = Healthcare segment, R = Research segment, C&O = Corporate and Other categoryWe believe that all of our existing facilities are adequate to meet our current needs and that suitable additional alternative spaceswill be available in the future on commercially reasonable terms.34Table of ContentsItem 3. Legal ProceedingsFrom time to time, in the ordinary course of business and like others in the industry, we receive requests for information fromgovernment agencies in connection with their regulatory or investigational authority or are involved in traditional employment orbusiness litigation. We review such requests and notices and take appropriate action.The final outcome of any current or future litigation or governmental or internal investigations cannot be accurately predicted,nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatoryauthorities. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred andthe amount of the loss can be estimated.For further details on the material legal proceedings to which we are currently a party, which is incorporated herein byreference, please refer to “Part II; Item 8. Financial Statements and Supplementary Data; Notes to Consolidated FinancialStatements; Note 19. Legal Proceedings” below.Item 4. Mine Safety DisclosuresNot Applicable.35Table of ContentsPART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity SecuritiesUnregistered Sales of Equity SecuritiesIn early 2018, in connection with the squeeze-out procedures under Swiss Law related to the acquisition of LifeWatch, weissued 58,786 shares of BioTelemetry Common Stock. The tender offer was subject to a Tier I exemption pursuant to Rule 14d-1(c) of the Exchange Act, as amended, and the issuance of BioTelemetry Common Stock in connection therewith was exempt fromregistration under the Securities Act of 1933, as amended, pursuant to Rule 802 thereof, because Life Watch is a foreign private issuerand U.S. holders held less than 10% of the LifeWatch Shares that were the subject of the tender offer.Market Information for Common StockOur common stock is traded on the NASDAQ Global Select Market under the symbol: “BEAT.”As of February 5, 2019, there were 33,607,798 shares of our common stock outstanding. Also as of that date, we had 60holders of record (this does not include persons whose stock is in nominee or “street name” accounts through brokers).DividendsWe have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds andany future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cashdividends on our common stock for the foreseeable future. Any future determination related to dividend policy will be made at thediscretion of our Board of Directors.Stock Performance GraphThe graph below compares the total stockholder return of an investment of $100 on December 31, 2013 through December 31,2018 for (i) our common stock (ii) The NASDAQ Health Care Index and (iii) The Russell 2000 Index. Each of the three measures ofcumulative total return assumes reinvestment of dividends, if any. The stock price performance shown on the graph below is based onhistorical data and is not indicative of future stock price performance.36Table of ContentsComparison of 5 Year Cumulative Total ReturnAmong BioTelemetry, Inc., The NASDAQ Health Care Indexand The Russell 2000 Index Year Ended December 31,Company/Index2013* 2014 2015 2016 2017 2018BioTelemetry, Inc.100.00 126.32 147.10 281.49 376.57 752.14NASDAQ Health Care Index100.00 128.47 137.28 114.74 140.01 134.92Russell 2000 Index100.00 104.89 100.26 121.63 139.44 124.09* Base Period The foregoing graph and chart shall not be deemed incorporated by reference by any general statement incorporating byreference this Annual Report on Form 10-K into any filing under the Securities Act of 1933, as amended, or under the SecuritiesExchange Act of 1934, as amended, except to the extent we specifically incorporate this information by reference, and shall nototherwise be deemed filed under those acts.Information regarding our equity compensation plans is incorporated by reference from our Proxy Statement, unless our ProxyStatement is not filed on or before May 1, 2019, in which case we will amend this Form 10-K to provide the omitted information inaccordance with the requirements of Instruction G to Form 10-K.Item 6. Selected Financial DataThe selected financial data set forth below are derived from our consolidated financial statements. The statement of operationsdata for the years ended December 31, 2018, 2017 and 2016, and the balance sheet data at December 31, 2018 and 2017 are derivedfrom our audited consolidated financial statements37Table of Contentsincluded elsewhere in this Annual Report on Form 10-K. The statement of operations data for the years ended December 31, 2015 and2014 and the balance sheet data at December 31, 2016, 2015 and 2014 are derived from our audited consolidated financial statements,which are not included herein. Certain reclassifications have been made below to prior period statements to conform to the currentperiod presentation.The following selected financial data should be read in conjunction with “Item 7. Management’s Discussion and Analysis ofFinancial Condition and Results of Operations” and “Item 8. Financial Statements and Supplementary Data” included in thisAnnual Report on Form 10-K.Statement of Operations Data:Year Ended December 31,(in thousands, except per share data)2018 2017 2016 2015 2014Revenue$399,472 $286,776 $208,332 $178,513 $166,578Cost of revenue148,986 114,406 78,882 71,956 73,114Gross profit250,486 172,370 129,450 106,557 93,464Operating expenses: General and administrative109,736 82,983 55,877 47,882 45,131Sales and marketing42,849 35,322 28,636 27,936 28,805Bad debt expense22,222 13,291 9,931 8,047 9,347Research and development11,206 11,101 8,355 7,111 7,396Other charges14,659 31,436 8,639 6,063 7,098Total operating expenses200,672 174,133 111,438 97,039 97,777Income/(loss) from operations49,814 (1,763) 18,012 9,518 (4,313)Other expense: Interest expense(9,429) (4,897) (1,830) (1,534) (713)Loss on extinguishment of debt— (543) — — (372)Loss on equity method investment(246) (384) (287) — —Other non-operating income/(expense), net1,365 (2,809) (125) (88) (6,708)Total other expense(8,310) (8,633) (2,242) (1,622) (7,793)Income/(loss) before income taxes41,504 (10,396) 15,770 7,896 (12,106)Benefit from/(provision for) income taxes370 (6,747) 37,667 (468) 2,313Net income/(loss)41,874 (17,143) 53,437 7,428 (9,793)Net loss attributable to noncontrolling interests(946) (1,187) — — —Net income/(loss) attributable to BioTelemetry, Inc.$42,820 $(15,956) $53,437 $7,428 $(9,793)Net income/(loss) per common share attributable toBioTelemetry, Inc.: Basic$1.31 $(0.53) $1.91 $0.27 $(0.37)Diluted$1.20 $(0.53) $1.75 $0.26 $(0.37)Weighted average number of shares outstanding: Basic32,709 30,386 27,920 27,116 26,445Diluted35,783 30,386 30,489 29,089 26,44538Table of ContentsBalance Sheet Data:December 31,(in thousands)2018 2017 2016 2015 2014Cash and cash equivalents$80,889 $36,022 $23,052 $18,986 $20,007Working capital97,037 39,153 28,053 23,157 13,879Total assets586,801 524,562 198,984 124,143 124,372Total long-term obligations226,693 223,904 28,563 24,329 25,375Total BioTelemetry, Inc.’s stockholders’ equity310,485 250,757 138,914 75,926 63,676Noncontrolling interests— (1,054) — — —Total equity$310,485 $249,703 $138,914 $75,926 $63,67639Table of ContentsItem 7. Management’s Discussion and Analysis of Financial Condition and Results of OperationsYou should read the following discussion and analysis of our financial condition and results of our operations in conjunctionwith our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form10-K. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Ouractual results and the timing of events may differ materially from those contained in these forward-looking statements due to a numberof factors—see “Cautionary Note Regarding Forward-Looking Statements” and “Part I; Item 1A; Risk Factors.” We report on acalendar year end, and except where otherwise indicated below, “2018” refers to the year ended December 31, 2018, “2017” refersto the year ended December 31, 2017 and “2016” refers to the year ended December 31, 2016.OverviewCompany BackgroundWe are the leading remote medical technology company focused on delivery of health information to improve quality of lifeand reduce cost of care. We provide remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services forclinical trials and original equipment manufacturing that serves both healthcare and clinical research customers. We operate under tworeportable segments: Healthcare and Research. The Healthcare segment is focused on the diagnosis and monitoring of cardiacarrhythmias or heart rhythm disorders. We offer cardiologists, electrophysiologists, neurologists and primary care physicians a fullspectrum of solutions, which provides them with a single source of cardiac monitoring services. These services range from thedifferentiated MCT service, to event, traditional Holter, extended-wear Holter, Pacemaker and INR monitoring. The Research segmentis engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and datamanagement services for drug and medical device trials. Included in the Corporate and Other category is the revenue received from thesale of non-invasive cardiac monitors to healthcare companies, wireless blood glucose meters and test strips to wholesale distributors ofdiabetes supplies and diabetic patients as well as product repairs, corporate overhead and other items not allocated to any of ourreportable segments.Recent DevelopmentsSubsequent EventOn January 25, 2019, we entered into an Agreement and Plan of Merger (the “Geneva Agreement”) with Geneva, aDelaware corporation and early stage company that provides remote monitoring for implantable cardiac devices utilizing a proprietarycloud-based platform, whereby Geneva will become a wholly-owned subsidiary of BioTelemetry.Pursuant to the terms of the Geneva Agreement, the holders of Geneva’s common and preferred stock and options exercisablefor Geneva’s common stock outstanding at closing will receive cash in the aggregate of $45.0 million, subject to certain closing andpost-closing adjustments, in addition to an earn-out of at least $20.0 million, payable either in cash or a combination of cash and stock,with no maximum Earn-Out Amount. The closing of the transactions contemplated by the Geneva Agreement is expected to becompleted later in the first quarter of 2019.40Table of ContentsCritical Accounting Policies and EstimatesThe discussion and analysis of our financial condition and results of operations are based on our financial statements, which wehave prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requiresus to make estimates and assumptions that affect the reported amount of assets and liabilities, revenues and expenses and relateddisclosures. We base our estimates and judgments on historical experience and on various other factors that we believe to be reasonableunder the circumstances; however, actual results may differ from these estimates. We review our estimates and judgments on anongoing basis.We believe that the following accounting policies and estimates are most critical to a full understanding and evaluation of ourreported financial results. Our significant accounting policies are more fully described in “Part II; Item 8. Financial Statements andSupplementary Data; Notes to Consolidated Financial Statements; Note 2. Summary of Significant Accounting Policies”below.Revenue RecognitionHealthcareHealthcare segment revenue includes revenue from MCT, event, traditional Holter, extended-wear Holter, Pacemaker and INRmonitoring services. A significant portion of our revenue is paid for by third-party commercial insurance organizations andgovernmental entities. We also receive reimbursement directly from patients through co-pays, deductibles and self-pay arrangements.For contracted payors, including Medicare, we determine revenue based on negotiated prices for the services provided. Basedon our history, we have experience collecting substantially all of the negotiated contracted rates and are therefore not providing animplicit price concession. As a result, any adjustments to the revenue recognized are due to patient default and are recorded as bad debtexpense.For non-contracted payors, we are providing an implicit price concession because we do not have a contract with theunderlying payor. As a result, we estimate our expected revenue based on historical cash collections. Subsequent adjustments to therevenue recognized are recorded as an adjustment to Healthcare revenue and not as bad debt expense.ResearchResearch segment revenue includes revenue for core laboratory services. Our Research segment revenue is provided on a fee-for-service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time andmaterials basis, and this revenue is recognized as the services are performed. Our site support revenue, consisting of equipment rentalsand sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. We recordreimbursements received for out-of-pocket expenses, including freight, as revenue in the accompanying consolidated statements ofoperations.See “Part II; Item 8. Financial Statements and Supplementary Data; Notes to Consolidated Financial Statements; Note3. Revenue Recognition” for more information.Accounts ReceivableHealthcare accounts receivable are related to the Healthcare segment and are recorded at the time revenue is recognized and arepresented on the consolidated balance sheet net of allowance for doubtful accounts. For contracted payors, including Medicare, wedetermine revenue based on negotiated prices41Table of Contentsfor the services provided. Based on our history, we have experience collecting substantially all of the negotiated contracted rates andare therefore not providing an implicit price concession. As a result, we record an allowance for doubtful accounts based on historicalcollection trends to account for the risk of patient default. Because of continuing changes in the health care industry and third-partyreimbursement, it is possible that our estimates could change, which could have a material impact on our operations and cash flows.Other accounts receivable are related to the Research segment and Corporate and Other category and are recorded at the timerevenue is recognized, or when products are shipped or services are performed. We estimate the allowance for doubtful accounts on aspecific account basis, and consider several factors in our analysis including customer specific information.We write off receivables when the likelihood for collection is remote and when we believe collection efforts have been fullyexhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. Inthe Healthcare segment, we wrote off $11.2 million and $8.8 million of receivables for the years ended December 31, 2018 and 2017,respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. There were nomaterial write-offs in the Research segment. We recorded bad debt expense of $1.1 million and $0.8 million related to a customerbankruptcy in the Corporate and Other category during the years ended December 31, 2018 and 2017, respectively, and wrote offthese amounts in 2018. We recorded consolidated bad debt expense of $22.2 million, $13.3 million and $9.9 million, respectively, forthe years ended December 31, 2018, 2017 and 2016, respectively.Stock-Based CompensationAccounting Standards Codification (“ASC”) 718 - Compensation—Stock Compensation (“ASC 718”), addresses theaccounting for share-based payment transactions in which an enterprise receives employee services in exchange for: (i) equityinstruments of the enterprise or (ii) liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settledby the issuance of such equity instruments. ASC 718 requires that an entity measure the cost of equity-based service awards issued toemployees, such as stock options and RSUs, based on the grant-date fair value of the award and recognize the cost of such awardsover the requisite service period (generally, the vesting period of the award). ASC 718 requires that an entity measure the cost ofliability-based service awards based on current fair value that is remeasured subsequently at each reporting date through the settlementdate. The compensation expense associated with PSUs is recognized ratably over the period between when the performance conditionsare deemed probable of achievement and when the awards are vested. Performance stock options (“PSOs”) are valued and stock-basedcompensation expense is recorded once the performance conditions of the outstanding PSOs have achieved probability. Prior to July 1,2018, we accounted for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees; see “Part II; Item 8. Financial Statements and Supplementary Data; Notes to Consolidated Financial Statements;Note 2. Summary of Significant Accounting Policies; t) Recent Accounting Pronouncements” for further details related to ouradoption of Accounting Standards Update (“ASU”) 2018-07, Compensation - Stock Compensation (Topic 718): Improvements toNonemployee Share-Based Payment Accounting, during the quarter ended September 30, 2018 and our current accounting for equityawards issued to non-employees.We have historically recorded stock-based compensation expense based on the number of stock options or RSUs we expect tovest using our historical forfeiture experience and we periodically update those forfeiture rates to apply to new grants. While we earlyadopted ASU 2016-09, Improvements to42Table of ContentsEmployee Share-Based Payment Accounting, during the year ended December 31, 2016, we have elected to continue to estimateforfeitures under the true-up provision of ASC 718. We record additional expense if the actual forfeiture rate is lower than estimated,and record a recovery of prior expense if the actual forfeiture rate is higher than estimated.We estimate the fair value of our stock options using the Black‑Scholes option valuation model. The Black‑Scholes optionvaluation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of theexpected volatility of the market price of our stock and the expected term of the award. We base our estimates of expected volatility onthe historical average of our stock price. The expected term represents the period of time that share‑based awards granted are expectedto be outstanding. Other assumptions used in the Black‑Scholes option valuation model include the risk‑free interest rate and expecteddividend yield. The risk‑free interest rate for periods pertaining to the expected term of each option is based on the U.S. Treasury yieldof a similar duration in effect at the time of grant. We have never paid, and do not expect to pay, dividends in the foreseeable future.We estimate the fair value of our PSUs using a Monte Carlo simulation. This model uses assumptions, including the risk freeinterest rate, expected volatility of our stock price and those of the performance group, dividends of the performance group membersand expected life of the awards. As noted above, we continue to estimate forfeitures under the true-up provision of ASC 718. If it isdeemed probable that the PSU performance targets will be met, compensation expense is recorded for these awards ratably over therequisite service period. The PSUs are forfeited to the extent the performance criteria are not met within the service period.Goodwill and Acquired Intangible AssetsGoodwill is the excess of the purchase price of an acquired business over the amounts assigned to assets acquired and liabilitiesassumed in a business combination. In accordance with ASC 350 - Intangibles - Goodwill and Other (“ASC 350”), goodwill isreviewed for impairment annually, or when events arise that could indicate that an impairment exists. In order to test goodwill forimpairment, ASC 350 allows reporting entities to take either a qualitative or quantitative approach to testing. Under the qualitativeapproach, an entity may assess qualitative factors to determine whether it is more-likely-than-not that the fair value of a reporting unit isless than its carrying amount. Such qualitative factors can include, among others, industry and market conditions, present andanticipated sales and cost factors, overall financial performance and relevant entity-specific events. If we conclude based on ourqualitative assessment that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying value, we perform aquantitative analysis in accordance with ASC 350. Under the quantitative approach, an entity compares the fair value of its reportingunits to their carrying value. If the reporting unit’s carrying value exceeds its fair value, an impairment loss equal to the difference isrecognized. The loss recognized shall not exceed the total amount of goodwill allocated to the reporting unit, and the income tax effectsfrom any deductible goodwill on the carrying value of the reporting unit when measuring the goodwill impairment loss, if any, areconsidered.For the purpose of performing our goodwill impairment analysis, we consider our business to be composed of three reportingunits: Healthcare, Research and Technology. When performing a quantitative analysis, we calculate the fair value of the reporting unitsutilizing the income and market approaches. The income approach is based on a discounted cash flow methodology that includesassumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-termdiscount rates, all of which require significant judgment. The market approach utilizes our market data as well as market data frompublicly-traded companies that are similar to us. There are inherent43Table of Contentsuncertainties related to these factors and the judgment applied in the analysis. We believe that the income and market approachesprovide a reasonable basis to estimate the fair value of our reporting units.Acquired intangible assets are recorded at fair value on the acquisition date. The estimated fair values and useful lives ofintangible assets are determined by assessing many factors, including estimates of future operating performance and cash flows of theacquired business, the characteristics of the intangible assets and the experience of the acquired business. Independent appraisal firmsmay assist with the valuation of acquired assets. The impairment test for indefinite-lived intangible assets other than goodwill consistsof a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset. We estimate the fair value ofthe indefinite-lived intangibles using the relief from royalty method. We amortize our finite-lived intangible assets over each asset’sestimated useful life using the straight-line method.We performed an impairment analysis of goodwill and indefinite-lived intangible assets for the years ended December 31,2018, 2017 and 2016. There was no goodwill impairment recorded as a result of these analyses.During our impairment testing of our intangible assets for the year ended December 31, 2017, giving particular consideration tothe LifeWatch integration and forward-looking integration plans, we determined that certain trade names and internally developedsoftware costs were no longer going to be used and were therefore impaired. This resulted in $11.0 million of intangible assetimpairment charges included within the Corporate and Other category as a component of the other charges line in our consolidatedstatements of operations. There were no other intangible asset impairments for the year ended December 31, 2017, and there were nointangible asset impairments for the year ended December 31, 2018.At December 31, 2016, we performed our required annual impairment tests of indefinite-lived intangible assets. Based on thatanalysis, we determined that there was no impairment.Income TaxesWe account for income taxes under the liability method, as described in ASC 740 - Income Taxes (“ASC 740”). Deferredincome taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting basesof assets and liabilities. When we determine that we will not be able to realize our deferred tax assets, we adjust the carrying value ofthe deferred tax assets through the valuation allowance.We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (i) we determinewhether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) forthose tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is morethan 50 percent likely to be realized upon ultimate settlement with the related tax authority.44Table of ContentsStatements of Operations OverviewRevenueThe vast majority of our revenue is derived from remote cardiac monitoring services in our Healthcare segment. The amount ofHealthcare segment revenue generated is based on the number of patients enrolled through physician prescriptions and the ratesreimbursed to us by commercial payors, physicians, patients and Medicare. MCT Medicare pricing was flat in 2018 but will declineslightly for 2019. Over time, we expect the price to remain relatively stable. We expect volumes to grow in the long-term as the marketgrows and we continue to gain market share.Revenue is generated in the Research segment through various study and consulting services, which include activities such ascore laboratory services, project management, data management, equipment rental and customer support. Research segment revenue isdriven by our ability to enter into service contracts at various phases of the pharmaceutical drug development life cycle. We expectvolume to increase as a result of our growing capabilities as a multi-service provider. Negotiated pricing for service contracts is subjectto market pressures, and as a result has decreased slightly over the last few years. With recent market consolidation, we areexperiencing stabilization in our prices. We expect revenue from the Research segment to increase over the long-term as we continueto increase our study volume.Revenue is generated in the Corporate and Other category from the sale of non-invasive cardiac monitors to healthcarecompanies, the sale of wireless blood glucose monitoring meters and test strips to wholesale distributors of diabetic supplies anddiabetic patients as well as product repairs and is recognized when products are shipped, or as services are completed. The salesvolume for our Corporate and Other category has decreased in the current year due to the timing of several large product sales duringthe year ended December 31, 2017. We expect our revenue in the Corporate and Other category to increase over the long-term as weintroduce new products.Gross ProfitGross profit consists of revenue less the cost of revenue.Cost of revenue for the Healthcare segment includes:•salaries and benefits for personnel providing various services and customer support to physicians and patients includingcustomer service, monitoring services, distribution services (scheduling, packaging and delivery of the devices to thepatients and practices), device repair and maintenance and quality assurance;•cost of patient-related services provided by third-party subcontractors including device transportation to and from thepatients and practices and wireless communication charges related to transmission of data to the monitoring centers;•consumable supplies sent to patients along with the durable components of our devices; and•depreciation of our medical devices.Cost of revenue for the Research segment includes:•cost of internal and third-party medical specialists and technicians;•salaries and benefits of personnel providing various services to customers including consulting, customer support, projectmanagement and certain information technology support;45Table of Contents•depreciation of our medical devices; and•cost of materials and transportation related to the shipment of products and supplies.Cost of revenue for the Corporate and Other category includes the cost of materials and labor related to the manufacture of ourproducts and product repair services.We expect multiple factors to influence our gross profit margins in the foreseeable future. Changes in reimbursement and payormix are two such factors. While we expect reimbursement to be stable, payor mix is unpredictable and dependent on the insurancecoverage of patients that are prescribed our services. We have a history of lowering the average cost of revenue as we increase volume.We expect to continue to achieve efficiencies in cost of revenue through process improvements, as well as from a reduction in the costof our devices. We expect these factors will have a favorable impact on our gross profit margins. While these factors could beoffsetting, it is difficult to predict how they will influence our gross profit margins.We expect to achieve some efficiencies in our Research segment cost of revenue through process improvements, and expect afavorable impact on gross margins due to the leveraging of the relatively fixed-cost infrastructure. If we experience increased servicecontract pricing or volume declines in our Research segment, it would have an adverse effect on our gross profit margin.General and AdministrativeGeneral and administrative expense consists primarily of salaries and benefits related to general and administrative personnel,management bonuses, professional fees primarily related to legal and audit services, amortization related to intangible assets, facilitiesexpenses and the related overhead.Sales and MarketingSales and marketing expense consists primarily of salaries, benefits and commissions related to sales personnel, travel andentertainment costs and marketing costs. Also included are costs associated with marketing programs such as trade shows andadvertising campaigns.Research and DevelopmentResearch and development expense consists primarily of salaries and benefits of personnel, as well as subcontractors who workon new product development and sustaining engineering of our existing products.Other ChargesWe account for expenses associated with our acquisitions and certain litigation as other charges as incurred. These expenses areprimarily a result of legal and professional fees surrounding our acquisitions, integration activities including severance and assetimpairments, as well as legal expense related to our patent litigation for which we are the plaintiff. Other charges are costs that are notconsidered indicative of the ongoing business operations.Interest ExpenseInterest expense consists primarily of the interest accrued related to our term loan, capital leases and where applicable, ourrevolving credit agreement, along with the amortization of deferred debt issuance costs.46Table of ContentsLoss on Extinguishment of DebtLoss on extinguishment of debt consists primarily of the write-off of the unamortized debt issuance costs upon settlement of ourprior credit agreements.Loss on Equity Method InvestmentLoss on equity method investment represents our portion of the results of operations of our equity method investees.Other Non-Operating Income/(Expense), netOther non-operating income/(expense), net represents other infrequently occurring non-operating items including settlementcharges and foreign exchange gains/(losses).Net Loss Attributable to Noncontrolling InterestsNet loss attributable to noncontrolling interests consists of the post-acquisition activity of the portion of LifeWatch that we hadnot yet acquired during the period from July 12, 2017 through December 31, 2017, as well as the 45% of LifeWatch Turkey HoldingAG that we did not own.Results of OperationsYears Ended December 31, 2018 and 2017Revenue Year Ended December 31, Change(in thousands, except percentages)2018 2017 $ %Healthcare$338,812 $234,385 $104,427 44.6 %Research50,561 38,790 11,771 30.3 %Other10,099 13,601 (3,502) (25.7)%Total revenue$399,472 $286,776 $112,696 39.3 %Total revenue increased for the year ended December 31, 2018. Healthcare revenues increased due primarily to an increase inpatient volume from the full-year impact of the LifeWatch acquisition, which closed on July 12, 2017. On an organic basis, Healthcarerevenue grew 13.8% due to an increase in patient volume driven by double-digit MCT growth and triple-digit extended-wear Holtergrowth, as well as a favorable payor mix. The Research revenue increase was driven by higher volume in oncology, early phase andAfib studies. The strength in Healthcare and Research revenue was partially offset by lower revenue in the Corporate and Othercategory due to the timing of several large product sales during the year ended December 31, 2017.47Table of ContentsGross Profit Year Ended December 31, Change(in thousands, except percentages)2018 2017 $ %Gross profit$250,486 $172,370 $78,116 45.3%Percentage of revenue62.7% 60.1% Gross profit increased for the year ended December 31, 2018 due primarily to the full-year impact of the LifeWatch acquisition,organic revenue growth and realized synergies from the integration of LifeWatch. The 260 basis point increase in gross marginpercentage was due to the impact of volume-related efficiencies, a favorable payor mix and synergies.General and Administrative Expense Year Ended December 31, Change(in thousands, except percentages)2018 2017 $ %General and administrative expense$109,736 $82,983 $26,753 32.2%Percentage of revenue27.5% 28.9% General and administrative expense increased for the year ended December 31, 2018 due primarily to the $14.9 million full-year impact of the LifeWatch acquisition, $9.0 million of additional headcount-related expense, $7.2 million of intangible assetamortization attributable to LifeWatch, $1.2 million of increased information technology expense as we continue to invest in ourbusiness systems and $0.8 million of increased professional fees, partially offset by $6.1 million of additional synergies stemming fromthe integration of LifeWatch.Sales and Marketing Expense Year Ended December 31, Change(in thousands, except percentages)2018 2017 $ %Sales and marketing expense$42,849 $35,322 $7,527 21.3%Percentage of revenue10.7% 12.3% Sales and marketing expense increased for the year ended December 31, 2018 due primarily to the $8.9 million full-year impactof the LifeWatch acquisition, $1.2 million of additional headcount-related expense and $1.2 million due to higher sales meeting costsand travel expense, partially offset by $3.9 million of additional synergies from the integration of LifeWatch.Bad Debt Expense Year Ended December 31, Change(in thousands, except percentages)2018 2017 $ %Bad debt expense$22,222 $13,291 $8,931 67.2%Percentage of revenue5.6% 4.6% Bad debt expense increased for the year ended December 31, 2018 due primarily to increased Healthcare segment revenue.Bad debt expense in Research was minimal and is recorded on a specific account basis.48Table of ContentsResearch and Development Expense Year Ended December 31, Change(in thousands, except percentages)2018 2017 $ %Research and development expense$11,206 $11,101 $105 0.9%Percentage of revenue2.8% 3.9% Research and development expense increased slightly for the year ended December 31, 2018 due to the $3.2 million full-yearimpact of the LifeWatch acquisition, partially offset by $2.0 million of synergies realized from the integration of LifeWatch, as well as$1.0 million of lower headcount-related expenses.Other Charges Year Ended December 31, Change(in thousands, except percentages)2018 2017 $ %Other charges$14,659 $31,436 $(16,777) (53.4)%Percentage of revenue3.7% 11.0% Other charges decreased for the year ended December 31, 2018 due primarily to a $7.5 million reduction of LifeWatchintegration charges and a $2.1 million reduction of other costs associated with previous acquisitions, as well as a $12.1 million assetimpairment charge that occurred in 2017. These reductions were partially offset by increases related to a $1.9 million impact fromchanges in contingent consideration, a $1.8 million write-off of a note receivable, as well as a $1.2 million increase in patent litigationfees in 2018.Other Expense Year Ended December 31, Change(in thousands, except percentages)2018 2017 $ %Interest expense$(9,429) $(4,897) $(4,532) 92.5 %Loss on extinguishment of debt— (543) 543 (100.0)%Loss on equity method investment(246) (384) 138 (35.9)%Other non-operating income/(expense), net1,365 (2,809) 4,174 (148.6)%Total Other expense$(8,310) $(8,633) $323 (3.7)%Percentage of revenue2.1% 3.0% Total other expense decreased slightly for the year ended December 31, 2018. Interest expense increased due to the full-yearimpact of the higher debt obligation, resulting from the SunTrust Credit Agreement entered into concurrent with the LifeWatchacquisition. Other non-operating income, net in 2018 was primarily composed of a current year foreign currency gain. Other non-operating expense, net in 2017 was due primarily to a $2.5 million legal settlement.49Table of ContentsIncome Taxes Year Ended December 31, Change(in thousands, except percentages)2018 2017 $ %Benefit from/(provision for) income taxes$370 $(6,747) $7,117 (105.5)%Effective tax benefit/(provision) rate(0.9)% (64.9)% For the year ended December 31, 2018, we recognized a net tax benefit due primarily to favorable tax deductions related tostock compensation.For the year ended December 31, 2017, we recognized a net tax provision due primarily to the re-measurement of our deferredtax assets and liabilities at the new federal corporate rate of 21%, net of the associated state tax impact, related to the Tax Cuts and JobsAct, which resulted in an $8.0 million tax expense.Years Ended December 31, 2017 and 2016Revenue Year Ended December 31, Change(in thousands, except percentages)2017 2016 $ %Healthcare$234,385 $165,664 $68,721 41.5%Research38,790 32,565 6,225 19.1%Other13,601 10,103 3,498 34.6%Total revenue$286,776 $208,332 $78,444 37.7%Total revenue increased for the year ended December 31, 2017 due primarily to the Healthcare, which was affected by theacquisition of LifeWatch, along with increased patient volumes as well as a favorable service mix. While overall pricing was stable, wesaw a decline in our Medicare rates. Research revenue increased due to the full year impact of the acquisition of our imaging business,VirtualScopics, which was acquired in May 2016, partially offset by lower cardiac study volumes. Other revenue also increased due tothe full year impact of Telcare, which was acquired in December 2016.Gross Profit Year Ended December 31, Change(in thousands, except percentages)2017 2016 $ %Gross profit$172,370 $129,450 $42,920 33.2%Percentage of revenue60.1% 62.1% Gross profit increased for the year ended December 31, 2017 due primarily to our recent acquisitions, organic growth, andrealized synergies from our acquisitions, partially offset by the impact of the decrease in Medicare rates. The decrease in gross marginpercentage was due to the impact of our recent acquisitions, whose revenue carry lower profit margins than our existing business.50Table of ContentsGeneral and Administrative Expense Year Ended December 31, Change(in thousands, except percentages)2017 2016 $ %General and administrative expense$82,983 $55,877 $27,106 48.5%Percentage of revenue28.9% 26.8% General and administrative expense increased for the year ended December 31, 2017 due primarily to the $19.9 million impactfrom our recent acquisitions, primarily LifeWatch, a $6.0 million impact from intangible asset amortization attributed to LifeWatch, aswell as a $2.2 million increase in technology costs, offset partially by $0.7 million in headcount related savings. The increase in thegeneral and administrative expense as a percent of revenue was the result of the intangible asset amortization recorded stemming fromthe LifeWatch acquisition.Sales and Marketing Expense Year Ended December 31, Change(in thousands, except percentages)2017 2016 $ %Sales and marketing expense$35,322 $28,636 $6,686 23.3%Percentage of revenue12.3% 13.7% Sales and marketing expense increased for the year ended December 31, 2017 due primarily to the$10.7 million impact fromour recent acquisitions, primarily LifeWatch, and $2.2 million in added employee related costs exclusive of our recent acquisitions,partially offset by approximately $5.0 million of synergies obtained from the recent acquisitions and $1.1 million due to lower salesmeetings costs. Sales and marketing expense decreased as a percentage of revenue due to the leverage and synergies obtained from ouracquired businesses.Bad Debt Expense Year Ended December 31, Change(in thousands, except percentages)2017 2016 $ %Bad debt expense$13,291 $9,931 $3,360 33.8%Percentage of revenue4.6% 4.8% Bad debt expense increased for the year ended December 31, 2017 due primarily to increased revenue from our recentlyacquired business and the timing of revenue and collections. Substantially all of our bad debt expense relates to the Healthcaresegment. Bad debt expense in the Research segment was minimal and is recorded on a specific account basis.51Table of ContentsResearch and Development Expense Year Ended December 31, Change(in thousands, except percentages)2017 2016 $ %Research and development expense$11,101 $8,355 $2,746 32.9%Percentage of revenue3.9% 4.0% Research and development expense increased for the year ended December 31, 2017 due primarily to the $5.2 million impactfrom our recent acquisitions, primarily LifeWatch, offset partially by $2.7 million of synergies obtained from the recent acquisitionsand other cost savings.Other Charges Year Ended December 31, Change(in thousands, except percentages)2017 2016 $ %Other charges$31,436 $8,639 $22,797 263.9%Percentage of revenue11.0% 4.1% Other charges increased for the year ended December 31, 2017 due primarily to $12.0 million of asset impairmentcharges, $4.9 million in additional professional fees, $4.1 million of severance and employee related costs, and $1.5 million of legalfees, primarily related to the acquisition of LifeWatch. These charges were partially offset by a $2.6 million decrease in the fair value ofacquisition-related consideration recognized for previous acquisitions.Other Expense Year Ended December 31, Change(in thousands, except percentages)2017 2016 $ %Interest expense$(4,897) $(1,830) $(3,067) 167.6%Loss on equity method investment(384) (287) (97) n/aOther non-operating expense, net(2,809) (125) (2,684) 2,147.2%Total Other expense$(8,090) $(2,242) $(5,848) 260.8%Percentage of revenue3.0% 1.1% Total other expense increased for the year ended December 31, 2017 due primarily to $3.1 million of interest expense resultingfrom our new credit agreement entered into concurrent with our LifeWatch acquisition and a $2.5 million non-operating charge for oursettlement with the Office of Civil Rights related to the theft of two unencrypted laptop computers in 2011. Additionally, we incurreda $1.3 million non-operating charge related to the derivative instrument premium for the acquisition of LifeWatch, and a $0.5million loss on the extinguishment of our previous credit agreement with Healthcare Financial Solutions, LLC, offset partially by anon-operating gain of approximately $1.3 million related to the favorable settlement with the former owner of Mednet.52Table of ContentsIncome Taxes Year Ended December 31, Change(in thousands, except percentages)2017 2016 $ %Benefit from/(provision for) income taxes$(6,747) $37,667 $(44,414) 117.9%Effective tax benefit/(provision) rate(64.9)% 238.9% For the year ended December 31, 2017, we recognized a net tax provision due primarily to the re-measurement of our deferredtax assets and liabilities at the new federal corporate rate of 21%, net of the associated state tax impact, related to the Tax Cuts and JobsAct, which resulted in an $8.0 million tax expense.For the year ended December 31, 2016, we recognized a net tax benefit due primarily to a $51.6 million benefit related to therelease of our valuation allowance. The release of our valuation allowance was partially offset by adjustments to deferred taxes andstate taxes levied on fiscal 2016 taxable income.Liquidity and Capital ResourcesThe following table highlights certain information related to our liquidity and capital resources:(In thousands, except ratios)December 31, 2018 December 31, 2017Cash and cash equivalents$80,889 $36,022Healthcare accounts receivable, net of allowance for doubtful accounts37,754 25,190Other accounts receivable, net of allowance for doubtful accounts14,874 13,296Availability under revolving credit facility50,000 50,000 Working capital$97,037 $39,153Current ratio3.0 1.8 Total capital lease obligations$1,769 $5,509Total debt$198,549 $199,35653Table of ContentsThe following table highlights certain cash flow activities: Year Ended December 31,(In thousands)2018 2017Net income/(loss)$41,874 $(17,143)Non-cash adjustments to net income70,154 66,193Cash used for working capital(39,282) (25,268)Cash provided by operating activities72,746 23,782 Cash used for acquisitions of businesses, net of cash acquired(3,750) (161,479)Purchases of property, equipment and investment in internally developed software(24,637) (13,697)Cash used in investing activities(28,851) (177,188) Cash provided by financing activities$601 $166,457The increase in cash provided by operating activities was due primarily to the increase in net income. Non-cash adjustments tonet income increased for the year ended December 31, 2018 due primarily to increases in bad debt expense, depreciation , amortizationof intangible assets, stock-based compensation and the impact from changes in contingent consideration, offset partially by the decreasein impairment charges and the change in deferred taxes. Cash used for working capital increased due primarily to the timing of cashreceipts and payments.During the year ended December 31, 2018 we had nominal spending on acquisitions of businesses, whereas during the yearended December 31, 2017 we acquired LifeWatch for $161.5 million in cash and $117.4 million in common stock. We increased ourpurchases for equipment in 2018, due primarily to higher Healthcare segment service volumes and the launch of our next generationproducts used in our monitoring services.In conjunction with the LifeWatch acquisition, we established a new SunTrust Credit Agreement with the Lenders in theamount of $205.0 million and extinguished the previous Healthcare Financial Solutions Credit Agreement. For further details regardingthe Credit Agreements, please see “Part II; Item 8. Financial Statements and Supplementary Data; Notes to ConsolidatedFinancial Statements; Note 11. Credit Agreement” below.Subsequent to December 31, 2018, we entered into the Geneva Agreement, whereby Geneva will become a wholly ownedsubsidiary of BioTelemetry. We expect to complete this acquisition later in the first quarter of 2019 with a cash outlay of approximately$45.0 million.54Table of ContentsContractual Obligations and CommitmentsThe following table describes our long-term contractual obligations and commitments as of December 31, 2018: Payments due by period(in thousands) Total Less than 1 year 1-3 Years 3-5 Years More than 5 YearsOperating lease obligations $23,458 $5,047 $7,828 $4,776 $5,807Capital lease obligations 1,769 1,652 117 — —Debt and interest obligations(1) 231,279 13,111 51,142 167,026 —Total(2)(3) $256,506 $19,810 $59,087 $171,802 $5,807________________(1) Our debt bears a variable interest rate, at our election, with an applicable margin determined by the credit agreement. The amounts above assume the rateand margin as of December 31, 2018 throughout the remaining term. The rate and margin may fluctuate, as may our election of LIBOR or Base Ratepricing, throughout the term of the loan. Excluded from the amounts in the table is the 0.25% commitment fee payable on the unused portion of our line ofcredit.(2) In connection with certain acquisitions completed in 2016 and 2018, we have contingent consideration obligations payable to the sellers in thesetransactions upon the achievement of certain milestones. The maximum aggregate undiscounted amounts potentially payable not included in the tableabove total $5.0 million.(3) As of December 31, 2018, our other long-term liabilities in our consolidated balance sheet consist primarily of reserves for uncertain tax positions. We areunable to make reasonably reliable estimates of both the timing of tax audit outcomes and if unfavorable, the timing of payments; therefore, such amountsare not included in the above contractual obligation table. See “Part II; Item 8. Financial Statements and Supplementary Data; Notes to ConsolidatedFinancial Statements; Note 17. Income Taxes” for further discussion related to uncertain tax positions.As of December 31, 2018, we were bound under facility leases and several office equipment leases that are included in thetable above. Our debt bears a variable interest rate of LIBOR plus the applicable margin, or the prime rate plus the applicable margin.If LIBOR rates, the prime rates, or the applicable margin increase, the interest obligation amounts on our debt disclosed above will beaffected.Recent Accounting PronouncementsFor further details on recently issued accounting pronouncements, please refer to “Part II; Item 8. Financial Statements andSupplementary Data; Notes to Consolidated Financial Statements; Note 2. Summary of Significant Accounting Policies; t)Recent Accounting Pronouncements.”Off-Balance Sheet ArrangementsAs of December 31, 2018, we did not have any relationships with unconsolidated entities or financial partnerships, such asentities referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitatingoff-balance sheet arrangements or other contractually narrow or limited purposes.55Table of ContentsItem 7A. Quantitative and Qualitative Disclosures About Market RiskOur cash and cash equivalents as of December 31, 2018 were $80.9 million. We do not invest in any short-term or long-termmarketable securities, nor do we hold any derivative financial instruments for trading or speculative purposes.At December 31, 2018, we had $198.5 million of variable rate debt, inclusive of debt discounts and deferred charges, at a rateof LIBOR plus the applicable margin, or the prime rate plus the applicable margin. A 1.0% change in either the LIBOR rate, primerate, or the applicable margin would result in a change in annual interest expense of approximately $2.0 million. For further detailsregarding the debt, rates or applicable margin, please refer to “Part II; Item 8. Financial Statements and Supplementary Data;Notes to Consolidated Financial Statements; Note 11. Credit Agreement” included in this Annual Report on Form 10-K.56Table of ContentsItem 8. Financial Statements and Supplementary DataReport of Independent Registered Public Accounting FirmTo the Stockholders and the Board of Directors of BioTelemetry, Inc.Opinion on the Financial StatementsWe have audited the accompanying consolidated balance sheets of BioTelemetry, Inc. (the Company) as of December 31, 2018 and2017, the related consolidated statements of operations, comprehensive income (loss), cash flows and equity for each of the three yearsin the period ended December 31, 2018, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(collectively referred to as the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all materialrespects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows foreach of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)(PCAOB), the Company’s internal control over financial reporting as of December 31, 2018, based on criteria established in InternalControl-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework)and our report dated February 21, 2019 expressed an unqualified opinion thereon.Basis for OpinionThese financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on theCompany’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required tobe independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations ofthe Securities and Exchange Commission and the PCAOB.We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the auditto obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to erroror fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regardingthe amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used andsignificant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe thatour audits provide a reasonable basis for our opinion./s/ ERNST & YOUNG LLP We have served as the Company’s auditors since 2004. Philadelphia, Pennsylvania February 21, 2019 57Table of ContentsBIOTELEMETRY, INC.CONSOLIDATED BALANCE SHEETS December 31,(in thousands, except shares and par value)2018 2017ASSETS Current assets: Cash and cash equivalents$80,889 $36,022Healthcare accounts receivable, net of allowance for doubtful accounts of $25,345 and $15,556 atDecember 31, 2018 and 2017, respectively37,754 25,190Other accounts receivable, net of allowance for doubtful accounts of $268 and $1,425 atDecember 31, 2018 and 2017, respectively14,874 13,296Inventory7,323 5,332Prepaid expenses and other current assets5,820 10,268Total current assets146,660 90,108Property and equipment, net48,377 49,194Intangible assets, net129,653 141,707Goodwill238,814 223,105Deferred tax asset19,975 17,681Other assets3,322 2,767Total assets$586,801 $524,562LIABILITIES AND EQUITY Current liabilities: Accounts payable18,157 14,529Accrued liabilities21,609 26,055Current portion of capital lease obligations1,652 4,023Current portion of long-term debt5,125 2,050Contract liabilities3,080 4,298Total current liabilities49,623 50,955Long-term portion of capital lease obligations117 1,486Long-term debt193,424 197,306Other long-term liabilities33,152 25,112Total liabilities276,316 274,859Stockholders’ equity: Common stock—$.001 par value as of December 31, 2018 and 2017; 200,000,000 shares authorizedas of December 31, 2018 and 2017; 33,406,364 and 32,460,668 shares issued and outstanding atDecember 31, 2018 and 2017, respectively33 32Paid-in capital426,054 409,517Accumulated other comprehensive income/(loss)256 (114)Accumulated deficit(115,858) (158,678)Total BioTelemetry, Inc.’s stockholders’ equity310,485 250,757Noncontrolling interests— (1,054)Total equity310,485 249,703Total liabilities and equity$586,801 $524,562See accompanying Notes to Consolidated Financial Statements.58Table of ContentsBIOTELEMETRY, INC.CONSOLIDATED STATEMENTS OF OPERATIONS Year Ended December 31,(in thousands, except per share amounts)2018 2017 2016Revenue$399,472 $286,776 $208,332Cost of revenue148,986 114,406 78,882Gross profit250,486 172,370 129,450Operating expenses: General and administrative109,736 82,983 55,877Sales and marketing42,849 35,322 28,636Bad debt expense22,222 13,291 9,931Research and development11,206 11,101 8,355Other charges14,659 31,436 8,639Total operating expenses200,672 174,133 111,438Income/(loss) from operations49,814 (1,763) 18,012Other expense: Interest expense(9,429) (4,897) (1,830)Loss on extinguishment of debt— (543) —Loss on equity method investments(246) (384) (287)Other non-operating income/(expense), net1,365 (2,809) (125)Total other expense, net(8,310) (8,633) (2,242)Income/(loss) before income taxes41,504 (10,396) 15,770(Provision for)/benefit from income taxes370 (6,747) 37,667Net income/(loss)41,874 (17,143) 53,437Net loss attributable to noncontrolling interests(946) (1,187) —Net income/(loss) attributable to BioTelemetry, Inc.$42,820 $(15,956) $53,437 Net income/(loss) per common share attributable to BioTelemetry, Inc.: Basic$1.31 $(0.53) $1.91Diluted$1.20 $(0.53) $1.75Weighted average number of common shares outstanding: Basic32,709 30,386 27,920Dilutive stock options and restricted stock units3,074 — 2,569Diluted35,783 30,386 30,489See accompanying Notes to Consolidated Financial Statements.59Table of ContentsBIOTELEMETRY, INC.CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) Year Ended December 31,(in thousands)2018 2017 2016Net income/(loss) attributable to BioTelemetry, Inc.$42,820 $(15,956) $53,437Other comprehensive income/(loss): Foreign currency translation gain/(loss)370 (80) (22)Comprehensive income/(loss) attributable to BioTelemetry, Inc.$43,190 $(16,036) $53,415See accompanying Notes to Consolidated Financial Statements.60Table of ContentsBIOTELEMETRY, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS Year Ended December 31,(in thousands)2018 2017 2016OPERATING ACTIVITIES Net income/(loss)$41,874 $(17,143) $53,437Adjustments to reconcile net income/(loss) to net cash provided by operating activities: Bad debt expense22,222 13,291 9,931Depreciation22,963 18,337 10,547Amortization of intangibles17,205 10,224 3,722Impairment charge— 12,045 —Stock-based compensation9,261 7,680 6,502Write off of derivative premium— 1,322 —Accretion of debt discount1,243 678 217Loss on extinguishment of debt— 543 —Gain on legal settlement— (1,333) —Tax (benefit)/expense(2,294) 6,050 (38,141)Other non-cash items(446) (2,644) 457Changes in operating assets and liabilities: Healthcare and other accounts receivable(35,742) (15,455) (8,707)Inventory(1,991) 665 (753)Prepaid expenses and other assets3,517 (694) (1,050)Accounts payable3,760 (8,320) 3,145Accrued and other liabilities(8,826) (1,464) (456)Net cash provided by operating activities72,746 23,782 38,851INVESTING ACTIVITIES Acquisition of businesses, net of cash acquired(3,750) (161,479) (24,970)Purchases of property and equipment and investment in internally developed software(24,637) (13,697) (10,899)Purchase of derivative instrument— (1,322) —Investment in equity method investee(464) (690) (312)Net cash used in investing activities(28,851) (177,188) (36,181)FINANCING ACTIVITIES Proceeds related to the exercising of stock options and employee stock purchase plan12,186 6,071 2,519Tax payments related to the vesting of shares(2,910) (1,933) (2,333)Issuance of long-term debt— 205,000 —Borrowings under revolving loans— — 14,500Repayments on revolving loans— (3,000) (11,500)Payment of debt issuance costs— (6,213) —Principal payments on long-term debt(2,050) (25,840) (1,438)Principal payments on capital lease obligations(3,740) (2,863) (321)Acquisition of noncontrolling interests(2,885) (4,765) —Net cash provided by financing activities601 166,457 1,427Effect of exchange rate changes on cash371 (81) (31)Net increase in cash and cash equivalents44,867 12,970 4,066Cash and cash equivalents—beginning of period36,022 23,052 18,986Cash and cash equivalents—end of period$80,889 $36,022 $23,052SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Non-cash purchases of property and equipment$505 $498 $—Non-cash fair value of common stock returned in legal settlement— 2,753 —Non-cash fair value of equity issued for acquisition of business— 117,440 2,885Non-cash fair value of non-trade receivables exchanged for investment in equity method investee395 — —Cash paid for interest7,836 3,888 1,273Cash paid for taxes$763 $1,648 $359See accompanying Notes to Consolidated Financial Statements.61Table of ContentsBIOTELEMETRY, INC.CONSOLIDATED STATEMENTS OF EQUITY BioTelemetry, Inc. Equity AccumulatedOtherComprehensiveIncome/(Loss) Common Stock Paid-inCapital AccumulatedDeficit NoncontrollingInterests TotalEquity(in thousands, except shares)Shares Amount Balance December 31, 201527,277,939 $27 $272,070 $(12) $(196,159) $— $75,926Share issuances related to stockcompensation plans917,912 1 2,518 — — — 2,519Stock-based compensation— — 6,502 — — — 6,502Shares withheld to cover taxes onvesting of share based awards(178,867) — (2,333) — — — (2,333)Issuance of stock related to 2014business combination244,519 — 2,885 — — — 2,885Currency translation adjustment— — — (22) — — (22)Net income— — — — 53,437 — 53,437Balance December 31, 201628,261,503 28 281,642 (34) (142,722) — 138,914Share issuances related to stockcompensation plans722,441 — 6,071 — — — 6,071Stock-based compensation— — 7,680 — — — 7,680Shares withheld to cover taxes onvesting of share based awards(79,589) — (1,933) — — — (1,933)Issuance of stock related tobusiness combinations3,615,840 4 116,788 — — 11,224 128,016Acquisition of noncontrollinginterest19,806 — 2,022 — — (11,091) (9,069)Common stock returned in legalsettlement(79,333) — (2,753) — — — (2,753)Currency translation adjustment— — — (80) — — (80)Net loss— — — — (15,956) (1,187) (17,143)Balance December 31, 201732,460,668 32 409,517 (114) (158,678) (1,054) 249,703Share issuances related to stockcompensation plans972,415 1 12,185 — — — 12,186Stock-based compensation— — 9,261 — — — 9,261Shares withheld to cover taxes onvesting of share based awards(85,505) — (2,909) — — — (2,909)Acquisition of noncontrollinginterest58,786 — (2,000) — — 2,000 —Currency translation adjustment— — — 370 — — 370Net income— — — — 42,820 (946) 41,874Balance December 31, 201833,406,364 $33 $426,054 $256 $(115,858) $— $310,485See accompanying Notes to Consolidated Financial Statements.62Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS1. Organization and Description of BusinessBioTelemetry, Inc. (“BioTelemetry,” “Company,” “we,” “our” or “us”), a Delaware corporation, is the leading remotemedical technology company focused on delivery of health information to improve quality of life and reduce cost of care. We provideremote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials and original equipmentmanufacturing that serves both healthcare and clinical research customers.We operate under two reportable segments: Healthcare and Research. During the first quarter of 2018, we aggregated theTechnology operating segment into the Corporate and Other category. The Healthcare segment is focused on the diagnosis andmonitoring of cardiac arrhythmias or heart rhythm disorders. We offer cardiologists, electrophysiologists, neurologists and primary carephysicians a full spectrum of solutions, which provides them with a single source of cardiac monitoring services. These services rangefrom the differentiated MCT service, to event, traditional Holter, extended-wear Holter, Pacemaker and INR monitoring. The Researchsegment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and datamanagement services for drug and medical device trials. Included in the Corporate and Other category is the manufacturing, testing andmarketing of cardiac and blood glucose monitoring devices to medical companies, clinics and hospitals and corporate overhead andother items not allocated to any of our reportable segments.We have grown both organically and through recent acquisitions; for further details related to our acquisitions, please see“Note 4. Acquisitions” below.Our common stock is traded on the NASDAQ Global Select Market under our symbol “BEAT.”2. Summary of Significant Accounting Policiesa) Principles of Consolidation & ReclassificationsThe accompanying consolidated financial statements have been prepared in accordance with U.S. generally acceptedaccounting principles (“U.S. GAAP”) and include the accounts of BioTelemetry and its wholly owned subsidiaries. All intercompanytransactions and balances have been eliminated in consolidation.Certain reclassifications have been made to prior period statements to conform to the current period presentation. These consistof:•combining the non-cash operating items of equity method investment loss, the change in fair value of acquisition-relatedcontingent consideration and lease income/(expense) into other non-cash items, a component of our net cash provided byoperating activities on our consolidated statements of cash flows; and•reclassifying trade payable invoices received but not yet processed in our purchasing system from accrued liabilities toaccounts payable in the consolidated balance sheets.The reclassifications had no impact on previously reported consolidated net income/(loss), cash flows from operating, financingand investing activities, or accumulated deficit.63Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)b) Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires that management make estimatesand assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date ofthe consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results maydiffer from those estimates.c) Fair Value of Financial InstrumentsFair value is defined as the exit price, the price that would be received to sell an asset or transfer a liability in an orderlytransaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniquesused to measure fair value into three broad levels, as defined below. Observable inputs are inputs a market participant would use invaluing an asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflectour own assumptions about the factors a market participant would use in valuing an asset or liability developed using the bestinformation available in the circumstances. The classification of an asset’s or liability’s level within the fair value hierarchy isdetermined based on the lowest level input that is significant to the fair value measurement.Level 1 -Quoted prices in active markets for an identical asset or liability.Level 2 -Inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, forsubstantially the full term of the asset or liability.Level 3 -Inputs that are unobservable for the asset or liability, based on our own assumptions about the assumptions a marketparticipant would use in pricing the asset or liability.Our financial instruments consist primarily of cash and cash equivalents, Healthcare accounts receivable, other accountsreceivable, accounts payable, contingent consideration, short-term debt and long-term debt. With the exception of contingentconsideration and long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1).Our long-term debt (classified as Level 2) is measured using market prices for similar instruments, inputs such as the borrowingrates currently available, benchmark yields, actual trade data, broker/dealer quotes and other similar data obtained from quoted marketprices or independent pricing vendors.The fair value of contingent consideration (classified as Level 3) is measured on a recurring basis using unobservable inputssuch as projected payment dates, probabilities of meeting specified milestones and other such variables resulting in payment amountswhich are discounted back to present value using a probability-weighted discounted cash flow model. Adjustments to contingentconsideration are recorded in other charges in the consolidated statements of operations.In addition to the recurring fair value measurements, the fair value of certain assets acquired and liabilities assumed inconnection with a business combination are recorded at fair value, primarily using a discounted cash flow model (classified as Level 3).This valuation technique requires us to make certain assumptions, including, but not limited to, future operating performance and cashflows, royalty rate and other such variables which are discounted to present value using a discount rate that reflects the risk factorsassociated with future cash flow, the characteristics of the assets acquired and liabilities assumed and the experience of the acquiredbusiness. Non-financial assets such as goodwill, intangible assets, and property64Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)and equipment are subsequently measured at fair value when there is an indicator of impairment and recorded at fair value only whenan impairment is recognized. We assess the impairment of goodwill and intangible assets annually or whenever events or changes incircumstances indicate that the carrying amount of an intangible asset may not be recoverable.d) Cash and Cash EquivalentsCash and cash equivalents are held in financial institutions or in custodial accounts with financial institutions. Cash equivalentsare defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readilyconvertible into cash and have minimal interest rate risk. We do not have restricted cash.e) Accounts Receivable and Allowance for Doubtful AccountsHealthcare accounts receivable is recorded at the time Healthcare segment revenue is recognized and is presented on theconsolidated balance sheet net of an allowance for doubtful accounts. For our contracted payors, we determine revenue based onnegotiated prices for the services provided. Based on our history, we have experience collecting substantially all of the negotiatedcontracted rates and are therefore not providing an implicit price concession. As a result, an allowance for doubtful accounts isrecorded based on historical collection trends to account for the risk of patient default. Because of continuing changes in the health careindustry and third-party reimbursement, it is possible that our estimates of collectability could change, which could have a materialimpact on our operations and cash flows.Other accounts receivable is related to the Research segment and Corporate and Other category and are recorded at the timerevenue is recognized, when products are shipped or services are performed. We estimate an allowance for doubtful accounts on aspecific account basis, and consider several factors in our analysis including customer specific information.We write off receivables when the likelihood for collection is remote and when we believe collection efforts have been fullyexhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. Inthe Healthcare segment, we wrote-off $11.2 million and $8.8 million of receivables for the years ended December 31, 2018 and 2017,respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. There were nomaterial write-offs in the Research segment. We recorded bad debt expense of $1.1 million and $0.8 million related to a customerbankruptcy in the Corporate and Other category during the years ended December 31, 2018 and 2017, respectively, and wrote offthese amounts in 2018. We recorded consolidated bad debt expense of $22.2 million, $13.3 million and $9.9 million for the yearsended December 31, 2018, 2017 and 2016, respectively.f) Concentrations of Credit RiskFinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents,Healthcare accounts receivable and other accounts receivable. We maintain our cash and cash equivalents with high quality financialinstitutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. Werecord an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written-offagainst the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased.65Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)At December 31, 2018, 2017 and 2016, one payor, Medicare, accounted for 15%, 21% and 11%, respectively, of our grossaccounts receivable.g) InventoryInventory is valued at the lower of cost (using first-in, first-out cost method) or market (net realizable value or replacementcost). Management reviews inventory for specific future usage, and estimates of impairment of individual inventory items are recordedto reduce inventory to the lower of cost or market.h) Property and EquipmentProperty and equipment is recorded at cost, except for assets acquired in business combinations, which are recorded at fairvalue as of the acquisition date. Depreciation is recorded over the estimated useful life of each class of depreciable assets, and iscomputed using the straight-line method. Leasehold improvements and assets acquired under a capital lease are amortized over theshorter of the estimated asset life or term of the lease and included in depreciation expense. Repairs and maintenance costs are chargedto expense as incurred. Costs of additions and improvements are capitalized.i) Impairment of Long-Lived AssetsThe carrying value of long-lived assets, other than goodwill and indefinite-lived intangible assets, is evaluated when events orchanges in circumstances indicate the carrying value may not be recoverable or the useful life has changed. We consider historicalperformance and anticipated future results in our evaluation of potential impairment. Accordingly, when indicators of impairment arepresent, we evaluate the carrying value of these assets in relation to the operating performance of the business and the undiscountedcash flows expected to result from the use of these assets. If the carrying amount of a long-lived asset exceeds its expectedundiscounted cash flows, an impairment charge is recognized to the extent the carrying amount exceeds its fair value.j) Derivative InstrumentDuring the second quarter of 2017, we purchased a foreign currency option with a notional value of $194.2 million to mitigatethe foreign exchange risk related to the Swiss Franc-denominated purchase price of LifeWatch AG (“LifeWatch”). This derivativeinstrument was not designated as a hedge for accounting purposes. We did not exercise this option and the contract expired during thethird quarter of 2017, resulting in a charge of $1.3 million, which was recorded as a component of other non-operatingincome/(expense), net in the consolidated statements of operations. We did not enter into any derivative transactions during 2018.k) Equity Method InvestmentsWe account for investments using the equity method of accounting if the investment provides us the ability to exercisesignificant influence, but not control, over the investee. Significant influence is generally deemed to exist if our ownership interest inthe voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee’s board ofdirectors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method ofaccounting, the investment is recorded at cost in the consolidated balance sheets under other assets and is periodically adjusted forcapital contributions, dividends received and our share of the investee’s earnings or losses together with other-than-temporaryimpairments which are recorded through loss on equity method investment in the consolidated statements of operations.66Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)l) Noncontrolling InterestsThe consolidated financial statements reflect the application of Accounting Standards Codification (“ASC”) 810 -Consolidations, which establishes accounting and reporting standards that require: (i) the ownership interest in subsidiaries held byparties other than the parent to be clearly identified and presented in the consolidated balance sheet within stockholder’s equity, butseparate from the parent’s equity; (ii) the amount of consolidated net income/(loss) attributable to the parent and the noncontrollinginterest to be clearly identified and presented on the face of the consolidated statements of operations; and (iii) changes in a parent’sownership interest while the parent retains its controlling financial interest in its subsidiary to be accounted for consistently.We acquired approximately 97% of LifeWatch on July 12, 2017. On that date, we acquired control of LifeWatch and beganconsolidating its financial statements. As of December 31, 2017, we owned 100% of LifeWatch.Also on July 12, 2017, LifeWatch owned 55% of LifeWatch Turkey Holding AG (“LifeWatch Turkey,” domiciled inSwitzerland), with a partner company located in Ankara, Turkey, to provide digital health solutions to the Turkish market. Concurrentwith our acquisition of LifeWatch, we acquired control of LifeWatch Turkey and began consolidating their financial statements.During 2018, after a formal restructuring of shareholdings approved by the board of directors of LifeWatch Turkey, we becamethe sole shareholder of LifeWatch Turkey. No cash or other consideration was exchanged to effect this transaction. As a result, we nolonger reflect a noncontrolling interest in our consolidated balance sheet; however, we continue to reflect the net loss attributable to thenoncontrolling interest in our consolidated statement of operations for the period of time where we did not own the entire entity.m) Goodwill and Acquired Intangible AssetsGoodwill is the excess of the purchase price of an acquired business over the amounts assigned to assets acquired and liabilitiesassumed in a business combination. In accordance with ASC 350 - Intangibles — Goodwill and Other (“ASC 350”), goodwill isreviewed for impairment annually, or when events arise that could indicate that an impairment exists. In order to test goodwill forimpairment, ASC 350 allows reporting entities to take either a qualitative or quantitative approach to testing. Under the qualitativeapproach, an entity may assess qualitative factors to determine whether it is more-likely-than-not that the fair value of a reporting unit isless than its carrying amount. Such qualitative factors can include, among others, industry and market conditions, present andanticipated sales and cost factors, overall financial performance and relevant entity-specific events. If we conclude based on ourqualitative assessment that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying value, we perform aquantitative analysis in accordance with ASC 350. Under the quantitative approach, an entity compares the fair value of its reportingunits to their carrying value. If the reporting unit’s carrying value exceeds its fair value, an impairment loss equal to the difference isrecognized. The loss recognized shall not exceed the total amount of goodwill allocated to the reporting unit, and the income tax effectsfrom any deductible goodwill on the carrying value of the reporting unit when measuring the goodwill impairment loss, if any, areconsidered.For the purpose of performing our goodwill impairment analysis, we consider our business to be composed of three reportingunits: Healthcare, Research and Technology. When performing a quantitative analysis, we calculate the fair value of the reporting unitsutilizing the income and market approaches. The67Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecastedincome, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significantjudgment. The market approach utilizes our market data as well as market data from publicly-traded companies that are similar to us.There are inherent uncertainties related to these factors and the judgment applied in the analysis. We believe that the income andmarket approaches provide a reasonable basis to estimate the fair value of our reporting units.Acquired intangible assets are recorded at fair value on the acquisition date. The estimated fair values and useful lives ofintangible assets are determined by assessing many factors including estimates of future operating performance and cash flows of theacquired business, the characteristics of the intangible assets and the experience of the acquired business. Independent appraisal firmsmay assist with the valuation of acquired assets. The impairment test for indefinite-lived intangible assets other than goodwill consistsof a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset. We used a qualitativeapproach to determine impairment for our indefinite-lived as well as for our finite-lived intangible assets. As a result of our qualitativetest for impairment for the year ended December 31, 2017, we noted entity-specific events which resulted in the write-off of theremainder of our indefinite-lived intangible assets other than goodwill, and a portion of our finite-lived intangible assets. See “Note 8.Goodwill and Intangible Assets” for further details regarding the impairment charges. We amortize our finite-lived intangible assetsover each asset’s estimated useful life using the straight-line method.n) Revenue RecognitionWe adopted ASC 606 - Revenue from Contracts with Customers (“ASC 606”) on January 1, 2018, which requires revenuerecognized to represent the transfer of promised goods or services to customers at an amount that reflects the consideration that acompany expects to receive in exchange for those goods or services.We utilized the modified retrospective method for adoption, allowing us to not retrospectively adjust prior periods. We appliedthe modified retrospective method only to contracts that were not complete at January 1, 2018 and accounted for the aggregate effect ofany contract modifications upon adoption. No cumulative adjustment to retained earnings was recorded.HealthcareHealthcare segment revenue includes revenue from MCT, event, traditional Holter, extended-wear Holter, Pacemaker andInternational Normalized Ratio (“INR”) monitoring services. A significant portion of our revenue is paid for by third-party commercialinsurance organizations and governmental entities. We also receive reimbursement directly from patients through co-pays, deductiblesand self-pay arrangements.For contracted payors, including Medicare, we determine revenue based on negotiated prices for the services provided. Basedon our history, we have experience collecting substantially all of the negotiated contracted rates and are therefore not providing animplicit price concession. As a result, any adjustments to the revenue recognized are due to patient default and are recorded as bad debtexpense.For non-contracted payors, we are providing an implicit price concession because we do not have a contract with theunderlying payor. As a result, we estimate our expected revenue based on historical cash collections. Subsequent adjustments to therevenue recognized are recorded as an adjustment to Healthcare revenue and not as bad debt expense.68Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)ResearchResearch segment revenue includes revenue for core laboratory services. Our Research segment revenue is provided on a fee-for-service basis, and revenue is recognized as the related services are performed. Our research customer contracts have legallyenforceable terms that are predominately thirty days due to termination for convenience clauses, which are held by the customer withno significant penalty. Given the short-term nature of these contracts and the structure of our billing practices, our billing practicesapproximate our performance if measured by an output method, where each output is an individual occurrence of each performanceobligation. Accordingly, we utilize the invoice practical expedient as defined in ASC 606, resulting in recognition of revenue in theamount that we have the right to invoice. We record reimbursements received for out-of-pocket expenses, including freight, as revenuein the accompanying consolidated statements of operations.OtherOther revenue includes revenue received from the sale of non-invasive cardiac monitors to healthcare companies, wirelessblood glucose meters and test strips to wholesale distributors of diabetes supplies and diabetic patients as well as product repairs and isrecognized when products are shipped.Revenue is recognized net of any taxes collected from customers and subsequently remitted to government authorities.See “Note 3. Revenue Recognition” for more information.o) Stock-Based CompensationASC 718 - Compensation—Stock Compensation (“ASC 718”), addresses the accounting for share-based payment transactionsin which an enterprise receives employee services in exchange for: (i) equity instruments of the enterprise or (ii) liabilities that are basedon the fair value of the enterprise’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718requires that an entity measure the cost of equity-based service awards issued to employees, such as stock options and restricted stockunits (“RSUs”), based on the grant-date fair value of the award and recognize the cost of such awards over the requisite service period(generally, the vesting period of the award). ASC 718 requires that an entity measure the cost of liability-based service awards basedon current fair value that is remeasured subsequently at each reporting date through the settlement date. The compensation expenseassociated with performance stock units (“PSUs”) is recognized ratably over the period between when the performance conditions aredeemed probable of achievement and when the awards are vested. Performance stock options (“PSOs”) are valued and stock-basedcompensation expense is recorded once the performance conditions of the outstanding PSOs have achieved probability. Prior to July 1,2018, we accounted for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees; see “t) Recent Accounting Pronouncements” below for further details related to our adoption of Accounting StandardsUpdate (“ASU”) 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based PaymentAccounting, during the quarter ended September 30, 2018 and our current accounting for equity awards issued to non-employees.We have historically recorded stock-based compensation expense based on the number of stock options or stock units weexpect to vest using our historical forfeiture experience and we periodically update those forfeiture rates to apply to new grants. Whilewe early adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, during the year ended December 31,2016, we have elected69Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)to continue to estimate forfeitures under the true-up provision of ASC 718. We record additional expense if the actual forfeiture rate islower than estimated and record a recovery of prior expense if the actual forfeiture rate is higher than estimated.We estimate the fair value of our stock options using the Black‑Scholes option valuation model. The Black‑Scholes optionvaluation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of theexpected volatility of the market price of our stock and the expected term of the award. We base our estimates of expected volatility onthe historical average of our stock price. The expected term represents the period of time that share‑based awards granted are expectedto be outstanding. Other assumptions used in the Black‑Scholes option valuation model include the risk‑free interest rate and expecteddividend yield. The risk‑free interest rate for periods pertaining to the expected term of each option is based on the U.S. Treasury yieldof a similar duration in effect at the time of grant. We have never paid, and do not expect to pay, dividends in the foreseeable future.We estimate the fair value of our PSUs using a Monte Carlo simulation. This model uses assumptions, including the risk freeinterest rate, expected volatility of our stock price and those of the performance group, dividends of the performance group membersand expected life of the awards. As noted above, we continue to estimate forfeitures under the true-up provision of ASC 718. If it isdeemed probable that the PSU performance targets will be met, compensation expense is recorded for these awards ratably over therequisite service period. The PSUs are forfeited to the extent the performance criteria are not met within the service period.p) Research and Development CostsResearch and development costs are charged to expense as incurred.q) Income TaxesWe account for income taxes under the liability method, as described in ASC 740 - Income Taxes (“ASC 740”). Deferredincome taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting basesof assets and liabilities. When we determine that we will not be able to realize our deferred tax assets, we adjust the carrying value ofthe deferred tax assets through the valuation allowance.We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (i) we determinewhether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) forthose tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is morethan 50 percent likely to be realized upon ultimate settlement with the related tax authority.On December 22, 2017, the Tax Cuts and Jobs Act (the “TCJA”) was enacted in the U.S. The TCJA represents sweepingchanges in U.S. tax law. Under ASC 740, the effects of changes in tax rates and tax laws on deferred tax balances are recognized inthe period in which the new legislation is enacted. The total effect of tax law changes on deferred tax balances is recorded as acomponent of income tax expense.In response to the TCJA, the Staff of the U.S. Securities and Exchange Commission (“SEC”) issued Staff Accounting BulletinNo. 118 (“SAB 118”) to provide guidance to registrants in applying ASC 740 in connection with the TCJA. SAB 118 provides thatin the period of enactment, the income tax effects of70Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)the TCJA may be reported as a provisional amount based on a reasonable estimate (to the extent a reasonable estimate can bedetermined), which would be subject to adjustment during a “measurement period.” The measurement period begins in the reportingperiod of the TCJA’s enactment and ends when a registrant has obtained, prepared, and analyzed the information that was needed inorder to complete the accounting requirements under ASC 740. SAB 118 also describes supplemental disclosures that shouldaccompany the provisional amounts. We applied the guidance in SAB 118 to account for the financial accounting impacts of the TCJAand have provided the applicable supplemental disclosures in “Note 17. Income Taxes.”As of December 31, 2017, we recorded the provisional impact from the TCJA in accordance with SAB 118. We finalized ouradjustments related to the impact of the TCJA during the year ended December 31, 2018.r) Net Income/(Loss) Per ShareWe compute net income/(loss) per share in accordance with ASC 260 - Earnings Per Share. Basic net income/(loss) per shareis computed by dividing net income/(loss) by the weighted average number of common shares outstanding during the period. Dilutednet income/(loss) per share is computed by giving effect to all potential dilutive common stock equivalents, including stock options,RSUs, PSOs and PSUs, using the treasury stock method. Potentially dilutive common stock equivalents are not included in theweighted-average shares outstanding for determining net loss per share for the year ended December 31, 2017, as the result would beanti-dilutive.Certain stock options, which are priced higher than the market price of our shares as of December 31, 2018, 2017 and 2016would be anti-dilutive and therefore have been excluded from the weighted average shares used in computing diluted net income pershare. These options could become dilutive in future periods. Similarly, certain recently granted RSUs are also excluded using thetreasury stock method as their impact would be anti-dilutive. The dilutive effect of weighted average shares outstanding excludesapproximately 0.5 million and 0.4 million shares for the years ended December 31, 2018 and December 31, 2016, respectively, as theireffect would have been anti-dilutive on our net income per share.s) Segment InformationASC 280 - Segment Reporting, establishes standards for reporting information regarding operating segments in annual financialstatements. Operating segments are identified as components of an enterprise which are engaged in business activities to generaterevenue and incur expenses, for which separate discrete financial information is available and regularly reviewed by the chief operatingdecision maker, or decision-making group, for evaluation on how to allocate resources and assess performance.We report our business under two segments: Healthcare and Research. The Healthcare segment is focused on remote cardiacmonitoring to identify arrhythmias or heart rhythm disorders. We offer cardiologists, electrophysiologists, neurologists and primary carephysicians a full spectrum of solutions, which provides them with a single source of remote cardiac monitoring services. The Researchsegment is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, scientific consulting anddata management services for drug and medical device trials. During the first quarter of 2018, as part of the LifeWatch integration, ourforward-looking integration and rebranding plans, as well as re-evaluating the significance and materiality of our segments, weaggregated the Technology operating segment into the Corporate and Other category. Included in the Corporate and Other category isthe manufacturing, testing and marketing of cardiac and blood glucose monitoring devices to medical71Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)companies, clinics and hospitals and corporate overhead and other items not allocated to any of our reportable segments.t) Recent Accounting PronouncementsAccounting Pronouncements Recently AdoptedIn June 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-07, Compensation - StockCompensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This update expands the scope ofTopic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments specifythat Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed ina grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply toshare-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods orservices to customers as part of a contract accounted for under ASC 606. The amendments in ASU 2018-07 are effective for publicbusiness entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption ispermitted. We early-adopted this standard on July 1, 2018, effective January 1, 2018, and this standard did not have a material impacton our financial position, results of operations or disclosures.In March 2018, the FASB issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting BulletinNo. 118, to add various SEC paragraphs pursuant to the issuance of SAB 118 to ASC 740. SAB 118 was issued by the SEC inDecember 2017 to provide immediate guidance for accounting implications of U.S. tax reform under the TCJA. We have evaluated thepotential impacts of SAB 118 and have applied this guidance to our consolidated financial statements and related disclosures as ofJanuary 1, 2018.In May 2017, the FASB released ASU 2017-09, Scope of Modification Accounting, which clarifies the changes to terms orconditions of a share-based payment award that requires application of modification accounting under Topic 718. A change to anaward should be accounted for as a modification unless the fair value of the modified award is the same as the original award, thevesting conditions do not change and the classification as an equity or liability instrument does not change. This update is effective forannual reporting periods, and interim periods within those annual periods, beginning after December 15, 2017. We adopted thisstandard effective January 1, 2018, and this standard did not have a material impact on our financial position, results of operations ordisclosures.In January 2017, the FASB released ASU 2017-01, Business Combinations: Clarifying the Definition of a Business, whichclarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions shouldbe accounted for as acquisitions or disposals of assets or businesses. The amendments in this ASU should be applied prospectively andare effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with earlyadoption permitted. No disclosures are required at transition. We adopted this standard effective January 1, 2018, and this standard didnot have a material impact on our financial position, results of operations or disclosures.In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which has been updated throughseveral revisions and clarifications since its original issuance (collectively, the “Revenue Updates”). The Revenue Updates requirerevenue recognized to represent the transfer of promised goods or services to customers at an amount that reflects the consideration thata company expects72Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)to receive in exchange for those goods or services. The Revenue Updates also require new, expanded disclosures regarding revenuerecognition. We adopted the Revenue Updates effective January 1, 2018. See “Note 3. Revenue Recognition.”Accounting Pronouncements Not Yet AdoptedIn August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a CloudComputing Arrangement That Is a Service Contract, to align the requirements for capitalizing implementation costs incurred in ahosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtaininternal-use software. The updated guidance also requires an entity to expense the capitalized implementation costs of a hostingarrangement that is a service contract over the term of the hosting arrangement. This guidance is effective for fiscal years beginningafter December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. We are in the process ofevaluating the impact of this guidance on our consolidated financial statements and related disclosures.In February 2016, the FASB issued ASU 2016-02, Leases. This standard, along with several subsequent updates (whichcollectively will be known as Accounting Standards Codification 842 - Leases (“ASC 842”), is an update and amendment to ASC840, Leases (“ASC 840”), and requires lessees to recognize most leases on their balance sheet, makes selected changes to lessoraccounting and requires disclosure of additional key information about leases. The standard is effective for annual and interim reportingperiods beginning after December 15, 2018. A modified retrospective transition approach is required, with certain practical expedientsavailable.The following are other key disclosures, as well as determinations made and actions taken by us, related to the adoption ofASC 842:•Elected the optional modified retrospective transition method as of January 1, 2019; therefore prior period amounts will notbe restated;•Established and implemented key implementation controls to ensure we meet the new reporting and disclosurerequirements;•Elected the following transition practical expedients:•to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into priorto the adoption of ASC 842;•to not separate lease and non-lease components when the requisite criteria is met to be treated as such;•Made policy elections as of January 1, 2019:•to not apply the recognition and measurement requirements to leases with an initial term of one year or less;•to apply the portfolio approach for the development of the discount rate related to leases with similar characteristics;•to keep leases with an immaterial right-of-use asset at inception, off the balance sheet and recognize this expense on astraight-line basis in our consolidated statements of operations;73Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)•Determined the completeness of our lease populations (both lessee and lessor) as of January 1, 2019;•Expect that the adoption of ASC 842 will materially change our balance sheet by increasing the lease right-of-use assetsand lease liabilities to be presented on the balance sheet due primarily to our real estate operating leases;•Do not expect ASC 842 to:•materially impact our liquidity or ability to enter or exit leases. ASC 842 does not change the cash payment streamrelated to our leases but will affect the presentation on our consolidated statement of cash flows with added disclosureof the non-cash impact for the change in assets and liabilities related to right-of-use assets and obligations;•have a material impact on our debt covenants;•Continue to evaluate new agreements executed after December 31, 2018, including identifying all contracts that are, orcontain, leases and to accumulate all the necessary information required to properly account for those leases under ASC842.We expect to complete our assessment of the full financial impact of ASC 842 during the first quarter of 2019, and will includeall required presentation and disclosures under ASC 842 in our Form 10-Q for the three months ending March 31, 2019.3. Revenue RecognitionWe adopted ASC 606 on January 1, 2018, which requires revenue recognized to represent the transfer of promised goods orservices to customers at an amount that reflects the consideration that a company expects to receive in exchange for those goods orservices.We utilized the modified retrospective method for adoption, allowing us to not retrospectively adjust prior periods. We appliedthe modified retrospective method only to contracts that were not complete at January 1, 2018 and accounted for the aggregate effect ofany contract modifications upon adoption. No cumulative adjustment to retained earnings was recorded.Disaggregation of RevenueWe disaggregate revenue from contracts with customers by payor type and major service line. We determined thatdisaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, amount,timing and uncertainty of our revenue streams. Disaggregated revenue by payor type and major service line for the year endedDecember 31, 2018 was as follows:74Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued) Year Ended December 31, 2018(in thousands)Healthcare Research Other Total ConsolidatedPayor/Service Line Remote cardiac monitoring services - Medicare$137,600 $— $— $137,600Remote cardiac monitoring services - commercial payors201,212 — — 201,212Clinical trial support and related services— 50,561 — 50,561Technology devices, consumable and related services— — 10,099 10,099Total$338,812 $50,561 $10,099 $399,472Remote Cardiac Monitoring Services Revenue (Healthcare segment)Healthcare segment revenue is generated by remote cardiac monitoring to identify cardiac arrhythmias or heart rhythmdisorders. We offer cardiologists, electrophysiologists, neurologists and primary care physicians a full spectrum of solutions whichprovides them with a single source of cardiac monitoring services.Performance obligations are determined based on the nature of the services provided. With our remote cardiac monitoringservices, the patient receives the benefits of the service over time, resulting in revenue recognition over time based on the outputmethod. We believe that this method provides an accurate depiction of the transfer of value over the term of the performance obligationbecause the level of effort in providing these services is consistent during the service period.A summary of the payment arrangements with payors is as follows:•Contracted payors (including Medicare): We determine the transaction price based on negotiated prices for servicesprovided, on a case rate basis, as provided for under the relevant Current Procedural Terminology (“CPT”) codes.•Non-contracted payors: Non-contracted commercial and government insurance carriers often reimburse out of networkrates provided for under the relevant CPT codes on a case rate basis. Our transaction price includes implicit priceconcessions based on our historical collection experience for our non-contracted patientsWe are utilizing the portfolio approach practical expedient in ASC 606 for our patient contracts in the Healthcare segment. Weaccount for the contracts within each portfolio as a collective group, rather than individual contracts. Based on our history with theseportfolios and the similar nature and characteristics of the patients within each portfolio, we have concluded that the financial statementeffects are not materially different than if accounting for revenue on a contract-by-contract basis.For the contracted portfolio, we have historical experience of collecting substantially all of the negotiated contractual rates anddetermined at contract inception that these customers have the intention and ability to pay the promised consideration. As such, we arenot providing an implicit price concession but, rather, have chosen to accept the risk of default, and adjustments to the transaction priceare recorded as bad debt expense.For our non-contracted portfolio, we are providing an implicit price concession because we do not have a contract with theunderlying payor, the result of which requires us to estimate our transaction price75Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)based on historical cash collections utilizing the expected value method. Subsequent adjustments to the transaction price are recordedas an adjustment to Healthcare segment revenue and not as bad debt expense.We have not made any significant changes to judgments in applying ASC 606 during the year ended December 31, 2018.Clinical Trial Support and Related Services Revenue (Research segment)Research segment revenue is generated by providing centralized core laboratory services, including cardiac monitoring,imaging services, scientific consulting and data management services for drug and medical device trials. These amounts are due frompharmaceutical companies and contract research organizations. We bill our customers on a fee for service basis. Under a typicalcontract, some customers pay us a portion of our fee for these services upon contract execution as an upfront refundable deposit.Upfront deposits are deferred and then recognized as the services are performed. If a contract is canceled prior to service beingprovided, the upfront deposit is refunded.Performance obligations are determined based on the nature of the services provided by us. Our core laboratory services areprovided over time as the customer receives benefits resulting in revenue recognition over the term of the contract. Our researchcustomer contracts have legally enforceable terms that are predominately thirty days due to termination for convenience clauses, whichare held by the customer with no significant penalty. Given the short-term nature of these contracts and the structure of our billingpractices, our billing practices approximate our performance if measured by an output method, where each output is an individualoccurrence of each performance obligation. Accordingly, we utilize the invoice practical expedient as defined in ASC 606, resulting inrecognition of revenue in the amount that we have the right to invoice.We have not made any significant changes to judgments in applying ASC 606 during the year ended December 31, 2018.Other Revenue (Other category)Our Other category revenue is primarily derived from the sale of non-invasive cardiac monitors to healthcare companies,wireless blood glucose meters and test strips to wholesale distributors of diabetes supplies and diabetic patients as well as productrepairs. Performance obligations are the sale of devices, related goods and repairs provided by us. These contracts transfer control to acustomer at a point in time based on the transfer of title for the underlying good or service. We provide standard warranty provisions.We determine the transaction price based on fixed consideration in our contractual agreements with our customers and allocatethe transaction price to each performance obligation based on the relative stand-alone selling price. We determine the relative stand-alone selling price utilizing our observable prices for the sale of the underlying goods.We have not made any significant changes to judgments in applying ASC 606 during the year ended December 31, 2018.Contract Assets and Contract LiabilitiesASC 606 requires an entity to present a revenue contract as a contract asset when the entity performs its obligations under thecontract by transferring goods or services to a customer before the customer pays consideration or before payment is due. ASC 606also requires an entity to present a revenue contract as76Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that isunconditional (e.g. receivable), before the entity transfers a good or service to the customer.We currently do not have any material contract assets. We recognize contract liabilities in the form of deferred revenue in theResearch segment in instances where a customer pays an upfront deposit upon contract execution for future services to be performedby us.As of December 31, 2018, we had contract liabilities of $3.1 million primarily related to the Research segment wherecustomers paid upfront deposits upon contract execution for future services to be performed by us. If the contract is canceled, theseupfront deposits are refundable if service was not yet provided. For the year ended December 31, 2018, the amount recognized asrevenue from the deferred revenue balance as of December 31, 2017 was $3.1 million. No significant changes or impairment lossesoccurred to contract balances during the year ended December 31, 2018.Practical Expedient ElectionsWe have elected the following practical expedients in applying ASC 606 across all reportable segments unless otherwise notedbelow.Unsatisfied Performance Obligations: Because all of our performance obligations relate to contracts with a duration of lessthan one year, we have elected to apply the optional exemption provided in ASC 606 and, therefore, are not required todisclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partiallyunsatisfied at the end of the reporting period.Contract Costs: All incremental customer contract acquisition costs are expensed as they are incurred as the amortizationperiod of the asset that we otherwise would have recognized is one year or less in duration.Significant Financing Component: We do not adjust the promised amount of consideration for the effects of a significantfinancing component as we expect, at contract inception, that the period between when we transfer a promised good or serviceto a customer and when the customer pays for that good or service will be one year or less.Sales Tax Exclusion from the Transaction Price: We exclude from the measurement of the transaction price all taxes assessedby a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction andcollected by us from the customer.Shipping and Handling Activities: For our technology devices, consumable and related service revenue, we account forshipping and handling activities we perform after a customer obtains control of the good as activities to fulfill the promise totransfer the good.4. AcquisitionsActiveCareOn October 2, 2018, we acquired, through our subsidiary Telcare Medical Supply, LLC, certain assets of ActiveCare, Inc.(“ActiveCare”) for $3.8 million in cash. The purchase price also includes a77Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)potential earn-out payment of $2.0 million, which is contingent on the achievement of certain revenue targets. The acquired net assetsprimarily consisted of customer relationships. The earn-out was assigned no value as of the acquisition date as it is currently notprobable of achievement. The accounting for this transaction, including the valuation of certain intangible assets, remains open as ofDecember 31, 2018. We have preliminarily accounted for this acquisition as a business combination. Our preliminary estimates aresubject to subsequent adjustment as additional information is obtained and we expect to finalize all accounting for this transaction whenthe valuation is complete. The transaction costs related to this acquisition and revenues and income of ActiveCare prior to ouracquisition were all immaterial.LifeWatch AGOn July 12, 2017, we acquired, through our wholly owned subsidiary Cardiac Monitoring Holding Company, LLC,approximately 97.0% of the outstanding shares of LifeWatch AG for aggregate consideration of 3,615,840 shares of BioTelemetrycommon stock with a fair value of $116.8 million and cash in the amount of $165.8 million. On that date, we acquired control ofLifeWatch and began consolidating its financial statements.Through December 31, 2017, we purchased 343,525 additional shares of LifeWatch for cash consideration of $4.8 million andthe issuance of 19,806 shares with a fair value of $0.6 million. We acquired the remaining untendered LifeWatch shares pursuant to asqueeze-out procedure in accordance with Swiss law and takeover regulations related to the offering occurring in early January 2018,with the settlement of $2.9 million cash, which was recorded as a component of accrued liabilities in our consolidated balance sheets,and 58,786 shares with a fair market value of $2.0 million, which was recorded as a component of paid-in capital in our consolidatedbalance sheets, both as of December 31, 2017. As of December 31, 2017, we owned 100% of LifeWatch.Also on July 12, 2017, in connection with the closing of the acquisition of LifeWatch, and refinancing of our existing debt, weentered into the SunTrust Credit Agreement pursuant to which we obtained loans as follows; (i) a term loan (funded on July 12, 2017)in an aggregate principal amount equal to $205.0 million, the proceeds of which were used to (a) pay our existing GE CreditAgreement of $24.9 million and acquired LifeWatch debt of $3.0 million, (b) pay a portion of the cash consideration for the acquisitionof LifeWatch, and (c) pay related transaction fees and expenses of the acquisition of LifeWatch; and (ii) a $50.0 million revolvingcredit facility for ongoing working capital purposes, which remains undrawn. The term loan will be repaid in quarterly installmentsbeginning January 1, 2018, with the remaining principal balance repaid on or before July 12, 2022. For more information regarding thefinancing of this acquisition, please refer to “Note 11. Credit Agreement.”The acquisition of LifeWatch strengthens our position as the leader in wireless medicine, creating the foremost connectedhealth platform, significantly enhancing our ability to improve quality of life and reduce cost of care. We accounted for the transactionas a business combination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values. Theexcess of the fair value of the purchase price over the fair value of the net assets acquired has been recognized as goodwill, whichrepresents the expected future benefits arising from the assembled workforce and other synergies attributable to cost savingsopportunities. We recognized $198.8 million of goodwill as a result of the acquisition, all of which has been assigned to the Healthcaresegment. None of this goodwill will be deductible for tax purposes.78Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)We finalized our estimates related to the LifeWatch acquisition by July 12, 2018. The measurement period adjustmentsrecorded in 2018 were due primarily to a $5.7 million adjustment to increase accrued liabilities related to the ZTech legal matter (see“Note 19. Legal Proceedings” for details) and an $8.9 million increase to other long-term liabilities.(in thousands, except lives)Amount WeightedAverage Life(Years)Fair value of assets acquired: Cash and cash equivalents$4,303 Healthcare accounts receivable10,089 Inventory1,136 Prepaid expenses and other current assets3,798 Property and equipment27,507 Other assets713 Identifiable intangible assets: Customer relationships126,800 10Technology3,217 3Total identifiable intangible assets130,017 Total assets acquired177,563 Fair value of liabilities assumed: Accounts payable10,292 Accrued liabilities15,579 Current portion of capital lease obligations4,664 Current portion of long-term debt3,027 Long-term capital lease obligations3,420 Deferred tax liabilities14,465 Other long-term liabilities32,364 Total liabilities assumed83,811 Total identifiable net assets93,752 Fair value of noncontrolling interest(9,961) Goodwill198,783 Net assets acquired$282,574 We have integrated the operations of LifeWatch into our Healthcare segment. As a result of this integration, it is impracticableto disclose the amount of revenue and income/(loss) attributable to LifeWatch.We incurred $31.0 million of acquisition related costs related to LifeWatch for the year ended December 31, 2017. These costswere included in other charges in our consolidated statements of operations.The following unaudited pro forma financial information has been prepared using historical financial results of BioTelemetryand LifeWatch as if the acquisition had occurred as of January 1, 2016. Certain79Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)adjustments related to the elimination of transaction costs, as well as the addition of depreciation and amortization related to fair valueadjustments on the tangible and identifiable intangible assets acquired, have been reflected for the purposes of the unaudited pro formafinancial information presented below. We believe the assumptions used in preparing the unaudited pro forma financial information arereasonable, but not necessarily indicative of actual results should the acquisition have occurred on January 1, 2016.Pro forma financial information for the periods presented is summarized as follows: Year Ended December 31,(pro forma, unaudited, in thousands, except share and per share amounts)2017 2016Revenue$349,900 $322,200Net income/(loss)(1,800) 23,400Net income/(loss) per common share: Basic$(0.05) $0.74Diluted$(0.05) $0.69Weighted average number of common shares outstanding: Basic34,022 31,556Diluted34,022 34,125Telcare, Inc.On December 1, 2016, we, through our wholly owned subsidiary BioTelemetry Care Management, LLC, entered into theShare and Asset Purchase Agreement with Telcare (the “Telcare Agreement”) pursuant to which we acquired the stock of TelcareMedical Supply, Inc. (“Telcare”) and certain assets of Telcare Inc. The total consideration paid at closing amounted to $7.0 million incash, with the potential for a performance-based earn out up to $5.0 million upon reaching certain revenue milestones. The fair value ofthe total consideration transferred in the acquisition, including the fair value of the contingent consideration, was $9.7 million at theacquisition date.The acquisition of Telcare provides us the opportunity to apply our expertise in remote monitoring to the diabetes market andincreases our presence in the digital population health management market. We accounted for the transaction as a businesscombination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values. The excess of the fairvalue of the purchase price over the fair value of the net assets acquired has been recognized as goodwill, which represents theexpected future benefits arising from the assembled workforce and other synergies attributable to cost savings opportunities. Werecognized $2.2 million of goodwill as a result of the acquisition, all of which has been assigned to the Corporate and Other category.We expect $0.3 million of this goodwill will be deductible for tax purposes.The amounts below represent our final fair value estimates, which were completed in the fourth quarter ended December 31,2017. The total consideration and related allocation for Telcare is summarized as follows:80Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)(in thousands, except lives)Amount WeightedAverage Life(Years)Fair value of assets acquired: Other accounts receivable$235 Inventory1,417 Prepaid expenses and other current assets1,261 Property and equipment55 Other assets933 Deferred tax assets1,463 Identifiable intangible assets: Customer relationships400 5Technology2,000 5Tradename400 IndefiniteTotal identifiable intangible assets2,800 Total assets acquired8,164 Fair value of liabilities assumed: Accounts payable459 Accrued liabilities206 Total liabilities assumed665 Total identifiable net assets7,499 Goodwill2,201 Net assets acquired$9,700 The acquisition has been included within the consolidated results of operations and financial condition from the date of theacquisition.The following unaudited pro forma financial information has been prepared using historical financial results of BioTelemetryand Telcare as if the acquisition had occurred as of January 1, 2015. Certain adjustments related to the elimination of transaction costs,as well as the addition of depreciation and amortization related to fair value adjustments on the tangible and identifiable intangibleassets acquired, have been reflected for the purposes of the unaudited pro forma financial information presented below. We believe theassumptions used in preparing the unaudited pro forma financial information are reasonable, but not necessarily indicative of actualresults should the acquisition have occurred on January 1, 2015.81Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)Pro forma financial information is summarized as follows:(pro forma, unaudited, in thousands, except per share amounts)Year EndedDecember 31, 2016Revenue$212,538Net income50,693Net income per common share: Basic$1.82Diluted$1.66The Telcare Agreement includes the potential for a performance-based earn out up to $5.0 million upon reaching certainmilestones. The fair value of the contingent consideration associated with the Telcare acquisition was $2.7 million as of the acquisitiondate and was included as a component of other long-term liabilities. For further details regarding contingent consideration, refer to“Note 6. Fair Value Measurements” below.VirtualScopics, Inc.On March 25, 2016, we, through our wholly owned subsidiary BioTelemetry Research Acquisition Corporation, entered into adefinitive Agreement and Plan of Merger (“VirtualScopics Merger Agreement”) with VirtualScopics, Inc. (“VirtualScopics”), aleading provider of clinical trial imaging solutions. Under the terms of the VirtualScopics Merger Agreement, we purchased: (i) anyand all outstanding shares of VirtualScopics’ $0.001 par value common stock for $4.05 per share; (ii) any and all outstanding shares ofVirtualScopics’ $0.001 par value Series A and Series B Convertible Preferred Stock for $336.30 per share; and (iii) any and alloutstanding shares of VirtualScopics’ $0.001 par value Series C-1 Convertible Preferred Stock for $920.00 per share. The all cashacquisition of VirtualScopics was completed on May 11, 2016. The total consideration paid at closing amounted to $15.0 million, netof cash acquired of $0.8 million.The acquisition of VirtualScopics expands our existing clinical research offerings and gives us further access to establishedcustomer relationships. We accounted for the transaction as a business combination, and as such, all assets acquired and liabilitiesassumed were recorded at their estimated fair values. The excess of the consideration paid over the fair value of the net assets acquiredhas been recognized as goodwill, which represents the expected future benefits arising from the assembled workforce and othersynergies attributable to cost savings opportunities. We recognized $4.3 million of goodwill as a result of the acquisition, all of whichhas been assigned to the Research segment. None of this goodwill will be deductible for tax purposes.The amounts below represent our final fair value estimates, which were completed in the second quarter of 2017. Measurementperiod adjustments were recorded in the fourth quarter of 2016 related to the recognition of a $0.3 million deferred tax liability, and inthe second quarter of 2017 primarily to recognize $0.3 million of deferred tax assets resulting from state net operating losses.82Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)The total consideration and related allocation for VirtualScopics is summarized as follows:(in thousands, except lives)Amount WeightedAverage Life(Years)Fair value of assets acquired: Cash and cash equivalents$849 Other accounts receivable3,679 Inventory111 Prepaid expenses and other current assets396 Property and equipment500 Deferred taxes20 Identifiable intangible assets: Customer relationships5,200 12Technology2,000 10Backlog3,100 4Total identifiable intangible assets10,300 Total assets acquired15,855 Fair value of liabilities assumed: Accounts payable325 Accrued liabilities2,945 Current portion of capital lease obligations59 Current portion of long-term debt91 Deferred revenue700 Long-term capital lease obligations162 Long-term debt97 Total liabilities assumed4,379 Total identifiable net assets11,476 Goodwill4,343 Net assets acquired$15,819 The acquisition has been included within the consolidated results of operations and financial condition from the date of theacquisition. For the period from May 11, 2016 to December 31, 2016, VirtualScopics contributed revenue of approximately $12.3million and net income of approximately $1.4 million to our consolidated results of operations.The following unaudited pro forma financial information has been prepared using historical financial results of BioTelemetryand VirtualScopics as if the acquisition had occurred as of January 1, 2015. Certain adjustments related to the elimination of transactioncosts and acquisition-related indebtedness, as well as the addition of depreciation and amortization related to fair value adjustments onthe tangible and identifiable intangible assets acquired, have been reflected for the purposes of the unaudited pro forma financialinformation presented below. No adjustments for synergies or certain other expected benefits of the acquisition have been included.We believe the assumptions used in preparing the unaudited pro forma83Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)financial information are reasonable, but not necessarily indicative of actual results should the acquisition have occurred on January 1,2015.Pro forma financial information is summarized as follows:(pro forma, unaudited, in thousands, except per share amounts)Year EndedDecember 31, 2016Revenue$214,271Net income55,413Net income per common share: Basic$1.98Diluted$1.82ePatch Division of DELTA Danish Electronics, Light, and AcousticsOn April 1, 2016, we, through our wholly owned subsidiary BioTelemetry Technology ApS, entered into an Asset PurchaseAgreement (“APA”) with DELTA Danish Electronics, Light & Acoustics (“DELTA”), pursuant to which we acquired substantiallyall of the assets of the ePatch division of DELTA, inclusive of all products and indications currently under development. The totalconsideration paid at closing amounted to $3.0 million in cash and 244,519 shares of our common stock valued at $2.9 million. Inaddition, there is the potential for a performance-based earn out up to $3.0 million upon reaching certain regulatory and revenuemilestones, as defined in the APA. The fair value of the total consideration transferred in the ePatch acquisition, including the fair valueof the contingent consideration, was $6.5 million at the acquisition date.The ePatch acquisition is expected to generate future cost savings for us and will provide control over proprietary componentsfor our next generation mobile cardiac telemetry device. We accounted for the transaction as a business combination, and as such, allassets acquired and liabilities assumed were recorded at their estimated fair values. The excess of the fair value of the purchase priceover the fair value of the net assets acquired has been recognized as goodwill, which represents the expected future benefits arisingfrom the assembled workforce and other synergies attributable to cost savings opportunities. We recognized $3.2 million of goodwill asa result of the acquisition, all of which has been assigned to the Corporate and Other category, and we expect all of this goodwill to bedeductible for tax purposes.The amounts below represent our final fair value estimates, which we completed in the first quarter of 2017. During the fourthquarter of 2016, we reduced the allocation to the technology intangible asset by $0.2 million as a result of additional informationobtained during the measurement period.84Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)The total consideration and related allocation for the ePatch acquisition is summarized as follows:(in thousands, except lives)Amount WeightedAverage Life(Years)Fair value of assets acquired: Inventory$100 Property and equipment175 Identifiable intangible assets: Customer relationships400 10Technology2,800 10Trade names100 IndefiniteTotal identifiable intangible assets3,300 Total assets acquired3,575 Fair value of liabilities assumed: Accrued liabilities266 Total liabilities assumed266 Total identifiable net assets3,309 Goodwill3,181 Net assets acquired$6,490 While the ePatch acquisition provides control over proprietary components of our next generation cardiac monitoring device,the acquisition did not have a material effect on our consolidated results of operations.The APA includes the potential for a performance-based earn out up to $3.0 million upon reaching certain regulatory andrevenue milestones. The fair value of the contingent consideration associated with the ePatch acquisition was $0.6 million as of theacquisition date and was included as a component of other long-term liabilities. For further details regarding contingent consideration,refer to “Note 6. Fair Value Measurements” below.5. InventoryInventory consists of the following: December 31,(in thousands)2018 2017Raw materials and supplies$3,667 $3,128Finished goods3,656 2,204Total inventory$7,323 $5,33285Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)Inventory, which includes purchased parts, materials, direct labor and applied manufacturing overhead, is stated at the lower ofcost or market (net realizable value or replacement cost), with cost determined by use of the first-in, first-out method.6. Fair Value MeasurementsWe have determined that our long-term debt, classified as Level 2, has a fair value consistent with its carry value, exclusive ofdebt discount and deferred charges, of $198.5 million and $199.4 million as of December 31, 2018 and 2017, respectively.Contingent consideration represents our contingent milestone payment obligations related to our acquisitions and is measured atfair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair valuehierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant. We assessthese estimates on an ongoing basis as additional data impacting the assumptions is obtained. The balances of the fair value ofcontingent consideration, if any, are recognized within other long-term liabilities on our consolidated balance sheets. Adjustments tocontingent consideration are recorded in other charges in the consolidated statements of operations.The following table provides a reconciliation of the beginning and ending balances of contingent payments associated withacquisitions during the years ended December 31, 2018 and December 31, 2017: Year Ended December 31,(in thousands)2018 2017Beginning balance$700 $3,305Changes in fair value of contingent consideration(700) (2,605)Ending balance$— $700During the year ended December 31, 2018 and 2017, the fair values of the contingent consideration decreased $0.7 million and$2.6 million, respectively, as it was no longer probable that certain of the contingencies related to both the Telcare or ePatchacquisitions would be met. There was no value assigned to the contingent consideration related to the ActiveCare acquisition as theachievement of the contingency was not probable as of December 31, 2018.86Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)7. Property and EquipmentProperty and equipment consists of the following: EstimatedUseful Life(Years) December 31,(in thousands, except years) 2018 2017Cardiac monitoring devices, device parts and components3 - 5 $76,088 $76,039Computers and purchased software3 - 5 16,800 22,357Equipment, tools and molds3 - 5 6,441 7,857Furniture, fixtures and other5 - 7 3,805 2,104Leasehold improvements* 5,877 5,434Capital leases* 6,568 7,305Total property and equipment, at cost 115,579 121,096Less accumulated depreciation (67,202) (71,902)Total property and equipment, net $48,377 $49,194* shorter of useful life or term of lease Depreciation expense associated with property and equipment, inclusive of amortization of assets recorded under capital leases,was $23.0 million, $18.3 million and $10.5 million, for the years ended December 31, 2018, 2017 and 2016, respectively.During the year ended December 31, 2017, considering the LifeWatch integration and forward-looking integration plans, wedetermined that certain software were no longer going to be used and was therefore impaired, resulting in $1.1 million of impairmentcharges included within the Corporate and Other category as a component of the other charges line in our consolidated statements ofoperations. There were no fixed asset impairments for the years ended December 31, 2018 and December 31, 2016.8. Goodwill and Intangible AssetsGoodwill was recognized at the time of our acquisitions. The following table presents the carrying amount of goodwillallocated to our reportable segments, as well as the changes to goodwill during the years ended December 31, 2018 and 2017: Reporting Segment Corporate andOther (in thousands)Healthcare Research TotalBalance at December 31, 2016$14,724 $16,643 $9,701 $41,068Initial goodwill acquired186,456 — — 186,456Measurement period adjustments(2,907) (350) (1,162) (4,419)Balance at December 31, 2017198,273 16,293 8,539 223,105Initial goodwill acquired— — 475 475Measurement period adjustments15,234 — — 15,234Balance at December 31, 2018$213,507 $16,293 $9,014 $238,81487Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)The goodwill acquired in the Healthcare segment is due to the LifeWatch acquisition; Research segment relates to theVirtualScopics acquisition; the Corporate and Other category primarily represents our Telcare and ePatch acquisitions. Refer to “Note4. Acquisitions” above for details related to the measurement period adjustments.At December 31, 2018, 2017 and 2016, we performed our required annual impairment test of goodwill. Based on theseimpairment tests, we determined that there was no goodwill impairment. The carrying amount of our goodwill as of December 31,2018 and 2017 was $238.8 million and $223.1 million, respectively.The gross carrying amounts and accumulated amortization of our intangible assets as of December 31, 2018 and 2017 are asfollows: WeightedAverage Life(Years) December 31,(in thousands, except years) 2018 2017Gross Carrying Value Customer relationships10.3 $146,200 $143,174Technology including internally developed software5.6 18,078 15,953Backlog3.7 6,860 6,860Covenants not to compete5.5 1,040 1,040Total intangible assets, gross 172,178 167,027Accumulated Amortization Customer relationships (24,870) (10,868)Technology including internally developed software (10,879) (8,573)Backlog (5,827) (5,052)Covenants not to compete (949) (827)Total accumulated amortization (42,525) (25,320)Total intangible assets, net $129,653 $141,707During our intangible asset impairment testing for the year ended December 31, 2017, considering the LifeWatch integrationand forward-looking integration plans, we determined that certain trade names and internally developed software costs were no longergoing to be used and were therefore impaired, resulting in $11.0 million of intangible asset impairment charges included within theCorporate and Other category as a component of the other charges line in our consolidated statements of operations. There were noother intangible asset impairments for the year ended December 31, 2017, and no intangible asset impairments for the years endedDecember 31, 2018 and 2016.88Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)The estimated amortization expense for finite-lived intangible assets for the next five years and thereafter is summarized asfollows at December 31, 2018:(in thousands) 2019$16,678202016,159202115,562202214,819202314,518Thereafter51,917Total estimated amortization$129,653Amortization expense for the years ended December 31, 2018, 2017 and 2016 was $17.2 million, $10.2 million and $3.7million, respectively. The 2017 amortization expense excludes impairment charges of $3.0 million related to indefinite-lived tradenames and $8.0 million related to developed technology and customer relationships. See “Note 13. Other Charges” below.9. Equity Method InvestmentsOn October 31, 2018, we acquired an ownership interest in ADEA Medical AB (“ADEA”), a limited liability companyincorporated and registered under the laws of Sweden, for approximately $0.9 million. This investment is accounted for under theequity method. ADEA serves as a distributor of remote cardiac monitoring devices and a service provider, primarily in northernEurope. ADEA had previously purchased product and had trade receivables and a note receivable with BioTelemetry and therefore isconsidered a related party. Additionally, our Executive Vice President & Chief Financial Officer sits on ADEA’s board of directors.Except for our investment in ADEA, there were no material related-party transactions during the year.We hold an ownership interest in Wellbridge Health, Inc. (“Wellbridge”). The investment is accounted for under the equitymethod. Our Chief Executive Officer sits on Wellbridge’s board of directors, and therefore, Wellbridge is considered a related party.Except for our periodic investment in Wellbridge through capital contributions, there were no related-party transactions.As of December 31, 2018, our investment in ADEA and Wellbridge represented 23.8% and 32.2%, respectively, of theiroutstanding stock. A summary of our investments is as follows: Year Ended December 31,(in thousands)2018 2017Beginning balance$1,431 $1,125Capital contributions859 690Loss from equity method investments(246) (384)Ending balance$2,044 $1,43189Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)10. Accrued LiabilitiesAccrued liabilities consists of the following: December 31,(in thousands)2018 2017Compensation$13,443 $13,694Professional fees4,260 3,816Operating costs1,095 1,170Non-income taxes906 588Interest702 306Facility costs106 802Severance55 1,605Squeeze-out of untendered LifeWatch shares— 2,885Other1,042 1,189Total$21,609 $26,05511. Credit Agreement2017 SunTrust Credit AgreementConcurrent with the acquisition of LifeWatch discussed in “Note 4. Acquisitions” above, we entered into a credit agreementwith SunTrust Bank, as a lender and an agent for the lenders (the “Lenders”) (together, the “SunTrust Credit Agreement”).Pursuant to the credit agreement, the Lenders agreed to make loans to us as follows; (i) a term loan in an aggregate principal amountequal to $205.0 million; and (ii) a $50.0 million revolving credit facility for ongoing working capital purposes. The proceeds of theloans were used to pay our existing GE Credit Agreement of $24.9 million and acquired LifeWatch debt of $3.0 million, pay a portionof the consideration for the acquisition of LifeWatch and pay related transaction fees and expenses of the acquisition of LifeWatch.The loans bear interest at an annual rate, at our election, of (i) with respect to LIBOR rate loans, LIBOR plus the applicablemargin and (ii) with respect to base rate loans, the Base Rate (the “prime rate” as published in the Wall Street Journal plus theapplicable margin). The applicable margin for both LIBOR and Base Rate loans is determined by reference to our Consolidated TotalNet Leverage Ratio, as defined in the credit agreement. As of December 31, 2018, the applicable margin is 1.75% for LIBOR loansand 0.75% for base rate loans.The outstanding principal of the loan will be paid as follows:•Beginning January 1, 2018, the principal amount of the term loan will be repaid, on a quarterly basis, in installments ofapproximately $0.5 million, plus accrued interest;•Beginning January 1, 2019, the principal amount of the term loan will be repaid, on a quarterly basis, in installments ofapproximately $1.3 million, plus accrued interest;90Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)•Beginning January 1, 2020, the principal amount of the term loan will be repaid, on a quarterly basis, in installments ofapproximately $3.8 million, plus accrued interest;•Beginning January 1, 2021, the principal amount of the term loan will be repaid, on a quarterly basis, in installments ofapproximately $5.1 million, plus accrued interest;•The remaining principal balance will be repaid on or before July 12, 2022 (or such earlier date upon an acceleration of theloans by Lenders upon an event of default or by our termination).The loans are secured by substantially all of our assets and by a pledge of our capital stock as well as a pledge of 65% of thecapital stock of its first tier material foreign subsidiaries, including 65% of the capital stock we own of LifeWatch.The carrying amount of the term loan was $198.5 million as of December 31, 2018, which is the principal amount outstanding,net of $4.4 million of unamortized deferred financing costs to be amortized over the remaining term of the credit facility. The revolvingcredit facility is subject to an unused commitment fee, which is determined by reference to the our Consolidated Total Net LeverageRatio, as defined in the credit agreement. Our unused commitment fee as of December 31, 2018 was 0.25% and the revolving creditfacility remains undrawn as of that date.2014 GE Credit AgreementOn December 30, 2014, we entered into a Credit Agreement with Healthcare Financial Solutions, LLC, (“HFS”), previouslyThe General Electric Capital Corporation (“GE Capital”), as agent for the lenders, and as a lender and swingline lender (the “GECredit Agreement”). Pursuant to the GE Credit Agreement, the Lenders agreed to make loans to us as follows: (i) Term Loans in anamount of $25.0 million as of the closing date with an uncommitted ability to increase such Term Loans up to an amount not to exceed$10.0 million and (ii) Revolving Loans up to $15.0 million.CovenantsThe SunTrust Credit Agreement contains affirmative and financial covenants regarding the operations of our business andcertain negative covenants that, among other things, limit our ability to incur additional indebtedness, grant certain liens, make certaininvestments, merge or consolidate, make certain restricted payments and engage in certain asset dispositions, including a sale of all, orsubstantially all, of our property. As of December 31, 2018, we were in compliance with our covenants.Debt ExtinguishmentIn connection with the SunTrust Credit Agreement in 2017, we paid the $24.9 million outstanding indebtedness under theCredit Agreement between BioTelemetry and HFS, previously GE Capital, as agent for the lenders, and as a lender, and we terminatedthe General Electric Credit Agreement. We wrote‑off the unamortized deferred financing fees related to the existing debt of $0.5million, which is included in loss on extinguishment of debt in our consolidated statements of operations for the year ended December31, 2017.91Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)12. LeasesWe lease our principal administrative and service facilities as well as office equipment, certain monitoring devices andinformation technology equipment under arrangements classified as leases under ASC 840 - Leases. We have non-cancelableoperating leases expiring at various dates through 2028. Certain leases are renewable at the end of the lease term. We have also enteredinto and acquired capital leases with various expiration dates through 2022, which were used primarily to finance office equipment,certain monitoring devices and other information technology equipment. Payments made under operating leases are charged tooperations on a straight-line basis over the period of the lease. Differences between straight-line expense and cash payments arerecorded as deferred rent. Rent expense was $6.3 million, $5.8 million and $4.2 million for the years ended December 31, 2018, 2017and 2016, respectively.See “Note 2. Summary of Significant Accounting Policies; t) Recent Accounting Pronouncements; AccountingPronouncements Not Yet Adopted” for further discussion regarding the transition from ASC 840 to ASC 842 effective January 1,2019.Future undiscounted minimum lease payments under non-cancelable operating and capital leases are summarized as follows atDecember 31, 2018:(in thousands)OperatingLeases CapitalLeases2019$5,047 $1,65220204,551 11720213,277 —20222,492 —20232,284 —Thereafter5,807 —Total minimum lease payments$23,458 $1,76913. Other ChargesWe account for expenses associated with exit or disposal activities in accordance with ASC 420 - Exit or Disposal CostObligations, and record the expenses in other charges in our consolidated statements of operations. The related accruals are recorded inthe accrued liabilities line of our consolidated balance sheets.We account for expenses associated with our acquisitions and certain litigation as other charges as incurred. These expenseswere primarily a result of activities surrounding our acquisitions and legal fees related to patent litigation in which we are the plaintiff.Other charges are costs that are not considered necessary to the ongoing business operations. A summary of these expenses is asfollows:92Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued) Year Ended December 31,(in thousands)2018 2017 2016Asset impairment charges$— $12,045 $—Legal fees4,792 8,689 7,177Severance and employee related costs4,484 4,747 645Professional fees2,691 5,614 719Write-off of note receivable1,793 — —Change in fair value of contingent consideration(700) (2,605) —Other costs1,599 2,946 98Total$14,659 $31,436 $8,63914. EquityCommon StockAs of December 31, 2018 and 2017, we were authorized to issue 200,000,000 shares of common stock. As of December 31,2018 and 2017, we had 33,406,364 and 32,460,668 shares issued and outstanding, respectively. During the three months ended March31, 2018, in accordance with the squeeze-out procedures under Swiss Law, we issued 58,786 shares to the remaining stockholders ofLifeWatch. See “Note 4. Acquisitions” for further details related to the LifeWatch acquisition.Preferred StockAs of December 31, 2018, we were authorized to issue 10,000,000 shares of preferred stock. As of December 31, 2018, wemaintained an unregistered blank check preferred stock class, and no shares were authorized. As of December 31, 2018 and 2017,there were no shares of preferred stock issued or outstanding.Noncontrolling InterestDuring 2018, after a formal restructuring of shareholdings approved by the board of directors of LifeWatch Turkey, we becamethe sole shareholder of LifeWatch Turkey. No cash or other consideration was exchanged to effect this transaction. As a result, we nolonger reflect a noncontrolling interest in our consolidated balance sheet; however, we continue to reflect the net loss attributable to thenoncontrolling interest on our consolidated statement of operations for the period of time where we did not own the entire entity.15. Stock-Based CompensationWe have three stock plans: our 2017 Omnibus Incentive Plan (“OIP”), our 2008 Equity Incentive Plan (the “2008 Plan”) andour 2003 Equity Incentive Plan (the “2003 Plan”) (collectively, the “Plans”). The OIP is the only remaining stock plan activelygranting new stock options or units. The purpose of these stock plans was, and the OIP is, to grant incentive stock options toemployees and non-qualified stock options, RSUs, PSOs, PSUs and other stock-based incentive awards to officers, directors,employees and consultants. The Plans are administered by our Board of Directors (the “Board”) or its delegates. The93Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)number, type, exercise price, and vesting terms of awards are determined by the Board or its delegates in accordance with the terms ofthe Plans. The stock options granted expire on a date specified by the Board but generally not more than ten years from the grant date.Stock option grants to employees generally vest over four years while RSUs generally vest after three years.2017 Omnibus Incentive PlanIn May 2017, our stockholders approved the OIP, which replaced the 2008 Plan, with 3,000,000 shares reserved for issuance.Stock options, RSUs, PSUs and PSOs are granted under the OIP. There were 2,274,086 shares available for grant under the OIP as ofDecember 31, 2018.2008 Equity Incentive PlanOur 2008 Plan became effective on March 18, 2008 and replaced our 2003 Plan. Under the terms of the 2008 Plan, allavailable shares in the 2003 Plan share reserve automatically rolled into the 2008 Plan. Any cancellations or forfeitures of granted stockoptions under the 2003 Plan also automatically rolled into the 2008 Plan. There are no shares available to grant under the 2008 Plansubsequent to the approval of the OIP.Stock option and PSO activity is summarized for the years ended December 31, 2018, 2017 and 2016 as follows:Stock OptionsNumber ofShares WeightedAverageExercise Price WeightedAverageRemainingContractualTerm(Years) AggregateIntrinsic Value(in thousands)Outstanding as of December 31, 20153,420,519 $6.69 Granted519,770 13.44 Forfeited(49,709) 9.97 Exercised(322,146) 4.56 Outstanding as of December 31, 20163,568,434 $7.82 Granted543,881 31.12 Forfeited(154,510) 16.22 Exercised(383,366) 9.91 Outstanding as of December 31, 20173,574,439 $10.78 Granted387,306 43.82 Forfeited(114,769) 30.64 Exercised(1,185,694) 8.08 Outstanding as of December 31, 20182,661,282 $15.94 6.0 $117,609Exercisable as of December 31, 20181,844,079 $7.90 4.8 $95,564Expected to vest as of December 31, 2018741,795 $34.08 8.7 $20,01094Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)Performance Stock OptionsNumber ofShares WeightedAverageExercise Price WeightedAverageRemainingContractualTerm(Years) AggregateIntrinsic Value(in thousands)Outstanding as of December 31, 2015200,000 $19.89 Granted— — Forfeited— — Exercised— — Outstanding as of December 31, 2016200,000 $19.89 Granted— — Forfeited— — Exercised(50,000) 18.33 Outstanding as of December 31, 2017150,000 $20.41 Granted— — Forfeited— — Exercised(15,000) 18.33 Outstanding as of December 31, 2018135,000 $20.64 8.0 $5,276Exercisable as of December 31, 2018135,000 $20.64 8.0 $5,276The PSOs met their performance criteria, vested, and were priced as follows:Performance Achievement Date Number ofShares WeightedAverageExercise PriceOctober 4, 2016 100,000 $18.33January 13, 2017 100,000 $21.45A summary of total outstanding stock options and PSOs as of December 31, 2018 is as follows: Options & PSOs Outstanding Options & PSOs ExercisableRange of ExercisePrices NumberOutstanding WeightedAverageRemainingContractualLife (in Years) WeightedAverageExercise Price NumberExercisable WeightedAverageRemainingContractualLife (in Years) WeightedAverageExercise Price$2.22 - $10.001,435,668 4.4 $5.12 1,370,006 4.3 $4.91$10.01 - $20.00430,944 6.4 13.03 359,694 6.2 12.17$20.01 - $35.00647,670 8.3 28.02 216,379 7.2 23.21$35.01 - $50.00175,500 8.8 37.81 33,000 8.6 37.15$50.01 - $73.62106,500 9.9 70.00 — 0.0 —$2.22 - $73.622,796,282 6.1 $16.17 1,979,079 5.0 $8.7795Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)The table below summarizes certain additional information with respect to our options: Year Ended December 31,(in thousands, except per share amounts) 2018 2017 2016Aggregate intrinsic value of options exercised during the year$49,188 $7,562 $3,546Cash received from the exercise of stock options9,855 4,714 1,470Weighted average grant date fair value per option$25.96 $18.05 $9.47The total compensation cost of options granted but not yet vested at December 31, 2018 was $14.5 million, which is expectedto be recognized over a weighted average period of approximately three years.The fair value of stock options was estimated at the date of grant using the following weighted average assumptions: Year Ended December 31, 2018 2017 2016Expected volatility55.2% 59.2% 64.4%Expected term (in years)7.4 7.3 8.0Risk-free interest rate2.78% 2.08% 1.61%Expected dividends0.0% 0.0% 0.0%RSU and PSU activity is summarized for the years ended December 31, 2018, 2017 and 2016 as follows: Restricted Stock Units Performance Stock Units Numberof Shares WeightedAverageGrant DateFairValue Numberof Shares WeightedAverageGrant DateFairValueUnits outstanding as of December 31, 2015690,936 $6.85 265,990 $8.68Granted225,198 11.06 — —Forfeited(11,905) 9.50 — —Vested(311,880) 4.08 (132,998) 8.68Units outstanding as of December 31, 2016592,349 $9.86 132,992 $8.68Granted117,614 25.98 — —Forfeited(48,974) 13.57 (132,992) 8.68Vested(193,860) 9.31 — —Units outstanding as of December 31, 2017467,129 $13.76 — $—Granted128,860 35.14 88,345 37.79Forfeited(12,466) 22.88 (1,236) 37.79Vested(224,840) 12.02 — —Units outstanding as of December 31, 2018358,683 $22.22 87,109 $37.7996Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)During 2018, we granted awards to certain participants in the form of PSUs. These PSUs will vest at the end of a three-yearperformance period only if specific financial performance metrics are met, and the vested shares will then be modified based on relativetotal shareholder return. The 88,345 PSUs were granted at “target” levels; however, for share pool purposes, we have reserved anadditional 87,109 shares if the combined financial performance and market conditions achieve maximum levels. The probability ofachieving any of the performance criteria was first attained during the fourth quarter of 2018, however, the market conditions are notyet final. Compensation expense related to these PSUs was recognized in accordance with ASC 718 for both employees and non-employees, as amended by the early adoption of ASU 2018-07 (see “Note 2. Summary of Significant Accounting Policies; t)Recent Accounting Pronouncements; Accounting Pronouncements Recently Adopted” for further detail regarding ASU 2018-07).In addition, a summary of total outstanding RSUs as of December 31, 2018 is as follows:Range of Grant Date FairValue RSUsOutstanding$9.57 - $12.00 134,278$12.01 - $31.50 112,281$31.51 - $73.62 112,124$9.57- $73.62 358,683Additional information about our RSUs and PSUs is summarized as follows: Year Ended December 31,(in thousands) 2018 2017 2016Aggregate market value of RSUs vested during the year$7,940 $4,768 $3,826Aggregate market value of PSUs vested during the year— — 2,093The total compensation cost of RSUs and PSUs granted but not yet vested at December 31, 2018 was $6.9 million, which isexpected to be recognized over a weighted average period of approximately two years. Additionally, there were 576,546 RSUs vestedbut not released at December 31, 2018.97Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)Employee Stock Purchase PlanIn July 2008, we made available an Employee Stock Purchase Plan (“2008 ESPP”) in which substantially all of our full-timeemployees became eligible to participate effective March 18, 2008. Under the 2008 ESPP, employees may contribute through payrolldeductions up to $21,500 in a calendar year towards the purchase of our common stock. The purchase price per share is equal to thelower of 85% of the fair market price on the first day of the offering period, or 85% of the fair market price on the day of purchase.Proceeds received from the issuance of shares are credited to stockholders’ equity in the period that the shares are issued. In May 2017,the stockholders approved the BioTelemetry, Inc. 2017 Employee Stock Purchase Plan (“2017 ESPP”), with 500,000 shares reservedfor issuance under the 2017 ESPP, which replaced the 2008 ESPP. The contribution limits, price discount and the offering periodsremain the same under the 2017 ESPP. In 2018, an aggregate of 121,655 shares were purchased in accordance with the 2017 ESPP.Net proceeds from the issuance of shares of common stock under the 2017 ESPP for the year ended December 31, 2018 were $2.3million. At December 31, 2018, 331,096 shares remain available for purchase under the 2017 ESPP.Our aggregate stock-based compensation expense is summarized as follows: Year Ended December 31,(in thousands)2018 2017 2016Stock options$4,550 $3,183 $2,030Performance stock options— 1,534 1,297Restricted stock units3,052 2,273 2,211Performance stock units589 — 444Employee stock purchase plan1,070 690 520Total stock-based compensation expense$9,261 $7,680 $6,502For the years ended December 31, 2018, 2017 and 2016, we recognized $11.6 million, $1.5 million and $1.7 million of taxbenefit from stock options exercised during the period as a component of our (provision for)/benefit from income taxes.16. Employee Benefit PlanWe sponsor a 401(k) Retirement Savings Plan (the “401k Plan”) for all eligible employees who meet certain requirements.Participants may contribute, on a pre-tax basis, up to the maximum allowable amount pursuant to Section 401(k) of the InternalRevenue Code (“IRC”). The plan also includes a Roth feature, allowing after-tax contributions, up to the maximum allowable amountpursuant to Section 401(k) of the IRC. In January 2014, we adopted an amendment to the 401k Plan that allowed for an employermatching contribution of 100% of the first 3% of the employees’ salary, and 50% of the next 2% of the employees’ salary. For theyears ended December 31, 2018, 2017 and 2016, we contributed $3.5 million, $2.6 million and $2.1 million, respectively. Employercontributions vest immediately.98Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)17. Income TaxesThe components of our (provision for)/benefit from income taxes are summarized as follows: Year Ended December 31,(in thousands)2018 2017 2016Current: Federal$— $(273) $(321)State(27) (424) (153)Foreign(1,897) — —Total provision for income taxes(1,924) (697) (474)Deferred: Federal875 (4,353) 32,484State690 151 5,657Foreign729 (1,848) —Total deferred (provision for)/benefit from income taxes2,294 (6,050) 38,141Total (provision for)/benefit from income taxes$370 $(6,747) $37,667Reconciliations between expected income taxes computed at the federal statutory rate for each of the years endedDecember 31, 2018, 2017 and 2016, and the (provision for)/benefit from income taxes is as follows: Year Ended December 31,(in thousands)2018 2017 2016Income tax (provision)/benefit at statutory rate$(8,716) $3,638 $(5,520)Permanent difference9,127 392 —(Increase)/decrease in valuation allowance714 (976) 51,630State income tax, net of federal benefit606 (177) (259)Deferred tax asset adjustments208 (485) (4,336)Unrecognized tax benefit(1,547) — (3,559)Foreign rate differential(36) (1,107) —Tax Reform impact— (8,048) —Other14 16 (289)(Provision for)/benefit from income taxes$370 $(6,747) $37,667For the years ended December 31, 2018, 2017 and 2016, we recognized $11.6 million, $1.5 million and $1.7 million of taxbenefit from stock options exercised during the period as a component of our (provision for)/benefit from income taxes.At December 31, 2018, we had federal net operating loss carryforwards of approximately $149.1 million to offset future federaltaxable income expiring in various years starting in 2023 through 2037 with the exception of the current year net operating losscarryforward of $1.0 million which is not subject to expiration. At December 31, 2018, we had state net operating loss carryforwardsof $80.2 million, which expire in various years starting in 2019 through 2038. We also had $129.4 million of foreign net operating99Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)loss carryforwards, and we have recorded a valuation allowance against a portion of the foreign net operating losses, which expire invarious years starting in 2019 through 2024.The timing and manner in which we can utilize our net operating loss carryforwards and future income tax deductions in anyyear may be limited. Section 382 of the IRC (“Section 382”)imposes limitations on a corporation’s ability to utilize net operating lossesif it experiences an “ownership change.” Section 383 imposes similar limitations on other tax attributes such as research anddevelopment credits. Currently, a portion of our loss carryforwards is limited under Section 382 and therefore, is not included in thetotal net operating losses disclosed above.The U.S. Internal Revenue Service concluded its examination of our U.S. federal tax returns for all years through 2011.Because of net operating losses, our U.S. federal tax returns for those years will remain subject to examination until the statute oflimitations passes for the tax returns which utilized those losses. Additionally, state tax return statutes generally remain open due tooperating losses.Deferred taxes result from temporary differences between the carrying amounts of assets and liabilities used for financialreporting purposes and the amounts used for income tax purposes. As of December 31, 2018, our gross deferred income tax assets of$56.0 million were primarily the result of federal and state net operating losses and credit carryforwards, stock-based compensation,non-deductible accruals, including an interest expense limitation, and allowance for doubtful accounts. A valuation allowance of $3.0million and $6.0 million was recorded against our deferred income tax asset balance as of December 31, 2018 and 2017, respectively.As of each reporting date, our management considers new evidence, both positive and negative, that could impactmanagement’s view with regard to future realization of deferred income tax assets.100Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)The significant components of our deferred taxes are as follows: December 31,(in thousands)2018 2017Deferred tax assets: Net operating loss carryforwards$33,803 $38,245Allowance for doubtful accounts6,526 5,324Non-deductible accruals4,980 4,471Stock based compensation expense3,337 4,300Transaction costs2,186 2,361Research and development and AMT credit carryforwards1,092 1,198Deferred revenue and deferred rent1,019 937Capital loss carryforwards2,114 —Property and equipment— 690Other, net917 158Total deferred tax assets55,974 57,684Less valuation allowance(3,021) (6,032)Net deferred tax assets52,953 51,652Deferred tax liabilities: Intangible assets(29,663) (33,854)Property and equipment(3,173) —Prepaid insurance(142) (117)Total deferred tax liabilities(32,978) (33,971)Net deferred tax asset$19,975 $17,681On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the TCJA. TheTCJA makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate taxrate from 35 percent to 21 percent; (2) requiring companies to pay a one-time transition tax on certain unrepatriated earnings of foreignsubsidiaries; (3) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (4) requiring a currentinclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (5) eliminating the corporate alternativeminimum tax (“AMT”) and changing how existing AMT credits can be realized; (6) creating the base erosion anti-abuse tax, a newminimum tax; (7) creating a new limitation on deductible interest expense; and (8) changing rules related to uses and limitations of netoperating loss carryforwards created in tax years beginning after December 31, 2017.The SEC staff issued SAB 118, which provides guidance on accounting for the tax effects of the TCJA. SAB 118 provides ameasurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accountingunder ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the TCJA for whichthe accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the TCJA isincomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If acompany cannot determine a provisional estimate to be included in the financial101Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately beforethe enactment of the TCJA.In 2018, we completed our analysis of the provisional items of the TCJA under SAB 118, resulting in immaterial adjustments,primarily related to cumulative temporary differences.The following summarizes the changes in our unrecognized tax benefit: Year Ended December 31,(in thousands)2018 2017Unrecognized tax benefit at the beginning of the year$39,710 $3,899Additions to unrecognized tax benefit related to current year— 35,811Additions to unrecognized tax benefit related to prior years13,122 —Unrecognized tax benefit at the end of the year$52,832 $39,710The balance of unrecognized tax benefits, if recognized, would affect the effective tax rate. As of December 31, 2018 and2017, we have recorded a net reserve of $31.3 million and $22.0 million, respectively, for unrecognized tax benefits as a component ofother long-term liabilities within our consolidated balance sheets. The unrecognized tax benefit, or a portion of an unrecognized taxbenefit, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar taxloss, or a tax credit carryforward.We recognize interest and penalties related to unrecognized tax benefits on the (provision for)/benefit from income taxes line inthe accompanying consolidated statements of operations. As of December 31, 2018, our accrued interest associated with our liabilityfor unrecognized tax benefits was $1.6 million. As of December 31, 2017, we had not recorded any interest associated with ourliability for uncertain tax positions. In addition, we have not recorded any penalties on our uncertain tax positions for each of the yearsended December 31, 2018 and 2017.It is reasonably possible that a portion of these unrecognized tax benefits could be resolved within the next twelve months thatmay result in a decrease in our effective tax rate.18. Segment InformationWe operate under two reportable segments: Healthcare and Research. The Healthcare segment is focused on the diagnosis andmonitoring of cardiac arrhythmias or heart rhythm disorders. We offer cardiologists, electrophysiologists, neurologists and primary carephysicians a full spectrum of solutions, which provides them with a single source of cardiac monitoring services. These services rangefrom the differentiated MCT service, to event, traditional Holter, extended-wear Holter, Pacemaker and INR monitoring. The Researchsegment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and datamanagement services for drug and medical device trials. During the first quarter of 2018, as part of the LifeWatch integration, ourforward-looking integration and rebranding plans, as well as re-evaluating the significance and materiality of our segments, weaggregated the Technology operating segment into the Corporate and Other category. Included in the Corporate and Other category isthe revenue received from the sale of non-invasive cardiac monitors to healthcare companies, wireless blood glucose meters and teststrips to wholesale distributors of diabetes102Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)supplies and diabetic patients as well as product repairs, corporate overhead and other items not allocated to any of our reportablesegments.Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segmentincome. Any remaining expenses including integration, restructuring and other charges, as well as the elimination of costs associatedwith intercompany revenue are included in the Corporate and Other category. Also included in the Corporate and Other category is ournet interest expense, other financing expenses, and income taxes. We do not allocate assets to the individual segments. Year ended December 31, 2018 Reporting Segment Corporateand Other Consolidated(in thousands)Healthcare Research Revenue$338,812 $50,561 $10,099 $399,472Gross profit220,883 21,603 8,000 250,486Income/(loss) before income taxes98,135 6,228 (62,859) 41,504Depreciation and amortization33,119 3,723 3,326 40,168Capital expenditures20,258 3,272 1,107 24,637 Year ended December 31, 2017 Reporting Segment Corporateand Other Consolidated(reclassified, in thousands)Healthcare Research Revenue$234,385 $38,790 $13,601 $286,776Gross profit153,029 15,909 3,432 172,370Income/(loss) before income taxes52,054 1,214 (63,664) (10,396)Depreciation and amortization29,255 4,148 (4,842) 28,561Capital expenditures12,542 1,274 (119) 13,697 Year ended December 31, 2016 Reporting Segment Corporateand Other Consolidated(reclassified, in thousands)Healthcare Research Revenue$165,664 $32,565 $10,103 $208,332Gross profit112,105 14,170 3,175 129,450Income/(loss) before income taxes53,025 2,229 (39,484) 15,770Depreciation and amortization10,216 3,837 216 14,269Capital expenditures8,885 1,941 73 10,89919. Legal ProceedingsThe final outcome of any current or future litigation or governmental or internal investigations cannot be accurately predicted,nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatoryauthorities. We record accruals for such103Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be estimated.Mednet SettlementIn the third quarter of 2017, a settlement was reached with the selling stockholder of Mednet Healthcare Technologies, Inc.,Heartcare Corporation of America, Inc., Universal Medical, Inc., and Universal Medical Laboratory, Inc. (collectively, “Mednet”),whereby 79,333 shares of BioTelemetry common stock with a fair value of $2.8 million were returned to us. These shares were part ofthe consideration paid in the acquisition of Mednet and had been subject to certain terms and conditions set forth in the Stock PurchaseAgreement (the “Mednet Agreement”). In accordance with the terms of the Mednet Agreement, we sought indemnification foralleged breaches of certain representations and warranties. Accordingly, in 2016 we recorded a $1.4 million indemnification asset.However, as a result of the settlement’s fair value exceeding the indemnification asset recorded, a gain of $1.3 million was recorded asa component of other non-operating expense, net in the consolidated statements of operations for the year ended December 31, 2017.United States Department of Health and Human Services’ Office for Civil Rights SettlementIn 2011, we experienced the theft of two unencrypted laptop computers and, as a result, were required to provide notices underthe Health Insurance Portability and Accountability Act Breach Notification Rule to the United States Department of Health andHuman Services’ Office for Civil Rights (“OCR”). During the first quarter of 2017, the OCR concluded its investigation into thematter and reached a settlement agreement with us. Per the agreement, we paid the OCR $2.5 million and agreed to submit a two-yearcorrective action plan. We did not admit any liability or wrongdoing. As a result of the settlement, we recorded a non-operating chargeof $2.5 million to other non-operating expense, net in the consolidated statements of operations for the year ended December 31, 2017.ZTech, Inc., Biorita LLC, and the Cleveland Clinic Foundation ArbitrationIn January 2017, ZTech, Inc., Biorita LLC, and the Cleveland Clinic Foundation (collectively, the “Claimants”) filed anarbitration demand against LifeWatch with the American Arbitration Association. Claimants alleged that LifeWatch violated the 2015Stock Purchase Agreement for the purchase of FlexLife Health, Inc., a remote INR monitoring business. The demand allegedLifeWatch did not make commercially reasonable efforts to achieve certain conditions precedent and did not have a reasonable basisfor terminating the business line. Claimants sought liquidated damages and attorneys’ fees. On May 9, 2018, the arbitration panelissued an award including accrued interest against LifeWatch in the amount of $6.0 million. The award liability, plus the accruedinterest through July 12, 2017, was recorded as a measurement period adjustment related to our LifeWatch acquisition due to new factslearned that existed as of the acquisition date (see “Note 4. Acquisitions”). The interest accrued since the acquisition date ofLifeWatch was recorded as a component of other non-operating expense within our consolidated statements of operations. The totalamount of the award and accrued interest was paid in May 2018.ScottCare LitigationIn May 2012, CardioNet, Inc. and Braemar Manufacturing, LLC filed suit against The ScottCare Corporation and AmbucorHealth Solutions, Inc. (collectively, “ScottCare”) in the U.S. District Court for the Eastern District of Pennsylvania for patentinfringement. We are seeking an injunction against each defendant, as well as monetary damages. ScottCare has asserted counterclaimsalleging the patents in the104Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)suit are invalid and not infringed. Summary judgment motions are pending with the district court. We are vigorously pursuing ourclaims and defending against the counterclaims. The probable outcome of this matter cannot be determined, nor can we estimate arange of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have notrecorded an accrual related to this matter.InfoBionic LitigationCardioNet, LLC and Braemar Manufacturing, LLC filed a patent infringement lawsuit against InfoBionic, Inc. (“InfoBionic”)in May 2015 in the U.S. District Court for the District of Massachusetts and filed the most recent amended complaint in March2017. We also initiated an arbitration proceeding against InfoBionic with the American Arbitration Association in July 2017 assertingclaims of misappropriation of trade secrets, unfair competition and unjust enrichment as a result of our discovery that InfoBionic is inunauthorized possession of our confidential and proprietary materials, including source code. We are seeking monetary and injunctiverelief. A final hearing is scheduled for May 2019.20. Quarterly Financial Data (Unaudited)The following tables summarize the unaudited quarterly financial data for the last two fiscal years.(in thousands, except per share amounts)FirstQuarter SecondQuarter ThirdQuarter FourthQuarter2018 Total revenue$94,496 $101,360 $100,013 $103,603Gross profit58,048 65,755 62,737 63,946Net income5,036 10,444 16,001 10,393Net income attributable to BioTelemetry, Inc.5,982 10,444 16,001 10,393Basic net income per share attributable to BioTelemetry,Inc.$0.18 $0.32 $0.48 $0.31Diluted net income per share attributable to BioTelemetry,Inc.$0.17 $0.29 $0.45 $0.29 2017 Total revenue$55,881 $58,129 $81,023 $91,743Gross profit32,909 35,967 49,069 54,425Net income/(loss)196 1,726 (2,564) (16,501)Net income/(loss) attributable to BioTelemetry, Inc.196 1,726 (2,285) (15,593)Basic net income/(loss) per share attributable toBioTelemetry, Inc.$0.01 $0.06 $(0.07) $(0.48)Diluted net income/(loss) per share attributable toBioTelemetry, Inc.$0.01 $0.05 $(0.07) $(0.48)105Table of ContentsBIOTELEMETRY, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)21. Subsequent EventOn January 25, 2019, we entered into an Agreement and Plan of Merger (the “Geneva Agreement”) with Geneva Healthcare,Inc. (“Geneva”), a Delaware corporation and early stage company that provides remote monitoring for implantable cardiac devicesutilizing a proprietary cloud-based platform, whereby Geneva will become a wholly owned subsidiary of BioTelemetry.Pursuant to the terms of the Geneva Agreement, the holders of Geneva’s common and preferred stock and options exercisablefor Geneva’s common stock outstanding (combined, the “Securityholders”) at closing will receive cash in the aggregate of $45.0million, subject to certain closing and post-closing adjustments related to, among other things, Geneva’s net working capital, cash andcertain transaction expenses as of the closing date. In addition, pursuant to the terms of Geneva Agreement, on the third anniversary ofthe closing date, the Securityholders are eligible to receive a revenue-based earn-out of at least $20.0 million, payable either in cash ora combination of cash and stock, with no maximum earn-out amount. The consideration for this transaction is expected to be fundedwith (1) cash on hand, (2) borrowings under BioTelemetry’s current revolving credit facility, (3) through the issuance of BioTelemetryCommon Stock, or (4) some combination thereof.The closing of the transactions contemplated by the Geneva Agreement is expected to be completed later in the first quarter of2019. We plan to assign Geneva to our Healthcare segment.106Table of ContentsItem 9. Changes in and Disagreements with Accountants on Accounting and Financial DisclosureNone.Item 9A. Controls and ProceduresEvaluation of Disclosure Controls and ProceduresPrior to the filing of this Annual Report on Form 10-K, an evaluation was performed under the supervision of and with theparticipation of our management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of theeffectiveness of our disclosure controls and procedures. Based on the evaluation, the CEO and CFO have concluded that, as ofDecember 31, 2018, our disclosure controls and procedures are effective to ensure that information required to be disclosed in reportsthat it files or submits under the Securities Exchange Act of 1934 (“Exchange Act”), is recorded, processed, summarized and reportedwithin the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, as appropriate, toallow timely decisions regarding required disclosure. It should be noted that the design of any system of controls is based in part uponcertain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving itsstated goals under all potential future conditions, regardless of how remote.Changes in Internal Control over Financial ReportingThere was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) or 240.15d-15(f) under theExchange Act) during the fourth fiscal quarter ended December 31, 2018 that has materially affected, or is reasonably likely tomaterially affect, our internal control over financial reporting.107Table of ContentsMANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTINGManagement is responsible for establishing and maintaining adequate internal control over financial reporting as defined inRules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonableassurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordancewith U.S. generally accepted accounting principles. Our internal control over financial reporting includes those policies and proceduresthat:(i)pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions anddispositions of our assets;(ii)provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements inaccordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being madeonly in accordance with authorizations of management and directors; and(iii)provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition ofour assets that could have a material effect on the financial statements.Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because ofchanges in conditions, or that the degree of compliance with the policies or procedures may deteriorate.Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2018. In makingthis assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission(“COSO”) in Internal Control—Integrated Framework (2013). Based on management’s assessment and those criteria, management hasconcluded that our internal control over financial reporting was effective as of December 31, 2018.The effectiveness of our internal control over financial reporting as of December 31, 2018 has been audited by Ernst &Young LLP, an independent registered public accounting firm, as stated in their report included in this Annual Report on Form 10-K.108Table of ContentsReport of Independent Registered Public Accounting FirmThe Stockholders and the Board of Directors of BioTelemetry, Inc.Opinion on Internal Control over Financial ReportingWe have audited BioTelemetry, Inc.’s internal control over financial reporting as of December 31, 2018, based on criteria establishedin Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013framework) (the COSO criteria). In our opinion, BioTelemetry, Inc. (the Company) maintained, in all material respects, effectiveinternal control over financial reporting as of December 31, 2018, based on the COSO criteria.We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)(PCAOB), the consolidated balance sheets of the Company as of December 31, 2018 and 2017, the related consolidated statements ofoperations, comprehensive income (loss), equity and cash flows for each of the three years in the period ended December 31, 2018,and the related notes and schedule listed in the Index at Item 15(a) of the Company and our report dated February 21, 2019 expressedan unqualified opinion thereon.Basis for OpinionThe Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment ofthe effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Controlover Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting basedon our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to theCompany in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and ExchangeCommission and the PCAOB.We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the auditto obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weaknessexists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing suchother procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for ouropinion.Definition and Limitations of Internal Control Over Financial ReportingA company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability offinancial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accountingprinciples. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to themaintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of thecompany; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements inaccordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only inaccordance with authorizations of management and109Table of Contentsdirectors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,use, or disposition of the company’s assets that could have a material effect on the financial statements.Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projectionsof any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes inconditions, or that the degree of compliance with the policies or procedures may deteriorate./s/ ERNST & YOUNG LLP Philadelphia, Pennsylvania February 21, 2019 110Table of ContentsItem 9B. Other InformationNone.111Table of ContentsPART IIIItem 10. Directors, Executive Officers and Corporate GovernanceInformation with respect to this Item is incorporated by reference from our definitive proxy statement in connection with the2019 Annual Meeting of Stockholders, or the Proxy Statement, unless the Proxy Statement is not filed by May 1, 2019, in which casewe will amend this Form 10-K to provide the omitted information in accordance with the requirements of Instruction G to Form 10-K.BioTelemetry emphasizes the importance of professional business conduct and ethics through its corporate governanceinitiatives. Our Board of Directors has adopted a code of business conduct and ethics that applies to all employees, directors andofficers, including our principal executive officer and principal financial officer. Our corporate governance information and materials,including our Code of Business Conduct and Ethics, are posted under “Corporate Governance” in the Investors section of our websiteat www.gobio.com. Our Board of Directors regularly reviews corporate governance developments and modifies these materials andpractices as warranted. To the extent we make amendments to or grant waivers from our Code of Business Conduct and Ethics in thefuture, we intend to disclose the amendments and waivers on our website.Item 11. Executive CompensationInformation required by this Item is incorporated by reference from the Proxy Statement unless the Proxy Statement is not filedon or before May 1, 2019, in which case we will amend this Form 10-K to provide the omitted information in accordance with therequirements of Instruction G to Form 10-K.Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder MattersInformation required by this Item is incorporated by reference from the Proxy Statement unless the Proxy Statement is not filedon or before May 1, 2019, in which case we will amend this Form 10-K to provide the omitted information in accordance with therequirements of Instruction G to Form 10-K.Item 13. Certain Relationships and Related Transactions, and Director IndependenceInformation required by this Item is incorporated by reference from the Proxy Statement unless the Proxy Statement is not filedon or before May 1, 2019, in which case we will amend this Form 10-K to provide the omitted information in accordance with therequirements of Instruction G to Form 10-K.Item 14. Principal Accountant Fees and ServicesInformation required by this Item is incorporated by reference from the Proxy Statement unless the Proxy Statement is not filedon or before May 1, 2019, in which case we will amend this Form 10-K to provide the omitted information in accordance with therequirements of Instruction G to Form 10-K.112Table of ContentsPART IVItem 15. Exhibits and Financial Statement Schedules(a)The following financial statements, schedules and exhibits are filed as part of this Annual Report on Form 10-K1.Financial Statements—The Financial Statements required by this item are listed on the Index to Financial Statements inPart II, Item 8 of this Annual Report on Form 10-K.2.Financial Statement Schedules•Schedule II—Valuation and Qualifying Accounts and Reserves; and•Other financial statement schedules are not included because they are not required or the information is otherwiseshown in the financial statements or notes thereto.3.Exhibits—The exhibits listed on the accompanying Exhibit Index are filed as part of, or are incorporated by referenceinto, this Annual Report on Form 10-K.(b)See Item 15(a)(3) above.(c)See Item 15(a)(2) above.113Table of ContentsItem 16. Form 10-K SummaryNone.SCHEDULE II(in thousands)BeginningBalance Additions Deductions EndingBalanceAllowance for Doubtful Accounts Year ended December 31, 2018$16,981 $22,222 $(13,590) $25,613Year ended December 31, 2017$12,863 $13,291 $(9,173) $16,981Year ended December 31, 2016$11,601 $9,931 $(8,669) $12,863(in thousands)BeginningBalance Additions Deductions EndingBalanceTax Valuation Allowance Year ended December 31, 2018$6,032 $— $(3,011) $3,021Year ended December 31, 2017$95 $5,937 $— $6,032Year ended December 31, 2016$49,759 $1,966 $(51,630) $95114Table of ContentsEXHIBIT INDEX Incorporated by Reference ExhibitNumber Description Form File No. Exhibit Filing Date Filed/FurnishedHerewith 2.1 Share and Asset Purchase Agreement, dated December 1, 2016,by and among Telcare Acquisition, LLC, BioTelemetry CareManagement, LLC, BioTelemetry, Inc. and Telcare, Inc. 10-K 000-55039 2.3 February 22, 2017 2.2 Transaction Agreement by and among Lifewatch AG,Biotelemetry, Inc. and Cardiac Monitoring Holding Company,LLC, dated April 4, 2017 10-Q 000-55039 2.1 November 7, 2017 3.1 Certificate of Incorporation of BioTelemetry, Inc. 10-Q 000-55039 3.1 August 8, 2017 3.2 Bylaws of BioTelemetry, Inc. 10-Q 000-55039 3.2 August 8, 2017 10.1 BioTelemetry, Inc. Form of Indemnity Agreement S-1 333-145547 10.1 August 17, 2007 10.2* BioTelemetry, Inc. 2017 Omnibus Incentive Plan S-8 333-218228 10.1 May 25, 2017 10.2(a) Form of Option Award Agreement under the BioTelemetry,Inc. 2017 Omnibus Incentive Plan 10-Q 000-55039 10.2 April 27, 2018 10.2(b) Form of Restricted Stock Unit Award Agreement under theBioTelemetry, Inc. 2017 Omnibus Incentive Plan 10-Q 000-55039 10.3 April 27, 2018 10.2(c) Form of Performance Stock Unit Award Agreement under theBioTelemetry, Inc. 2017 Omnibus Incentive Plan 10-Q 000-55039 10.4 April 27, 2018 10.3* BioTelemetry, Inc. 2008 Non-Employee Directors’ StockOption Plan and Form of Stock Option Agreement thereunder S-1 333-145547 10.4 February 28, 2008 10.4* BioTelemetry, Inc. 2017 Employee Stock Purchase Plan S-8 333-218228 10.2 May 25, 2017 10.5* CardioNet, Inc. Long Term Incentive Plan 8-K 001-33993 10.2 October 28, 2008 10.6* CardioNet, Inc. Compensation Program for Non-EmployeeDirectors 8-K 001-33993 99.5 January 28, 2009 10.7* Employment Agreement, dated as of June 15, 2010, betweenJoseph H. Capper and CardioNet, Inc. 8-K 001-33993 99.2 June 18, 2010 10.8* Employment Agreement, dated as of January 28, 2010,between CardioNet, Inc. and Heather Getz 10-K 001-33993 10.36 February 23, 2010 10.9* Employment Agreement, dated as of December 7, 2010,between CardioNet, Inc. and Daniel Wisniewski 10-K 001-33993 10.38 February 25, 2011 10.10* Employment Agreement dated as of February 7, 2011, betweenCardioNet, Inc. and Peter Ferola 10-Q 001-33993 10.1 May 6, 2011 10.11* Employment Agreement dated as of July 30, 2010, betweenCardioNet, Inc. and Fred Anthony Broadway III 10-K 001-33993 10.26 February 22, 2013 10.12 Credit Agreement by and among Biotelemetry, Inc. andSunTrust Bank, as agent for the lenders and swingline lender,dated July 12, 2017 10-Q 000-55039 10.1 November 7, 2017 10.13* Termination Agreement, dated October 31, 2018, by andbetween LifeWatch GmbH and Dr. Stephan Rietiker † 21 Subsidiaries of BioTelemetry, Inc. † 23 Consent of Ernst & Young LLP. †115Table of Contents Incorporated by Reference ExhibitNumber Description Form File No. Exhibit Filing Date Filed/FurnishedHerewith 31.1 Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities andExchange Act of 1934, as amended. † 31.2 Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities andExchange Act of 1934, as amended. † 32 Certification of Chief Executive Officer and Chief FinancialOfficer pursuant to 18 U.S.C. Section 1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002. + 101.INS XBRL Instance Document. † 101.DEF XBRL Taxonomy Extension Definition Linkbase Document. † 101.SCH XBRL Taxonomy Extension Schema Document. † 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document. † 101.LAB XBRL Taxonomy Extension Label Linkbase Document. † 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document. †*Indicates a management plan or compensatory plan or arrangement.†Filed herewith+Furnished herewith116Table of ContentsSIGNATURESPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused thisreport to be signed on its behalf by the undersigned, thereunto duly authorized.Date:February 21, 2019BioTelemetry, Inc. By: /s/ JOSEPH H. CAPPER Joseph H. CapperPresident and Chief Executive OfficerPursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the followingpersons on behalf of the registrant and in the capacities and on the dates indicated.Signature Title Date /s/ JOSEPH H. CAPPERPresident and Chief Executive Officer (Principal ExecutiveOfficer)February 21, 2019Joseph H. Capper /s/ HEATHER C. GETZExecutive Vice President and Chief Financial Officer(Principal Financial and Accounting Officer)February 21, 2019Heather C. Getz /s/ KIRK E. GORMANChairman and DirectorFebruary 21, 2019Kirk E. Gorman /s/ ANTHONY J. CONTIDirectorFebruary 21, 2019Anthony J. Conti /s/ JOSEPH A. FRICKDirectorFebruary 21, 2019Joseph A. Frick /s/ COLIN HILLDirectorFebruary 21, 2019Colin Hill /s/ STEPHAN RIETIKERDirectorFebruary 21, 2019Stephan Rietiker, M.D. /s/ REBECCA RIMELDirectorFebruary 21, 2019Rebecca Rimel /s/ ROBERT J. RUBINDirectorFebruary 21, 2019Robert J. Rubin, M.D.117Exhibit 10.13TERMINATION AGREEMENTby and between1.LifeWatch GmbHCHE- I 09.281.219Baarerstrasse 1396300 ZugEmployer or Companyand2.Stephan RietikerObere Rebhalde 296340 BaarEmployeeRECITALReference is made to the employment agreement between the Employee and the Company dated May 12, 2014, effective as of June 1,2014 (Employment Agreement).The Employee also serves as a director of the Company and the Company’s Swiss subsidiaries, namely LifeWatch Turkey HoldingAG (CHB-3 89.239.219) and LifeWatch Europe AG (CHE- 109.293.323) together the Directorships.The Employer plans to close down its Swiss Operations as a result of the take-over, which has been completed by the end of 2017.Based upon that, the Employer and the Employee enterinto the following agreement in order to set forth the terms and conditions of the termination of the Employment Agreement by mutualconsent in full and final settlement of any claim thereunder (Agreement).The Employee’s Directorships shall continue and not be terminated by this Agreement.1.TERMINATION OF EMPLOYMENT AGREEMENTThe employment relationship between the Employer and the Employee shall be terminated by mutual consent effective as ofOctober 31, 2018 (Termination Date). An extension of the employment relationship beyond the Termination Date for any reason(e.g. illness, accident) is expressly excluded.As of October 31, 2018 the Employee is released from the management of the Company and from any obligation related to or inconnection with the employment relationship, but shall remain a director of the Company and the Company’s subsidiaries.2.DIRECTORSHIPSIn consideration of the benefits received under this Agreement, the Employee agrees to continue to serve, without additionalcompensation, save as for out of pocket expenses, as a director of the Company and the Company’s Subsidiaries after theTermination Date.Employer will enter into a consulting agreement with Employer, covering the Employee’s Directorship with the Company and theCompany’s Subsidiaries on or before the Termination Date. The consulting agreement shall deal with Employee’s assignment asdirector of the Company and the Company’s Subsidiaries, the respective responsibilities, tasks and confidentiality, and also covercertain ongoing matters and the corporate housekeeping (i.e. pending matters, such as [*]) as well as expenses incurred by theEmployee in connection therewith.3.SALARY PAYMENTS AND NOTICE PAYThe Employee’s salary entitlement shall remain unchanged until the Termination Date.The Employer will pay Employee, starting as of November 1, 2018 a notice pay of CHF 225‘00 gross, plus the side benefitsprovided, i.e. expense allowance of CHF 9‘000 and pension fund contribution of CHF 38’259.The notice pay and side benefits will be paid out in 6 equal monthly installments. Expenses incurred until October 31, 2018 will besubmitted for approval no later than November 15 and paid out with the November payroll payment.Apart from the Transition Bonus pursuant to Section 4 There will be no additional payments due to the Employee or owed by theEmployer for the Employees Directorship, except for out of pocket expenses.4.TRANSITION BONUSThe Employee will receive a transition bonus of CHF 450’000 gross, to be paid by January 15, 2019.For the avoidance of doubt, no pension fund contributions etc. will be paid (Employer share) and / or deducted (Employee share)with regard to the transition bonus.In consideration of the transition bonus, unused vacation days, if any until the Termination Date, Employee shall be fullycompensated and the Employee confirms to have no claims vis-à-vis the Employer with respect to extra hours and overtime(Überstunden und Überzeit).5.PROPERTY OF THE COMPANY AND E-MAIL ACCOUNTUntil the end of 2018, the Employee will handover to the Company’s archive any property belonging to the Company, togetherwith all working material as well as anything the Employee has received from the Employer, or from companies connected to theEmployer, or from third parties on behalf of the Employer, as well as any work product created by the Employee during theemployment relationship.The Employee is entitled to keep the laptop provided by Employer. Before the End of 2018, the Employee will personally bringthe laptop to the Employer’s IT-department, allowing the Employer to make a copy of the hard-drive first and then wipe the hard-drive clean of all data and proprietary programs.The Employee will be allowed to keep the E-Mail account for the duration of his Directorship and/or further notice, but agrees andwill allow an electronic forwarding routine, whereby all e-mails received by Employee are being forwarded to the Heather Getz().6.REFERENCE LETTERThe Employer shall issue to the Employee a reference letter, duly signed by Joseph Capper and Kirk Gorman both on behalf of theCompany and as representatives of the BioTelemetry group of companies.7.CONFIDENTIALITYThe Employee undertakes not to discuss or use at any time, whether before the Termination Date or thereafter, any informationrelating to the Employer or the Employer’s business, as well as to the content of this Agreement and with best efforts to keep allconfidential information confidential and to treat all confidential information with utmost confidentiality.8.NON-COMPETEThe Employee undertakes not to take up a new position with a competitor of the Employer or the BioTelemetry group ofcompanies, doing business in the United States of America (Non-Compete); such Non-Compete shall be limited until December31, 2019.9.SETTLEMENT CLAUSEIn consideration of the payments received under this Agreement, and upon due performance by both Parties of their respectiveobligations under this Agreement, any and all claims of either Party against the other arising in connection with the employmentrelationship and the termination thereof, irrespective of whether they have already arisen or not shall be fully satisfied anddischarged and no further action shall be brought by the parties hereto in any forum of any jurisdiction. This waiver of claims shallalso be valid with regard the BioTelemetry group of companies.The Employee expressly accepts that this Agreement is concluded to the Employee’s advantage and reflects a balancedcompromise between the interests of the Parties.The Confidentiality Clause according to Clause 7 and the None-Compete according to Clause 8 of the Agreement shall survive.Furthermore, this Settlement Clause shall not be applicable to the Employee’s directorship; all issues arising out of the directorshipor related thereto are explicitly excluded.10.APPLICABLE LAW AND JURISDICTIONThis Agreement shall in all respects be governed by, and construed and interpreted in accordance with, the laws of Switzerland.[Remainder of the page intentionally left blank; signature page to follow]***Place and Date: Place and Date:Zug, October 31, 2018 Zug, October 31, 2018 The Employer The Employee/s/ JOSEPH CAPPER /s/ STEPHAN RIETIKERJoseph Capper Stephan Rietiker /s/ KIRK GORMAN Kirk Gorman Exhibit 21BIOTELEMETRY, INC.SUBSIDIARIES*Name Jurisdiction of IncorporationCardioNet, LLC DelawareVirtualScopics, LLC DelawareBioTelemetry Care Management, LLC DelawareTelcare Medical Supply, LLC DelawareTelcare, LLC DelawareBraemar Manufacturing, LLC DelawarecardioCORE Lab, LLC DelawareLifeWatch Corp. DelawareLifeWatch Services Inc. Delaware* Pursuant to Item 601(b)(21)(ii) of Regulation S-K, the names of other subsidiaries of BioTelemetry Inc. are omitted because,considered in the aggregate, they would not constitute a significant subsidiary as of the end of the year covered by this Annual Reporton Form 10-K.Exhibit 23Consent of Independent Registered Public Accounting FirmWe consent to the incorporation by reference in the following Registration Statements:(1)Registration Statement (Form S-3 No. 333-216189) of BioTelemetry, Inc.,(2)Registration Statement (Form S-8 No. 333-149800) pertaining to the 2003 Equity Incentive Plan, the 2008 Equity IncentivePlan, the 2008 Employee Stock Purchase Plan, and the 2008 Non-Employee Directors’ Option Plan,(3)Registration Statements (Forms S-8 No. 333-202280, No. 333-209646, No. 333-216181) pertaining to the 2008 EquityIncentive Plan, and the 2008 Employee Stock Purchase Plan, and(4)Registration Statement (Form S-8 No. 333-218228) pertaining to the 2017 Omnibus Incentive Plan, and the 2017 EmployeeStock Purchase Plan;of our reports dated February 21, 2019, with respect to the consolidated financial statements and schedule of BioTelemetry, Inc., andthe effectiveness of internal control over financial reporting of BioTelemetry, Inc. included in this Annual Report (Form 10-K) ofBioTelemetry, Inc. for the year ended December 31, 2018./s/ ERNST & YOUNG LLP Philadelphia, Pennsylvania February 21, 2019 Exhibit 31.1CERTIFICATION PURSUANT TORULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934I, Joseph H. Capper, certify that:1.I have reviewed this annual report on Form 10-K of BioTelemetry, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects thefinancial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under oursupervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements forexternal purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recentfiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to theregistrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controlover financial reporting.Date: February 21, 2019 /s/ JOSEPH H. CAPPER Joseph H. Capper President and Chief Executive Officer(Principal Executive Officer)Exhibit 31.2CERTIFICATION PURSUANT TORULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934I, Heather C. Getz, certify that:1.I have reviewed this annual report on Form 10-K of BioTelemetry, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects thefinancial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under oursupervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements forexternal purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recentfiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to theregistrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controlover financial reporting.Date: February 21, 2019 /s/ HEATHER C. GETZ Heather C. Getz Executive Vice President and Chief Financial Officer(Principle Financial and Accounting Officer)Exhibit 32CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Annual Report of BioTelemetry, Inc. on Form 10-K for the year ended December 31, 2018, as filed with the Securities andExchange Commission on the date hereof (the “Report”), each of Joseph H. Capper, the President and Chief Executive Officer of BioTelemetry, Inc. andHeather C. Getz, the Executive Vice President and Chief Financial Officer of BioTelemetry, Inc. hereby certifies, pursuant to and for purposes of 18 U.S.C.Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of BioTelemetry,Inc./s/ JOSEPH H. CAPPER /s/ HEATHER C. GETZJoseph H. CapperPresident and Chief Executive Officer Heather C. GetzExecutive Vice President and Chief Financial OfficerFebruary 21, 2019 February 21, 2019This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission andis not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or Securities Exchange Act of 1934, asamended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in suchfiling.

Continue reading text version or see original annual report in PDF format above